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Abstract 
There is an urgent need to develop sensitive and specific biomarkers of response to 
treatment in oncology. This thesis explores the utility of three novel positron emission 
tomography (PET) radiotracers: [18F]-3'deoxy-3'fluorothymidine (FLT), [11C]choline 
and [18F]-AH111585. All patients in the PET studies had breast cancer. 
Aims: 1) To quantify the uptake and retention of [18F]FLT, [11C]choiine and [18F]-
AH111585 in breast cancer, and evaluate the role of mathematical modelling 
compared to standard techniques for quantifying tracer uptake. 2) To correlate 
[18F]FLT and [11C]choiine PET data with immunohistochemical markers of 
proliferation. 3) To establish if [18F]FLT and [11C]choline PET are reproducible in 
breast cancer. 4) To determine the effect of anti-cancer treatment on [18F]FLT and 
[11C]choline PET. 5) To evaluate the diagnostic utility of [18F]-AH111585, a novel 
avps imaging agent, in breast cancer. 
Methods: 15 patients with primary and metastatic breast cancer were studied with 
[18F] FLT-PET at baseline, 2-7 days later, and then 7 days post-chemotherapy. 
[11C]Choline-PET was evaluated in 21 separate breast cancer patients, 13 for 
repeatability and 8 for response to trastuzumab. Finally, in 7 further patients [18F]-
AH111585-PET was used to monitor angiogenesis in metastatic breast cancer. 
Findings: All tumour lesions had positive uptake of FLT, which correlated with cell 
proliferation, FLT uptake was found to have good repeatability,, and patients who 
clinically responded to chemotherapy also demonstrated significant early changes in 
FLT uptake. 
In the choline studies, all tumour lesions demonstrated significant uptake compared to 
normal tissue, and patients who clinically responded to trastuzumab also had a 
decrease in choline retention parameters. 
In seven patients studied with [18F]-AH111585-PET all but one lesion had significant 
retention of the tracer, suggesting that this agent may be promising for imaging 
angiogenesis. 
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CHAPTER 1: Background 
1.0 Introduction 
This thesis will focus on the development of new molecular markers for positron 
emission tomography (PET) and their ability to determine response to treatment in 
cancer. A brief overview on cancer will now be presented, followed by a section on 
breast cancer which will be used as a model system in this thesis. The molecular 
mechanisms leading to tumour proliferation, signal transduction pathways of interest, 
and tumour angiogenesis then follow. Finally, current methods for assessing tumour 
response, the science behind PET and rationale for using: [18F]fluorothymidine 
([18F]FLT), [11C]choline, and [18F]-AH111585 as radiotracers in this thesis will be 
presented. 
1.1 Cancer 
Cancer is a genetic disease. Tumour development is thought to arise by a 
complex process known as transformation which consists of initiation leading to 
changes in the genetic material of the cell, followed by promotion of the initiation cell 
and finally by metastasis. During transformation the physiological properties of cells 
become altered; conferring a survival advantage (comparable to Darwinian evolution) 
from the normal to malignant phenotype. This has been particularly well characterised 
in the Fearon-Vogelstein model of colorectal carcinoma where a genetic basis for the 
histological pathway from normal tissue to hyperplasia, dysplasia, carcinoma in situ, 
and invasive carcinoma was presented (Fearon et al. 1990). The hallmarks of cancer 
cells include: self-sufficiency in growth signals, insensitivity to anti-grov/th signals, 
evasion of apoptosis (programmed cell death), limitless capacity to replicate, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan et al. 2000). 
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Most cancers have mutations in oncogenes, tumour suppressor genes or DNA 
repair genes. Oncogenes are mutant versions of normal genes which drive cell growrth. 
The difference between an oncogene and a normal gene can be as little as one single 
amino acid, which can have a dramatic effect on protein function. The most commonly 
mutated oncogene is called ras, with a frequency of 20-30% in human tumours. When 
the ras oncogene is transfected into appropriate models the cells can acquire a 
metastatic and invasive phenotype (Thorgeirsson et al. 1985). This is also true for 
other oncogenes such as mos, raf, src, fes, and fms. 
Tumour suppressor genes work normally to suppress the development of 
malignancy. The two best known examples are p53 and retinoblastoma (Rb). Many 
tumours result from loss or malfunction of the proteins that these genes encode. The 
Rb protein, in its active form, slows DNA replication. Up to 40% of cancers have 
inactivated Rb which causes cell proliferation to continue unchecked (Knudsen et al. 
2006). The p53 oncogene has been referred to as the guardian of the genome, as its 
role is to prevent damaged DNA from replicating and to promote apoptosis 
(programmed cell death) in cells with abnormal DNA. Faulty p53 protein allows 
abnormal DNA to replicate; the cells pass on their faulty DNA to their progeny which 
can then acquire additional mutations permitting tumorigenesis. The p53 gene appears 
to be defective in most human cancers (Lane 1992; Gomez-Lazaro et al. 2004). 
The third group of genes which are involved in cancer development are the 
DNA repair genes. Processes which damage DNA include ultraviolet radiation, ionising 
radiation, and endogenous free radicals. The integrity of DNA is often damaged during 
replication, and this is checked and fixed by DNA repair genes. Genes which are 
important in DNA repair in colon cancer include MLH1, MSH2, PMS1 and PMS2. A 
second category of genes which act indirectly in DNA repair encode checkpoint 
proteins, which prevent progression through the cell cycle if faults have occurred. This 
includes ATM and p53. If the DNA repair mechanisms are not effective then damaged 
DNA will be passed onto the progeny. The activity of most anticancer drugs is 
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dependent on overwhelming the tumour cell's natural ability to repair drug induced 
damage to its DNA. 
New cancer therapies are being developed using gene therapy to replace 
defective genes, or inactivate defective gene products. Whilst most gene therapies are 
still in the early phases of development, molecular targeted agents are gaining 
increasing importance in the medical treatment of cancer. One of the earliest examples 
of such agents is tamoxifen, a selective oestrogen receptor modulator, which has been 
used for over 30 years in the treatment of breast tumours which have over-expression 
of the oestrogen receptor. 
1.2 Breast cancer 
Breast cancer is a leading cause of cancer death in women from the 
industrialised world; 1 in 8 women will develop breast cancer at some stage in their 
lifetime. Approximately 30% of patients who present with locoregional disease will 
develop metastatic disease, which despite recent advances in treatment, is incurable 
for the vast majority of patients. In Europe in 2004, it is estimated that the incidence of 
new breast cancer cases was 371000, and that there were 129000 deaths due to the 
disease(Boyle et al. 2005). Since 1990 there has been a decreased mortality in the 
western world from breast cancer. This has been attributed to screening with 
mammography, more precise diagnosis, and better treatments including the extensive 
use of tamoxifen in appropriate patients. Although genetic causes due to inherited 
mutations in the BRCA 1 and 2 genes are responsible for some cases, the vast 
majority (8 out of 9 cases) have no history of the disease in a first degree relative. Most 
cases occur in women aged over 50. The current accepted risk factors for 
development of breast cancer are shown in Table 1.1 (Veronesi et al. 2005). 
24 
Table 1.1; Risk factors for developing breast cancer 
Relative Risk Group Affected 
Age >10 Elderly 
Location 5 Western world 
Breast density 
Age at menarche 
>5 
3 
High density detected on 
mammogram 
Age < l l y r s 
Age at menopause 2 Age > 54 yrs 
Age at first pregnancy 3 Age > 40 yrs 
Family history S2 1®' degree relative 
Previous benign breast disease 4-5 Atypical ductal hyperplasia 
Contralateral breast cancer >4 Previous breast cancer 
Socioeconomic group 2 1,2 
Premenopausal body mass index, BMI 0.7 High BMI 
Postmenopausal BMI 2 High BMI 
Alcohol 
Ionising radiation exposure 
1.07 
3 
7% increase with every 
daily drink 
Girls after age 10 yrs 
Breastfeeding and parity 
Oral contraceptive pill 
Decreased by 
4.3% for every 
12 months 
breastfeeding 
and 7% for 
every birth 
1.2 
Women who don't 
breastfeed 
Current users 
Hormone replacement therapy 1.66 Current users 
Diethylstilbestrol 2 Use during pregnancy 
(data taken from Veronesi and Boyle 2005). 
In contrast to carcinoma of the colon, the intervening stages of the spectrum 
spanning from benign tissue to malignant breast cancer have not been determined. 
This is underlined by the fact that dysplastic changes are often evident in non-
malignant breast proliferative diseases such as papillomas. The condition atypical 
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ductal hyperplasia was previously viewed as the link between healthy duct hyperplasia 
and ductal carcinoma in situ (DClS). However cytogenetic analysis is unable to 
separate DClS from atypical ductal hyperplasia, with the result that this is now not 
seen as a precancerous lesion. 
The techniques used to diagnose breast cancer in conjunction with biopsy 
include physical examination, mammography, ultrasound, magnetic resonance 
imaging (MRl), and PET. The first three investigations remain the most commonly 
used, with MRl and PET being reserved for difficult cases such as lobular carcinoma, 
and staging of distant metastases, respectively. 
Adjuvant treatment for early stage breast cancer involves surgery followed by 
radiotherapy. Patients at high risk of recurrence are treated with anthracycline based 
cytotoxic chemotherapy, which is designed to eradicate any micrometastases. In cases 
where it is thought down staging of the tumour prior to surgery may result in a breast 
conserving operation instead of mastectomy, the chemotherapy is given first and is 
referred to as neoadjuvant treatment. This has the advantage of determining the 
chemosensitivity of the tumour in vivo, without affecting survival (Kaufmann et al. 
2006). 
Approximately 75% of patients with breast cancer will have positive 
immunostaining for the oestrogen and/or progesterone receptor. Endocrine 
manipulation in terms of drugs such as tamoxifen, aromatase inhibitors (used in post-
menopausal women to prevent production of oestradiol in peripheral tissues), and 
ovarian ablation is important in patients with positive oestrogen receptor status. These 
treatments have been shown to improve risks of local recurrence, contralateral breast 
cancer, and overall survival (EBCTCG 1992; Group 1992). Endocrine treatment is 
typically given following primary adjuvant therapy for approximately 5 years, though 
recent trials suggest that prolonged treatment may be of benefit in high-risk individuals 
(Goss et al. 2005). The practice of using tamoxifen for 2% years and then switching to 
an aromatase inhibitor has also shown to be beneficial (Coombes et al. 2003; 
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Coombes et al. 2004). The role of endocrine therapy with regard to progesterone 
receptor status is currently being evaluated; it may be of benefit as there is evidence of 
cross-talk between the two receptors and their signal transduction pathways (Cui et al. 
2005; Winer et al. 2005). For patients with advanced disease, treatment options 
include endocrine therapy for those patients with positive hormonal receptors, systemic 
chemotherapy, and radiotherapy for palliation of bone and brain metastases. 
The treatments in this thesis include cytotoxic chemotherapy and trastuzumab. 
Trastuzumab is a humanised monoclonal antibody targeted to the human epidermal 
growth factor receptor 2 (HER2)-neu (also known as c-erbB2) receptor which is over 
expressed in approximately 20-30% of breast tumours, and has been shown to 
improve survival and decrease local recurrence in both the adjuvant and metastatic 
setting (Hortobagyi 2005; Slamon et al. 2006). 
Over-expression of the HER-2/neu receptor is associated with the 
pathogenesis and prognosis of breast cancer (Slamon et al. 1987; Slamon et al. 1989). 
One of the proposed mechanisms of action of trastuzumab is that it prevents HER-
2/neu receptor dimerisation and internalisation leading to inhibition of downstream 
signalling (Nahta et al. 2003). The rationale for using [11C]choline-PET as a readout 
of inhibition of this pathway will be explained later in this chapter. 
1.3 Tumour Proliferation 
Cell proliferation is essential for tumour growth. Normally the cell cycle is tightly 
regulated so that there is a balance between proliferating and non-proliferating cells 
appropriate for the tissue concerned. Loss of regulation for instance at the restriction 
point at the end of Gi is thought to be critical in the development of cancer and may 
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occur due to altered signal transduction pathways (Malumbres et al. 2001), 
(Malumbres et al. 2001)(see fig 1.0). Once past the G1 restriction point, cells become 
independent of mitogenic signals and growth factors. In this section the cell cycle, 
growth factors, current classical methods for measuring cell proliferation, and PET 
imaging applications will be described. 
1.3.1 Cell Proliferation and Cyclins 
All eukaryotic cells have a cell cycle divided into 4 phases through which they 
progress in order to divide: Gi, S, G2, and M. In addition, there is a fifth phase, Go that 
should be considered as a resting phase(Lajtha 1963). Cells in this phase of the cycle 
can re-enter the cycle after mitogenic induction. Phosphorylation of the tumour 
suppressor protein Rb is one of the key mechanisms that controls progression through 
the Gi/S phase of the cell cycle (Dyson 1998). Hypophosphorylated Rb is bound to 
and inhibits E2F (Flemington et al. 1993). Upon phosphorylation of Rb, E2F is released 
and activates transcription factors such as dihydrofolate reductase (DHFR), tyrosine 
kinase (TK), thymidylate synthase (TS), DNA polymerase, E2F itself, and cyclin E 
(Harbour et al. 2000). Repression of E2F is mediated by histone deacetylase (HDAC) 
recruitment to Rb and inhibition of E2F promoters which renders cells independent of 
extracellular mitogenic signals (Soghomonyan et al. 2005). 
Most oncogenic processes exert their greatest effect by targeting the regulation 
of the Gi phase (Sherr 1996). Cyclin-cyclin dependent kinases (cdks) complexes drive 
cells in Gi, to initiate S phase and in G2 to initiate mitosis (Molinari 2000). Cdks are 
expressed at a constant level during the cell cycle. The level of cyclin expression 
however, varies with cell cycle stage as they are subject to ubiquitin-proteosome 
degradation(Coqueret 2002). In Gi, genes encoding D type cyclins (D1-3) become 
activated and bind to either cdk 4 or 6. Only D type cyclins are mitogen dependent. 
Factors such as STAT proteins, NF-KB, CREB, and nuclear receptors have been found 
to transactivate the cyclin D promoter. Transcription of the cyclin D1 gene, synthesis, 
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and association with cdk4 has been found to be strongly dependent on receptor 
mediated ras and PIS kinase signalling(Marshall 1999). Upon the binding of cyclin D to 
its dependent kinase, the protein-substrate binding site becomes exposed and ATP 
phosphates become correctly positioned to allow the transfer of phosphate from ATP 
to the target protein (Nabel 2002). 
Figure 1.1 : The Cell Cycle 
Mi togen ic s igna ls 
a 
Cyc lm B 
Cyc l in D Cyc lm D 
cdk4/6 
cdk4/6 
Cyc l in E Cyc lm A 
c d k 2 R-point • cdk2 
An t im i t ogen i c s igna ls (CKIs) 
INK 4A-D, Cip, 
i t i i * prntoinR Cyc l in A 
TK 
TS 
DHFR 
DNA po l ymerase 
c d k 2 
1.4 Growth factors 
Under normal physiology, there is a balance between cell survival and 
programmed cell death by apoptosis. This is controlled by the response of the cell to 
cell survival and cell death signals in the extracellular environment. This process 
ensures that healthy cells survive and that unhealthy cells are destroyed. 
One of the most important cell survival proteins is the epidermal growth factor 
(EGF). A summary of the role of EGF in anti-apoptotic signalling is shown in Figure 
1.2. EGF elicits cellular responses by binding to specific transmembrane receptor 
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tyrosine kinases (RTK) which set off a chain of signalling events within the cell by 
activating serine-threonine kinases that phosphorylate serine or threonine residues on 
other protein kinases and/or transcription factors. 
In the EGF receptor family (otherwise known as ErbB family) there are four 
closely related transmembrane RTKs: ErbB1 (EGFR), ErbB2 (HER2/neu), ErbB3 
(her3), and ErbB4 (her4), which bind to a wide range of ligands. All the members of 
this family are broadly composed of the same structure: an extracellular ligand binding 
domain, a transmembrane spanning region, and an intracellular region containing 
tyrosine kinase. EGF binds exclusively to EGFR; ErbB2 is thought to be a co-receptor 
as no known ligand binds to it directly. Signalling through EGF is regulated by the 
expression level of ErbB receptors, the amount of EGF, and the presence of other 
positive and negative signalling regulators(Henson et al. 2006). 
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Figure 1.2 EGF signalling pathways for proliferation and apoptosis 
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When EGF binds to ErbB1, the receptor homo- or hetero-dimerises with the 
other three receptors, and then activates RTKs by phosphorylation{Citri et al. 2006). 
The phosphorylated RTK then binds to the adaptor protein She, which then complexes 
with Grb-2. Grb-2 in turn activates the guanine-nucleotide exchange factor Sos. Sos 
stimulates the exchange of GDP for GTP in ras. Activated ras stimulates signal 
transduction through a mitogen activated protein kinase (MARK) cascade. She may 
also be phosphorylated by one of the src family kinases or other kinases. After this 
point the EGF receptors are either down regulated and degraded via endocytosis or 
recycled back to the plasma membrane (Henson et al. 2006). 
Figure 1.3: EGF signalling 
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1.4.1 Ras-MAPK pathway 
The MARK signalling cascades are responsible for relaying extracellular signals 
responsible for cell proliferation and differentiation into the cell and cell nucleus. Such 
signals include growth factors, cytokines, and stresses such as UV irradiation. The 
stimulation of this pathway culminates in gene transcription (including immediate-early 
genes) and chromatin remodelling (see Figure 1.4). 
MAPKs are a super family of protein serine-threonine kinases, which can be 
activated by a diverse array of stimuli including EGF. A highly specific ligand-receptor 
interaction initiates activation of the MARK cascade which is followed by amplification 
of the signal due to larger amounts of substrate in each subsequent step resulting in a 
signal of high intensity. Usually the kinase cascade consists of MAP kinase kinase 
kinase (MARKKK) followed by MAR kinase kinase (MARKK) followed by MARK. Each 
of these kinases is activated by phosphorylation (two serine residues in the case of 
MARKK, and one threonine and one tyrosine residue in the case of MARK). Low level 
noise in the system is eliminated by the biological demand for two phosphorylations; a 
single phosphorylation will not result in signal transduction. Measurement of activated 
MARK can be measured in fresh or fixed tissues by immunohistochemistry. 
The extracellular regulated kinases, ERK 1 and 2 are types of MARK which 
play an important role in breast cancer. This signalling cascade relays signals from cell 
surface receptors to transcription factors, thus regulating gene expression. ERK 1 and 
2 are activated by phosphorylations on residues T183 and Y185, which result in 
dimerisation of ERK with other ERK proteins including nuclear translocation and 
activation of a variety of nuclear targets. ERK1 and 2 are mainly regulated by peptide 
growth factors; the other major regulators of ERK-1 and -2 apart from EGF are insulin-
like growth factor-1, prolactin, heregulin and its family members: insulin, TGF-a and 
TGF-p. Other pathways which can activate ERK-1 and -2 involve G-protein receptor 
mediated processes or calcium related receptors (Rearson et al. 2001). 
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Figure 1.4. MAPK signalling cascades 
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(where GPCR= G protein coupled receptors, SAPK= stress activated protein kinase, 
all others represent tyrosine kinases involved in the MAPK signalling cascade). 
Oestrogen can activate the Ras/Raf/MAPK signalling cascade by direct 
interactions through the oestrogen receptor and c-src (Migliaccio et al. 1996). 
Progesterone activation of the pathway can occur by cross-talk between the 
progesterone receptor and the oestrogen receptor (Migliaccio et al. 1998). 
1.4.2 Ras 
Ras GTPase proteins activate multiple signalling pathways. Ras genes were 
first discovered in the1960s as homologues to the viral oncogenes of transforming 
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retroviruses. Three mammalian isoforms have been identified: H-ras (Harvey murine 
sarcoma virus), K-ras (Kirsten murine sarcoma virus), and n-ras (neuroblastoma cell 
line). The over-activation of wild-type ras or mutations in ras (involving a single amino 
acid substitution at codons 12,13, or 61) have been shown to induce malignant 
transformation in many cancers (Rowinsky et al. 1999). Ras binds to at least three 
different effector proteins: Raf, phosphatidylinositol-3-kinase (PI3 kinase), and the 
RalGDS proteins. Deregulation of the ras-MAPK pathway in tumour cells can result 
from mutations in ras (reported in up to 30% of cancers) and over-expression of cell 
surface receptors. Mutations of ras lock it in the GTP-bound state such that it remains 
constitutively active. Whilst mutations of ras are common in cancer, prolonged 
activation of ras can occur via other mechanisms involving loss of the tumour 
suppressor gene, NF1. Activation of ras by phosphorylation of GDP, leads to the 
activation of raf-l. Raf-1 kinase then phosphoryiates MEK1/2, which then 
phosphorylates and activates ERK1/2. ERK1/2 translocates to the cell nucleus where it 
phosphoryiates a variety of substrates including transcription factors (such as myc, 
ELK-1, c-Fos, and cyclin d), and leads to the inhibition of apoptosis via down-
regulation of p53, inactivation of caspase and the pro-apoptotic protein, BAD.(Shaw et 
al. 2006). 
1.4.3 PIS kinase/AKT pathway 
To date only one of the three classes of PI3 kinases - class 1A has been 
implicated in cancer. This is a heterodimer of a regulatory p85 subunit and a catalytic 
p i 10 subunit. PI3 kinase is activated by both RTKs and ras, and in turn 
phosphoryiates phosphatidylinositol-4,5-bisphosphate(P!P2) forming 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 acts as an anchor for AKT (a 
serine threonine kinase, also known as protein kinase B PKB)(Burgering et al. 1995) 
Mutations in the p i 10 subunit of PI3 kinase, have been reported in breast cancers with 
a frequency of 25%(Samuels et al. 2004). In breast epithelial cell lines expression of 
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the specific mutant isoforms {E545K and H1047R) of p110 is associated with 
anchorage independent proliferation, growth-factor independent proliferation, 
resistance to anoikis and the chemotherapy drug, paclitaxel{lsakoff at al. 2005). 
The most common method for PI3 kinase activation appears to be loss of the 
tumour suppressor enzyme phosphatase with tensin homology (PTEN) which is 
responsible for catalysing the dephosphorylation of PIS (i.e. the reverse of the reaction 
catalyzed by PI3 kinase)(Maehama et al. 1998). Although immunohistochemical 
analysis of breast tumour samples has found hyperactive Akt in 50% of cases, 
mutations of PTEN have only been found in 3%, leading some authors to speculate 
that the alternative mechanisms for Akt activation include mutations in ras or 
inactivation of p53(Cully et al. 2006). The recent discovery of the Parkinson's disease 
associated gene (PARK7 also known as DJ1) over expression which is inversely 
correlated with PTEN expression was found to be associated with increased cell 
survival in breast cancer is a third method by which Akt could be come hyper-activated 
(Kim et al. 2005). 
Activated Akt transduces signals that regulate multiple biological processes 
including apoptosis, cell metabolism, gene expression and cell proliferation (see Figure 
5). Akt inhibits glycogen synthetase kinase 3 (GSK-3) through serine phosphorylation, 
which in turn controls crucial cell-cycle regulators e.g. cyclin D1, therefore leading to 
transcription to proceed unchecked(Cross et al. 1995). Cell growth and ATP production 
are stimulated by directly activating glycolysis and fatty acid synthesis via 
phosphofructo-2-kinase and ATP citrate lyase respectively (Garber 2006). Akt also 
regulates cellular uptake of glucose (see section on FDG later in this chapter). The 
pro-apoptotic proteins BAD, caspase 9, and FOXO are also inhibited by Akt, The 
activity of the anti-apoptotic proteins; malignant target of rapamycin (MTOR), HIF-1a, 
and c-AMP response element binding protein (CREB) are stimulated by Akt. In breast 
cancer, tumours which were positive for activated-Akt have been shown to be more 
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resistant to endocrine treatment than those which were negative(Tokunaga et al. 
2006). 
Figure 1.5: PIP3/Akt Signalling pathway 
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1.4.4 mTOR 
Recent studies suggest that the ras and PIS kinase pathways form an 
intersecting biochemical network which converges on the serine/threonine kinase 
mTOR to stimulate cell growth(Shaw et al. 2006). Translation by the mTOR complex, 
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mTORCI, is responsible for controlling the cell-growth regulator HIF-1a, which in turn 
drives cell growth, glycolysis, and angiogenesis. Rapamycin treatment of a breast 
cancer mouse model with an activated PI3 kinase pathway resulted in decreased 
proliferation, angiogenesis, and increased apoptosis in premalignant and malignant 
lesions(Namba et al. 2006). ErbB2 increases angiogenesis and the metastatic 
potential of breast cancer cells via production of vascular endothelial growrth factor 
(VEGF) which is mediated by ERK/AKT/PIS kinase and mTOR (Klos et al. 2006). In 
nutrient-poor conditions mTOR is inhibited through the LKB1 pathway(Shaw et al. 
2004). 
The recent advances in understanding the mechanisms above which drive 
cancer proliferation will aid in the developments of new molecular based treatments. 
Studies to prove the validity of these targets are ongoing (Johnston 2006; Klos et al. 
2006). 
1.5 Angiogenesis 
In a seminal paper by Folkman in 1971, the necessity for tumours to develop 
their own blood supply was postulated. He believed that growing tumours need to 
develop new blood vessels. To do so they secrete an angiogenic factor (at that time 
named tumour angiogenic factor, TAP), and that by inhibiting angiogenesis tumour 
growth would be limited, see Figure 5 (Folkman 1971). Purification of the angiogenic 
factor, a cationic polypeptide, was finally achieved in 1984(Shing et al. 1984). Tumour 
enlargement greater than 2mm is dependent on what is now referred to as an 
angiogenic switch whereby proangiogenic factors outweigh angiogenic inhibitors 
resulting in neovascularisation. Currently 17 proangiogenic factors have been isolated 
(see Table 1.2). Physiological angiogenesis only occurs in endometrial endothelium, 
wound healing and inflammation. In other tissues angiogenesis is inhibited by 
angiogenic inhibitors such as thrombospondin-1. In the absence of angiogenesis 
tumours enter a dormant state characterised by a balance between proliferation and 
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apoptosis with a volume of a few mm^ (i.e. 10^-10® cells). Tumour angiogenesis also 
encourages metastatic spread by providing a route for cells to escape through the 
systemic circulation (Folkman 2002; Carmeliet 2005) to distant sites. 
Figure 1.6: Folkman model of tumour anqioqenesis 
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Tumour angiogenesis has recently become a key target in therapeutics. Most 
agents are directed towards vascular endothelial growth factor (VEGF) Although the 
early clinical trials of some angiogenesis inhibitors was complicated by adverse 
reactions, bevacizumab, a humanised monoclonal antibody targeted towards VEGF is 
now licensed in combination with 5-fluorouracil for the treatment of metastatic 
colorectal cancer. Bevacizumab acts by binding the VEGF ligand and preventing 
receptor binding and signal transduction. 
The main anti-angiogenic agents which have been developed are designed to 
target the VEGF ligand or inhibit matrix metalloproteinases(Cooney et al. 2006). 
integrins have been explored as a therapeutic target. Inhibition of endothelium derived 
nitric oxide synthase (an angiogenesis promoter) has been shown to inhibit expression 
of the avPa integrin(Murohara et al. 1999). A humanised monoclonal antibody to the 
avPa integrin, Vitaxin, has been developed and reached phase 1 clinical trials in 
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patients with metastatic cancer. Although only a small group of patients were treated, 
disease stabilisation lasting 22 months occurred in 1 patient (Gutheil et al. 2000; Posey 
et al. 2001). Cilengitide is an RGD peptide which has shown promising results when 
given in combination with radioimmunotherapy in a preclinical breast cancer 
model(Burke et al. 2002). Increased apoptosis of tumour and endothelial cells was 
noticed in mice treated with cilengitide and radioimmunotherapy compared to 
radioimmunotherapy alone(Burke et al. 2002). This agent has now entered phase 1/2 
clinical trials in metastatic cancer patients (Eskens et al. 2003). 
In breast cancer, angiogenesis is associated with a more aggressive 
phenotype. A study of 197 patients with node-positive and node-negative breast 
cancer found that expression of avPa integrin was the most important predictor of 
relapse-free survival (Gasparini et al. 1998). The avPs integrin is expressed on 
endothelial cells, osteoclasts, and melanoma cells. avPa supports adhesion and 
migration of breast, melanoma, and prostate tumour cells on bone matrix 
proteins(Sung et al. 1998; Byzova et al. 2000; Cooper et al. 2002; Nemeth et al. 2003), 
The effect of growth factors such as EGF, insulin, and PDGF on mitosis is potentiated 
by avPa integrin, integrin mediated cell attachment can even result in transactivation of 
growth factor receptors in the absence of their cognate ligands. 
The Chalkley count determines the vessel content in immunostained 
cryosections as the relative area of the immunostained vessels expressed as an index. 
Breast tumour angiogenesis was measured using the Chalkley count in 836 patients 
by Hansen et al, and found to correlate strongly with the presence of lymph node 
metastases, tumour grade, and large tumour size(Hansen et al. 2000). The authors 
found that estimation of tumour angiogenesis using this method was an independent 
prognostic factor, i.e. there was an inverse correlation between Chalkley count with 
recurrence free and overall survival. VEGF expression also correlates with risk and 
40 
outcomes in breast cancer, and is associated witli tumour resistance to tamoxifen and 
chemotherapy(Foekens et al. 2001). 
Many commonly prescribed treatments for breast cancer also have an anti-
angiogenic mode of action. The anti-angiogenic activity of tamoxifen is due to direct 
inhibition of VEGF and basic fibroblastic growth factor (bFGF), which is independent of 
oestradiol (Gagliardi et al. 1993; Gagliardi et al. 1996).The anti-angiogenic action is 
thought to be enhanced by metronomic scheduling of treatment, whereby low doses of 
drugs are given for prolonged periods(Hanahan et al. 2000). This is in contrast to the 
typical scenario for cytotoxic agents where maximum tolerated doses (MTD) are given 
to promote cell kill. In a preclinical pancreatic islet cell tumour model, using upfront 
MTD chemotherapy with cyclophosphamide followed by metronomic therapy with the 
same drug combined with inhibition of VEGF and platelet derived growth factor, 
resulted in complete responses compared to MTD alone which led to initial tumour 
regression followed by rapid regrowth (Pietras et al. 2005). 
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Table 1.2; Human angiogenic growth factors and inhibitors 
Pro-angiogenic factors Angiogenesis Inhibitors 
Angiogenin Angioarrestin 
Angiopoietin-1 Angiostatin (plasminogen 
Del-1 fragment) 
Fibroblast growth factors: acidic Antiangiogenic antithrombin III 
(aFGF) and basic (bFGF) Cartilage-derived inhibitor (GDI) 
Follistatin CD59 complement fragment 
Granulocyte colony-stimulating Endostatin (collagen XVIII 
factor (G-CSF) fragment) 
Hepatocyte growth factor (HGF) Fibronectin fragment 
/scatter factor (SF) Gro-beta 
lnterleukin-8 (IL-8) Heparinases 
Leptin Heparin hexasaccharide 
Midkine fragment 
Placental growth factor Human chorionic gonadotropin 
Platelet-derived endothelial cell (hCG) 
growth factor (PD-ECGF) Interferon alpha/beta/gamma 
Platelet-derived growth factor-BB Interferon inducible protein (IP-
(PDGF-BB) 10) 
Pleiotrophin (PTN) lnterleukin-12 
Progranulin Kringle 5 (plasminogen 
Proliferin fragment) 
Transforming growth factor-alpha Metalloproteinase inhibitors 
(TGF-alpha) (TIMPs) 
Transforming growth factor-beta 2-Methoxyestradiol 
(TGF-beta) Placental ribonuclease inhibitor 
Tumor necrosis factor-alpha Plasminogen activator inhibitor 
(TNF-alpha) Platelet factor-4 (PF4) 
Vascular endothelial growth Prolactin 16kD fragment 
factor (VEGF) Proliferin-related protein (PRP) 
Retinoids 
Tetrahydrocortisol-S 
Thrombospondin-1 (TSP-1) 
Transforming growth factor-beta 
(TGF-b) 
Vasculostatin 
Vasostatin (calreticulin fragment) 
1.5.1 Integrins 
One of the projects in this thesis will focus on an [18F]-labelled peptide which is 
proposed as a novel PET radiotracer for angiogenesis by binding to the avPs integrin. 
The integrins are a family of heterodimeric transmembrane proteins which act as an 
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integral membrane complexes involved in the transmembrane association between the 
extracellular matrix and the cytoskeleton (Tamkun et al. 1986). Integrins are formed by 
the noncovalent association of two subunits (a and P). To date 18a and 8p genes, 
which are capable of forming 24 different a-p combinations at the protein level, have 
been identified. Some subunits are present only in a single heterodimer, however 12 
contain the p i subunit and five contain the aV subunit. 
Integrins function as receptors for spatially restricted extracellular ligands 
including components of the extracellular matrix and several matrix associated growth-
factors and proteases. The ligand specificity is mainly determined by the composition 
of the heterodimer. The structure of the heterodimer is composed of a large 
extracellular domain (1000 amino acids for a and 750 amino acids for P), a single 
transmembrane domain (22-24 amino acids), and a short cytoplasmic tail (15 to 58 
amino acids, apart from the P4 subunit which contains 1000 residues). On the 
extracellular surface integrins engage extracellular matrix macromolecules or co-
receptors on adjacent cell surfaces. Integrins in the cytoplasm co-ordinate signalling 
complexes and cytoskeletal polymers. 
Therefore, integrins are seen to have a crucial role in the tissue 
microenvironrnent, cell movement, and differentiation(Bokel et al. 2002). In non-ligated 
integrins (i.e. resting), the p domain interacts with the a domain, maintaining the 
receptor as inactive. When the cytoplasmic protein talin binds to the cytoplasmic p 
domain the integrin becomes activated and capable of binding extracellular ligands, 
which initiate cytoskeletal rearrangement and cell signalling (Calderwood et al. 2002), 
Integrins themselves lack enzymatic activity; therefore they need to recruit 
cytoplasmic structural (e.g. talin) and signalling proteins (e.g. Src kinases) to initiate 
signal transduction. The activation of signalling pathways by growth factors is 
enhanced by concomitant activation of integrins (Alghisi et al. 2006),Integrins are 
capable of binding to multiple ligands, and many ligands are capable of binding to 
multiple integrin receptors. The most important of the ligand-integrin reactions are 
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summarised in Table 1.3. Integrin-ligand interactions can be divided into four main 
groups based on the molecular structure of the interaction, namely: arginine-glycine-
aspartate (RGD) binding, an acidic motif (LDV) functionally related to RGD, A-domain 
(31 integrins which are involved in collagen and laminin binding, and non-aA-domain-
containing laminin binding integrins(Humphries et al. 2006). 
The role of integrins in stimulating angiogenesis is accomplished via four main 
signalling pathw/ays; Ras-MAPK, PI3K/Akt, Rho-family GTPases, and NF-KB (Giancotti 
et al. 1999; Del Pozo et al. 2002; Stupack et al. 2002). 
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Table 1.3: Integrins and their ligands 
Ligand Integrin 
Vitronectin allbps, a8p1, aVp3, aVpS 
Von Willebrands Factor aVp3, allbp3 
PECAM-1 (platelet endothelial cell adhesion 
molecule 1) 
Tenascin 
aVp3 
a9pi , a8pi 
LAP-TGF-P (latency assoc. peptide 
transforming growth factor P) 
Fibrillin 
aVp3, aVp6, aVpS, aVpi 
aVp3 
Fibrinogen aVp3, aMp2, aXp2, allbp3 
Factor X aMp2 
iC3b (Inactivated complement component 3b) aMp2, aXp2 
E-cadherin aEp7 
Collagen a10pi , a2pi , a i p i , a 1 i p i 
Laminin 
Thrombospondin 
a10p1, a2p1, a i p i , a7p i , a6p4, a6pi , 
a3p1 
a3pi , a2pi , a4pi , avp3, allbp3 
ICAM (intercellular cell adhesion molecule) aXp2, aMp2. aLp2, aDp2 
MAdCAM-1 (mucosal addressin cell adhesion 
molecule 1) 
VCAM-1 (vascular cell adhesion molecule 1) 
a4p7, a4pi 
aDp2, a9pi , a4p7, a4p1 
Fibronectin 
Osteopontin 
MFG-E8, Del-1 (milk fat globule EGF factor 8) 
a4pi , a4p7, a8pi , aSpi, 
aVp3, allbp3 
a4pi , a4p7, a8p1, a5p1, 
aVp6, aVp3, aVpS 
aVp3, aVpS 
aVpi , 
a9pi , 
avpe, 
aVp1. 
BSP (bone sialoprotein) aVp3, aVp5 
The role of the avPs integrin in angiogenesis was first established by studying 
the effects of a cyclic peptide and monoclonal antibody antagonist to avPa on tumours 
implanted onto chick chorioallantioic membrane(Brooks et al. 1994). Treatment with 
antagonists led to tumour regression and apoptosis of the proliferative angiogenic 
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cells. Using the same model, it was found that the peptide inhibited neovascularisation 
induced by basic fibroblastic growth factor (bFGF), tumour necrosis factor a (TNFa), 
and human melanoma fragments; but no effect was found on pre-existing 
vessels(Brooks et al. 1994). The explanation of inhibition of angiogenesis being 
dependent on a single integrin is countered by the fact that proliferative endothelial 
cells express multiple integrins. However sustained MARK activity in chick 
chorioallantoic membranes is dependent on the avPs integrin (Eliceiri et al. 1998). 
Expression of non-ligated Psand Ps integrins activate a caspase 8 cell death pathway, 
on the other hand Pa and Ps integrin ligation prevents this pathway from causing cell 
death and increases cell survival(Stupack et al. 2001). 
1.6 Current methods for studying cell proliferation and angiogenesis 
1.6.1 Proliferation 
For several years proliferation has been assessed by microscopic analysis of 
mitoses (Kempson 1976). The mitotic count is defined as the number of mitoses per 
high power field. Although commonly used in clinical practice it is subject to limitations, 
including inter-observer variation, different methods of analysis, no account of cell size, 
and the results may be affected by the time delay between surgery and fixation (Quinn 
et al. 1990; Thunnissen et al. 2001). The mitotic index is the number of mitoses 
expressed as a percentage of the number of interphase nuclei counted, usually 1000. 
Although this is more standardised than the mitotic count, it is also more laborious to 
measure. 
Alternatively, immunohistochemistry can be performed to analyse cell cycle 
proteins, Ki67 and proliferation cell nuclear antigen (PCNA). Ki67 is a 395kDa protein, 
which undergoes phosphorylation and dephosphorylation during mitosis(MacCallum et 
al. 1999). It is subject to proteolytic degradation, and its localisation within the nucleus 
changes during the cell cycle(Schluter et al. 1993). Expression of Ki67 rises in late Gi 
to peak at M phase, and is low in newly divided cells (MacCallum et al. 1999; Shaw et 
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al. 2004). Whilst the function of Ki67 remains unclear, it appears to be vital for cell 
proliferation as its removal using antisense oligonucleotides prevents cell 
proliferation(Schluter et al. 1993). 
Ki67 can be assayed using a monoclonal antibody to Ki67, or MIB1 antibody, 
which is directed towards an epitope of the Ki67 antigen. The advantage of MIB1 is 
that it can be used in formalin fixed tissue, whereas the monoclonal antibody to Ki67 
can only be used in fresh frozen tissue(Brown et al. 2002). Ki67 immunohistochemical 
staining has been shown to be of prognostic value in breast cancer (Jacquemier et al. 
1998; Haubner et al. 2005), and in subtypes of lymphoma where it may correlate with 
both survival and relapse-free survival (d'Argy et al. 1988; Abele et al. 1997; Mochen 
et al. 1997; Korkolopoulou et al. 2001; Ramirez de Molina et al. 2002). In colorectal 
cancer most studies suggest no correlation between Ki67 and overall survival in the 
primary tumour, although one study has shown correlation between Ki67 expression 
and metastatic disease (Kyzer et al. 1997; Brown et al. 2002). The less clear 
agreement between Ki67 and survival has also been shown in cervical cancer 
(Coleman 1991; Tsang et al. 1999; Pollen et al. 2001; Graflund et al. 2002; Perumal et 
al. 2006). Ki67 immunohistochemistry has found a role in diagnosis by differentiating 
benign from malignant disease, such as follicular hyperplasia from lymphoma (Brown 
et al. 2002). 
PCNA is involved in both DNA repair and synthesis and functions as an 
auxiliary protein for DNA polymerase-5(Bravo et al. 1987). Expression of PCNA is 
higher in late Gl-phase, S-phase, and early G2 phase, than in quiescent 
ceils(McCormick et al. 1992). It is tightly bound in the nucleus during DNA replication. 
PC10, 19A2, and 19F4 are amongst the monoclonal antibodies available for the 
detection of PCNA(Hall et al. 1990). Although PCNA can be detected in formalin fixed 
tissue, levels of expression change depending on the length and mode of 
fixation(Rowlands et al. 1991). PCNA is a useful prognostic marker in gastric cancer 
(Schipper et al. 1998). 
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The proportion of cells in S-phase is also a useful index of proliferation. Flow 
cytometry can be used to measure the percentage of cells in S phase (the S phase 
fraction). Results from such studies have been shown to be of prognostic importance 
in primary and metastatic breast cancer (Chassevent et al. 2001; Chang et al. 2003) 
and non-Hodgkins lymphoma(Pauwels et al. 2000). The results may be affected by 
technical difficulties in creating a suspension of single cells, and some conflict remains 
as to whether formalin fixed tissue is as beneficial as fresh tissue for analysis (Hall P.A 
1991). 
[3H]-thymidine is the gold standard for measuring the percentage of cells in the 
S phase in vitro (known as the labelling index, LI). This tracer has been used for many 
years for autoradiography and flow cytometry. Cell cultures are treated or animals 
injected with [^H]-thymidine and cells analysed or animals sacrificed and tumours 
analysed one hour later. Thymidine metabolites are washed away during processing 
and mitotic cells counted using auto radiographic techniques. The procedure is slow, 
involves manual counting, and takes several weeks for the auto radiographic film to be 
developed. Replacement of the methyl group of thymidine with iodine or bromine 
yields iodo- or bromo-deoxyuridine (lUdR, BrdU), which can be used in vitro or in vivo 
and are incorporated into cells that are synthesizing DNA. Monoclonal antibodies or 
fluorescent dyes in combination with a laser cytometer detect the BrdU- or lUdR-
labelled cells obtained from biopsies(Rew et al. 2000). 
1.6.2 Angiogenesis 
In relation to studying the rate of tumour angiogenesis, the ideal would be to 
study the number of new vessels developed in a region or change in vascular surface 
area per day. Whilst this is an attractive concept, it is limited to normal tissues with 
stable populations of cells as proliferation of the tumour cells in addition to vascular 
endothelium makes such assessments and determination of end-points difficult. 
Scientists have relied upon microvessel density (MVD) counted in samples from 
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tumour biopsies as an alternative measure. The limitations of this technique are the 
invasiveness of the biopsy procedure, and the heterogeneity of tumour angiogenesis 
as MVD is rarely uniform(Eberhard et al. 2000). As the tumour becomes larger in size, 
central areas may become necrotic whilst still having active angiogenesis at the 
periphery. Unless the biopsy includes the active area (also known as the "hot spot") 
then incorrect conclusions may be drawn, rendering quantification of response to 
treatment difficult. 
The Chalkley point grid overlay morphometric technique provides an objective 
estimate of MVD rather than exact MVD and is calculated by counting the number of 
grid points which hit stained microvessels(Fox et al. 1995). High Chalkley counts were 
predictive of overall survival in a study of patients node negative and node positive 
breast cancer(Hansen et al. 2000) .As MVD is a ratio of tumour cells to vessels, 
changes in either component will affect the overall MVD. The fraction of apoptotic 
endothelial cells also needs to be considered in addition to the MVD, and can be 
measured using immunohistochemical measurement of single stranded 
DNA(Chalmers et al. 2006), or the terminal deoxynucleotidyl transferase-mediated 
nick-end labelling (TUNEL) assay which labels 3' free hydroxyl ends of fragmented 
DNA with flourescein-dUTP catalyzed by terminal deoxynucleotidyl 
transferase(Matsunaga et al. 2004). Anti-angiogenic therapy may be successful in 
reducing the number of endothelial cells and, as a consequence, the number of viable 
tumour cells may also decrease without a change in overall MVD. Tumour angiogenic 
factors also increase vascular permeability which is not a component of MVD. The 
same is also true for capillary size, which is abnormal in tumours and distorts the 
relationship between vessel number and blood volume (Miller et al. 2005). 
A consensus has been reached for the determination of angiogenesis in tumour 
specimens(Vermeulen et al. 2002). Endothelial cell fraction is determined by double 
immunostaining biopsies with separate antibodies for the tumour (such as Ki-67) and 
the endothelium. A ratio of tumour cell proliferation to endothelial cell proliferation can 
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thus be obtained. Pericyte recruitment to the tumour microvasculature is thought to be 
indicative of vessel maturation. The pericyte coverage index uses immunostaining for 
CD34, CD31, and actin in tumour and adjacent normal tissue. The principle for this 
method came from observations in the post-natal retina that blood vessel remodelling 
is only possible in the absence of a pericyte covering(Benjamin et al. 1998). 
Imaging of tumour vasculature can be used to study vascular parameters 
including blood flow, blood volume, semiquantitative and quantitative kinetic 
haemodynamic parameters. Sensitive techniques to measure such parameters include 
dynamic contrast enhanced computed tomography (CT) or magnetic resonance 
imaging (MRI), PET and ultrasound using microbubble technology. [150]H20-PET is 
the most accurate method for determining tissue blood flow(Miller et al. 2005). The 
short half-life of 2 minutes precludes using the tracer outside centres with an on-site 
cyclotron. An alternative strategy is to image molecular markers of angiogenesis; the 
targets for such tracers include VEGF-receptor 2, av33 integrin, endoglin, and 
endosialin. With the exception of radiolabelled water PET studies, the imaging 
methods mentioned above are still in development. 
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1.7 Clinical response assessment to cancer therapy 
Despite recent advances in the development of novel targeted therapeutics, the 
options of methods for response assessment to anti-cancer treatment rely largely upon 
physical changes in tumour volume. As a surrogate to tumour volume, criteria have 
been developed to define clinical response in solid tumours by using changes in the 
maximum target lesion(s) diameter, known as the Response Evaluation Criteria in 
Solid Tumours (RECIST)(Therasse et al. 2000), see table 1.4. 
Table 1.4: The RECIST Criteria 
Complete response Complete resolution of all target lesions 
Partial response Decrease of s 30% of longest diameter 
Stable disease Neither partial response or progressive disease 
Progressive disease More than 20% increase in size 
The lesion diameter changes can be assessed in several ways: clinical 
examination, ultrasound, computed tomography (CT), or magnetic resonance imaging 
(MRI). The tests mentioned above for detecting physical changes in tumour volume 
have limitations, for each method there will be inherent variable sensitivity and 
specificity dependent on the type of scanner, operator, and tumour (size, location, and 
histological type). A recent study, which evaluated clinical examination, ultrasound, 
mammography, and MRI in patients who received neoadjuvant treatment for breast 
cancer found that the accuracy for predicting complete pathological response was 75, 
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89, 82, and 89% respectively, and recommended that patients continue to have 
histological confirmation of response(Schott et al. 2005). 
Recently, the logic for using RECIST for new treatments has been questioned, 
as it is unlikely to be appropriate for treatments which result in cytostasis (Michaelis et 
al. 2006). Indeed any treatment which results in necrosis, apoptosis, or development of 
inflammation may not produce a decrease in physical tumour size and therefore be 
wrongly categorised as ineffective due to a lack of response by RECIST. The 
identification of progressive disease may be delayed when using the RECIST criteria 
compared to using the previous standard World Health Organsiation (WHO) criteria, 
which were based on the product of the maximum bidimensional tumour 
diameter(Therasse et al. 2006). The lack of a physical response on standard 
anatomical imaging may cause the failure of new compounds to progress beyond 
phase II clinical trials as size reductions of 15-20% are often expected from previous 
experience with cytotoxic agents(Ratain et al. 1993). PET has been found to be more 
accurate than CT for predicting early response of gastrointestinal stromal tumours to 
imatinib(Antoch et al. 2004). 
One alternative has been to use time to progression (TTP) or progression free 
survival (PFS) as surrogate endpoints for the assessment of cytostatic agents in phase 
II trials. PFS does directly relate to patient benefit, which is not always the case with 
physical tumour size reduction. However the use of TTP is biased as it depends on 
how frequently evaluation is performed. The use of a control group (treated with an 
alternative agent) who are evaluated at the same time intervals could reduce this bias, 
but also requires larger numbers of patients entered into the study and results in 
increased expenditure(Michaelis et al. 2006). 
An index of tumour viability before and after treatment is clearly required. The 
measurement of tumour antigens, which are detectable in serum (such as prostate 
specific antigen (PSA), carcinoembryonic antigen (CEA) and Ca-125) has been utilised 
for some years; however the sensitivity of such tests remains problematic. Serological 
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tumour markers for monitoring response should reflect tumour burden; an inherent 
principle in their use is the assumption that there is homogeneity of production of the 
marker by the entire tumour population which may not actually be the case. 
A biomarker has recently been defined by the FDA in the United States as "a 
characteristic that is objectively measured and evaluated as an indicator of biologic 
processes, pathological processes, or pharmacologic responses to therapeutic 
intervention". Surrogate markers are seen as those which measure the drug effect 
without directly measuring the drug target. The ideal biomarker should be sensitive and 
specific, easily accessible for collection, simple and adaptable for clinical use. Simply 
because a tumour expresses a specific biomarker doesn't guarantee 100% therapeutic 
success for target-specific agents. In this regard, the pharmacokinetics of the drug are 
important, i.e. absorption of the drug, delivery of the drug to the target in sufficient 
quantities, metabolism (which can be affected by polymorphisms in cytochrome 
p450s), and excretion (which can decrease in patients with renal and hepatic 
impairment). 
Tumour cells may possess additional molecular abnormalities allowing indirect 
down-stream activation of signalling cascades and bypassing the initial target. 
Heterotypia in the receptor phenotype is a real phenomenon, as demonstrated recently 
by lack of response in lung cancer patients to the EGFR inhibitor gefitinib. A point 
mutation in tumour DNA which resulted in a threonine-methionine amino acid switch at 
position 790 in the EGFR receptor was found to be responsible (Kobayashi et al. 
2005). Alternative strategies involving biomarkers to predict response to treatment are 
currently being explored; these include the rapidly expanding fields of proteomics and 
gene expression profiling. These latter methods may, in the future, permit 
individualisation of treatment but require further wide scale validation before they can 
be incorporated into routine clinical care. 
Response assessment needs be optomised and become more specific to the 
treatment target(s). Increased accuracy in determining response will enable patient 
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outcomes to improve, minimise prolonged courses of ineffective treatments together 
with their associated potential toxicities. The outlook for patients with advanced cancer 
remains bleak. If drug resistance could be predicted early then treatment could be 
tailored to an alternative agent with a superior anti-cancer effect. In this regard, a 
unique opportunity exists for molecular imaging of biological processes and of the 
signal transduction pathways which drive them as a predictive clinical tool. 
1.7.1 Tumour tissue 
Sampling of tumour tissue can be obtained at surgery during excision, or as a 
core or fine needle aspirate. Imaging technologies such as ultrasound or computed 
axial tomography (CT) may be necessary to guide the procedure. The tissue can then 
be snap frozen in liquid nitrogen and used later for Western blotting and polymerase 
chain reaction (PGR). Other samples are stored in paraffin prior to haematoxylin and 
eosin (H+E) or stained for specific molecular markers using immunohistochemistry and 
analysed by a pathologist. Tumour heterogeneity is a significant challenge, and 
biomarkers may additionally label connective tissue and stroma as well as tumour 
cells. To address these issues multiple biopsies are often performed, and techniques 
such as laser capture microdissection have been developed to obtain pure cell 
populations for isolation of DNA, RNA, and protein. High-throughput analysis of these 
samples can be achieved by using cDNA expression microarrays. 
The other challenges in using tumour tissue from patients for biomarker assays 
include the invasiveness and safety of the biopsy procedure limiting the ability to 
perform serial measurements, sampling errors, and the finite amount of available 
tissue. The anatomical location of the tumour or tumour metastasis may in fact 
preclude biopsy. Obtaining biopsies to assess drug pharmacodynamics is usually 
performed as a research procedure, and may be difficult to justify ethically or obtain 
patient consent where there is no expected therapeutic gain to the individual patient. 
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1.7.2 In Vitro and Preclinical systems for evaluating tumour response 
When choosing a surrogate tissue, i.e. a tissue other than the actual tumour, 
the ability to detect marker expression is crucial, for example skin biopsies are suitable 
for detecting EGFR but not phosphorylated ERK. One of the main disadvantages for 
using surrogate tissue instead of tumour is that it may not accurately reflect tumour 
biological events. To date few studies have been published which correlate the 
pharmacodynamic effects in surrogate tissue with that of tumour. 
Peripheral blood mononuclear cells (PBM) are the most commonly used 
surrogate, primarily because of the ease of access - samples can be obtained by any 
health care worker trained in phlebotomy. Typically a 10ml sample of peripheral blood 
is taken and centrifuged at room temperature for 15 min at 2500 rpm. The 
mononuclear cell layer is then diluted with PBS to 50 ml and sedimented at 1200rpm 
for 10 min(Di Paolo et al. 2007). The cells are then re-suspended and counted. Finally 
the iysates are dialyzed and lypohiiized, subjected to electrophoresis on SDS-
polyacrylamide gels, transferred to nitrocellulose, and probed with the relevant primary 
and secondary antibodies. 
Skin sampling is also relatively non-invasive and can be performed as an 
outpatient procedure. Multiple biopsies can be taken with minimal morbidity. The 
development of gefitinib (an epidermal growth factor receptor, EGFR, inhibitor) is an 
example of where skin biopsies provided an important role in assessing drug 
pharmacodynamics. Typically 0.5cm^ of tissue is taken and then either studied 
immediately, frozen or embedded in paraffin for analysis later. This technique is useful 
for immunohistochemistry and analyses which depend upon the PGR, but 
unfortunately the amount of tissue is insufficient for Western blotting. 
Buccal mucosa cells are the easiest surrogate tissue to obtain, their 
procurement is painless and can be achieved by any healthcare worker. Due to their 
high turnover rate, they are useful in the study of anti-proliferative agents (Adjei et al. 
2003). Like skin however, the size of the samples limits their utility to 
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immunohistochemistry and PGR. The technique involves patients fasting, as digestive 
enzymes in the mouth may reduce the number of cells available and interfere with the 
results. Immediately prior to sampling patients rinse their mouths with 100 ml of saline 
twice, and then a wooden tongue depressor is used to scrape the inside of the mouth. 
The samples (usually four in total) are then spread onto separate microscope slides 
and then dried and fixed in acetone prior to storage(Bartelink et al. 2000). 
The use of such systems depends upon the same pathways and same dose 
response relationship being present in the tumour as in the surrogate tissue. Drug 
resistance mechanisms present in the surrogate tissue are also important. The use of 
surrogate tissues still requires further validation leaving the gold standard as tumour 
biopsies. 
In the preclinical setting (in vivo and in vitro), tumours can be selectively 
modified to optimise the assay with gene transfections and knockouts, experiments 
can be performed multiple times with the same cell population, and homogeneity exists 
in the cell lines and animal models used for hypothesis testing. Pre-clinical evaluation 
of tumour chemosensitivity is essential for drug development. Tumour xenografts 
represent one of the most common mechanisms for this approach, and provide an 
excellent method of target validation. In vitro studies of biopsy tissue and cell cultures 
have the ability to detect changes in molecular biology which lead to tumour growrth 
and sensitivity. Several factors such as the host environment, tumour genotype, and 
immune system are challenges of this methodology. Translation into clinical practice is 
not always straightforward, for example striking responses seen in mouse tumours 
treated with the anti-angiogenic agent endostatin were not translated into human 
response(0'Reilly et al. 1997; Herbst et al. 2002). 
In vitro assays can be used to test chemosensitivity or chemoresistance of 
tumour cells(Krasna et al. 2003). The assays comprise of 4 basic steps: isolation of 
cells, incubation of cells with drugs, measurement of cell survival, and interpretation of 
the result. Although chemoresistance assays have a high predictive value for excluding 
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ineffective drugs, no prospective trial using either chemosensitivity or chemoresistance 
assays lias been shov\/n to improve patient survival. For example, such an in vitro 
assay was used to evaluate cytotoxic chemotherapy in 77 patients with breast and 
ovarian tumours and compared to clinical response. The overall positive predictive 
value for chemosensitivity was only 50%, however the negative predictive value (i.e. 
for chemoresistance was 100%)(Agiostratidou et al. 2001).Whilst chemosensitivity 
assays remain an exciting concept in drug development, their use is currently not 
recommended outside a clinical trial setting(Schrag et al. 2004). 
Human xenografts, transgenic, and orthoptic models. 
The models described below are commonly used in drug development today. 
Fundamentally what is required is a model which is accurately predictive of clinical 
response in humans. Murine models were initially developed 50 years ago. The use of 
human xenografts in immunodeficient mice has played a vital role in assessing anti-
tumour activity of new drugs(Sausville et al. 2006). Typically the mice are divided into a 
treatment and control group, and response is defined by size reduction of the 
transplanted tumour. Limitations of the technique include the rapidity of tumour growth 
compared to humans, absence of metastases, expense, and lack of characterisation of 
response at the molecular target. Implantation of human tumours in mice may affect 
tumour biological features such as their metastatic potential which can be much lower 
in the mice compared to patients, though the correlation with human tumours is 
thought to be better for orthoptically transplanted tumours compared to tumours which 
are transplanted into subcutaneous or intramuscular sites. Despite the massive efforts 
in research using xenografts, only a limited number of drugs which are clinically active 
at well tolerated doses have been developed(Troiani et al. 2008). 
Orthoptic models (where the tumour is implanted into their natural sites) offer 
an alternative to xenografts, as do transgenic models where spontaneous 
development of specific tumours occurs due to oncogene transfections(Hoffman 1999). 
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Examples of such models include spontaneous orthoptic bone metastasis models of 
breast, prostate, and lung cancer. 
Over the past two decades preclinical evaluation systems have evolved from 
testing non-specific cytotoxic agents in general tumour types to target specific 
systems. By using PET in a preclinical setting, valuable information about precise 
mechanisms of drug resistance can be obtained and correlated with specific 
biomarkers from ex-vivo tumour specimens. MicroPET systems are essential for the 
development of new PET radiotracers, and are now being recognised as a method 
which can expedite drug development. This technology allows correlation of in vivo 
PET data with events happening at the molecular level enabling technologies such as 
gene therapy and hypoxia probes to be developed (Groot-Wassink et al. 2002; Barthel 
et al. 2004). 
1.8 PET As A Tumour Biomarker 
One technique which has already gained wide acceptance as an imaging 
biomarker is positron emission tomography (PET) using 2-[18F]fluorodeoxyglucose 
(FDG) (Larson et al. 2006). PET is the most sensitive method for imaging molecular 
processes in vivo. By imaging regions in their entirety it can provide a quantitative 
measure of regional variation in metabolic processes. Compared to other methods for 
studying molecular processes that typically involve biopsies, PET is non-invasive 
which enables serial studies to be performed. Criteria and recommendations for using 
FDG-PET to stage and measuring tumour response to treatment have been 
established (Young et al. 1999). 
In America FDG-PET scans are reimbursable for the following tumours/lesions: 
solitary pulmonary nodule, non-small cell lung cancer, oesophageal cancer, colorectal 
cancer, melanoma, lymphoma, head and neck (excluding central nervous system), 
breast, and cervical cancer(Czernin et al. 2002). The majority of indications in 
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oncology are for diagnosis and staging; apart from breast cancer where there is an 
allowance for monitoring response of locally advanced and metastatic disease when a 
change in therapy is anticipated(Czernin et al. 2002). 
FDG is the most commonly used tracer for PET studies, however changes in 
FDG uptake may occur due to other biological processes which affect glucose 
metabolism such as inflammation. More specific radiotracers are currently being 
developed. Probes for PET are developed by identifying a target process and then 
synthesizing a positron-labelled molecule which can be used as a surrogate biological 
assay. Generally, the PET imaging probe traces between one and four steps of a 
biochemical process. This enables kinetic analysis to estimate the concentration of the 
reactants over time and measure the rate of the process. 
In drug development, pharmacokinetic studies of tracer doses of radiolabelled 
drugs can be given as a pre-Phase 1 clinical trial, or as part of phase 1 and 2 studies 
(Aboagye et al. 2003). PET can provide information about the distribution, excretion, 
and metabolism of drug in tumours and normal tissue. Examples of drugs which have 
been directly labelled with radioisotopes and used as PET probes include: a 
methylating agent used in the treatment of glioma [11C]temozoloamide (Brown et al. 
2002), the alkylating agent [11C]-1,3,bis(2-choloroethyl)-1-nitrosurea(BCNU) (Tyler et 
al. 1986), a topoisomerase inhibitor [11C]-N-[2-9dimethylamino)ethyl]acridine-4-
carboxamide (DACA)(Brady et al. 1997), [13N]cisplatin (Ginos et al. 1987), the anti-
pyrimidine [18F]-5-fluoruracil (Dimitrakopoulou-Strauss et al. 1998), and 
[18F]tamoxifen(lnoue et al. 1996). 
PET-based pharmacodynamic studies can utilise selective or generic biological 
endpoints. Typical examples of generic endpoints include changes in glucose 
utilisation (FDG), proliferation ([11C]thymidine or [18F]fluorothymidine), amino acid 
metabolism ([11C]methionine or methyl-fluorodopa), and tricarboxylic acid cycle 
activity (using [11C]acetate). Specific biological endpoints using selective tracers 
include: thymidylate synthase inhibition using [1 ICJthymidine (Wells et al. 2003), 
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hypoxia using [18F] labelled nitroimidazoles(Valk et al. 1992; Rasey et al. 2000), and 
detection of oestrogen receptor status and Erbb2 status with 16-a-[18F]-17-p-
oestradiol(Mortimer et al. 1996) and [68Ga] labelled trastuzumab(Smith-Jones et al. 
2006), respectively. With the exception of FDG, validation studies are being performed 
to assess the clinical utility of these probes. 
The anatomical resolution of PET images is low, however combination of PET 
with CT or MRI should optomise lesion detection and monitoring(Delbeke et al. 2006). 
The metabolism of the PET tracer is also an important consideration as PET cannot 
distinguish between the injected compound (referred to as the parent) and its 
metabolites. Therefore PET probes should ideally be metabolised slowly, otherwise a 
method for calculating the concentration of metabolites is required to determine their 
contribution to the PET signal from a region of interest(Shields et al. 1992). The 
concentration of metabolites can be measured in arterial blood during dynamic studies 
calculated by sampling blood from the radial artery together with various correction 
methods. 
This thesis will focus on pharmacokinetic analyses of new radiotracers in 
clinical PET. Before discussing the specific PET radiotracers, a general overview of 
cancer imaging is presented below. 
1.9 Physical Imaging in Cancer 
Successful diagnosis and treatment response monitoring in cancer is dependent upon 
adequate imaging techniques. This section will focus on physical imaging, and will be 
followed by a more detailed explanation of molecular imaging technologies, with a 
focus on PET which is the subject of this thesis. 
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1.9.1 Ultrasound 
Ultrasound relies on sonar technology to form pictures of the region of the body 
being scanned. A transducer is held over the region and emits a high frequency sound 
wave which is then reflected back by the tissues at different rates (depending on their 
density) and detected by the transducer. Cystic structures do not return the signal such 
as the bladder will appear dark, and on the reverse solid structures such as stones 
appear white. 
The advantages of the technique are that it is painless, does not involve 
ionising radiation, the images reflect real-time, it can be used to assist other 
procedures e.g. needle biopsy of a breast mass, and compared to other technologies it 
is relatively straightforward to use and inexpensive. The disadvantages are that it has 
limited repeatability as it is highly operator dependent, obese patients may have 
suboptimal images due to body habitus interfering with sonar transduction, and finally it 
is not good for imaging bony and air-filled structures (such as the lungs). In oncology 
ultrasound is used mainly for the detection of metastases in the liver, breast imaging to 
determine the size and location of lesions, for detection of gynaecological cancers, and 
as said above, as a targeting aid for tumour biopsies. 
For studying breast cancer, ultrasound is optimal for detecting small lesions in 
pre-menopausal women with dense breasts and for differentiating solid from cystic 
lesions(Benson et al. 2004). In a study of 67 patients, breast ultrasound was found to 
underestimate the size of the tumour by 40% when compared to pathological findings 
(Van Goethem et al. 2004), and another study found a correlation of only 0.45 between 
ultrasound measurements and pathological size(Davis et al. 1996). Recent 
developments in ultrasound technology include the use of microbubbles as contrast 
agents e.g. for the detection of liver metastases(Blomley et al. 2002; Cosgrove et al. 
2004). The microbubbles are gas particles covered in lipid or lipoprotein shells which 
reflect sound leading to increased brightness on the ultrasound image. 
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1.9.2 X-ray 
X-ray is the most commonly used imaging modality in modern medicine today. 
The principle on which it is based involves directing a beam of photons through the 
patient onto a film, and the resulting image represents a map of tissue opaqueness to 
the photon beam. Different strengths of photons can also affect the image so that 
lower energies are used for mammograms (typically 40 kilovolts) compared to x-rays of 
more solid structures such as bone. 
Mammography is used for diagnosis of breast cancer both as a screening tool 
and in the assessment of symptomatic patients. It remains the test of choice in women 
with non-dense breasts. Typically suspicious areas are seen as abnormal 
microcalcifications. The limitations of mammography include its inability to separate 
tissues of different densities, and difficulties in detecting lobular carcinoma, Paget's 
disease of the nipple, inflammatory breast carcinoma, and small peripheral tumours. 
Computed tomography (CT) is a form of X-ray where the beam and detectors 
are physically rotated around the patient. The data are acquired in 2D and can be 
reconstructed to form 3D images, with excellent anatomical resolution. CT is 
commonly used for the staging of tumours and for monitoring response. In breast 
cancer, the main utility is for visceral metastases as its use is limited for detecting 
primary lesions. The dose of radiation in CT scans is viewed as moderate to high, for 
example the effective dose of a chest CT examination is 5.8mSv compared to 
0.01 mSv for a standard chest X-ray. 
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1.9.3 Magnetic Resonance Imaging (MR!) 
MRI is used widely to determine tumour morpliology, define tumour location, 
and extent of tumour size and depth of invasion into local and distant tissues. The use 
of gadolinium based contrast agents can provide additional information by enhancing 
visibility of lesions particularly in brain studies, where abnormal uptake can be seen in 
tumours due to abnormal blood vessel growth and/or breakdown of the blood-brain 
barrier. Dynamic contrast enhanced MRI (DCE-MRI) is used to obtain information of 
contrast uptake overtime so that kinetic parameters such as the permeability-surface 
area product and rate of uptake of the agent (Ktrans) from the vascular space can be 
defined(Padhani et al. 2004). 
Recently DCE-MRI was used to measure changes in tumour angiogenesis in 
inflammatory breast cancer treated with the anti-VEGF agent, bevacizumab (Wedam 
et al. 2006). Diffusion weighted MRI is used to measure parameters associated with 
the rate of diffusion of water molecules without the need for contrast. Functional MRI 
(fMRI) is relies upon venous oxygenation (i.e. deoxyhaemoglobin) to act as an 
endogenous contrast agent, so that local changes in deoxyhaemoglobin levels lead to 
altered signal intensity. To date the main utility of fMRI has been in neurological 
studies. 
The advantages of the aforementioned magnetic resonance techniques are the 
lack of radiation used and high spatial resolution of the produced images which allows 
in-depth studies of anatomy (which is higher for standard MRI compared to DCE-MRI 
and fMRI). The disadvantages include suboptimal imagining of bony structures, cost, 
and the inability to study patients with implanted objects such as cardiac pacemakers. 
In breast cancer, MR! is mainly used for tumours which are difficult to image by other 
techniques e.g. lobular carcinoma which has a diffuse growth pattern, and for 
diagnosing metastases to the central nervous system. 
Magnetic resonance spectroscopy (MRS) can distinguish and measure the 
concentration of different chemical compounds non-invasively. MRS provides distinct 
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chemical spectra instead of anatomical images. Biological processes such as 
proliferation and apoptosis can result in changes in the phospomonoester and 
fructose-1,6-biphosphate peaks. The radioisotopes used for MRS include: [1H], 
[13C],[19F] and [31P], MRS studies can be combined with MRI as a useful tool for 
drug development, although the sensitivity of MRS needs to be improved for 
pharmacokinetic studies as currently only drugs given in quantities of s0.5g/m^ can be 
detected (Workman et al. 2006). 
1.10 Nuclear Imaging 
Nuclear imaging employs a gamma camera to detect gamma rays emitted by 
compounds labelled with radioisotopes to study human anatomy and physiology. The 
radionuclide can be administered to patients via inhalation, injection, or ingestion. 
1.10.1 The Gamma Camera 
The gamma camera was invented by H. Anger in 1952, and further modified in 
1957 by the addition of photomultiplier tubes. Since then, it has changed little since its 
original design and is widely used in clinical medicine today. One of the commonest 
isotopes used for radiolabelling compounds under study is Technetium 99m, which has 
a half-life of 6 hours. 
After emission from the body, the gamma particles pass through a collimator 
and are projected onto a detector crystal made of thallium-activated sodium iodide. 
The rays then react with the iodide ions of the crystal by the photoelectric effect or 
Compton scattering to cause the release of electrons, which in turn react with the 
lattice of the crystal to produce light by a process known as scintillation. The light is 
detected by photomultiplier tubes which lie behind the crystal and converts the energy 
into electrons. As only a small amount of light is emitted by the scintillation detector, 
the electron signal is multiplied many times by the photomultiplier tubes into a large 
cluster of electrons which are converted into an electrical pulse by an anode at the 
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base of the photomultiplier tube. A typical gamma camera contains 37-91 
geometrically arranged tubes. Position logic circuits follow the array of the tubes, and 
receive the impulses in a summing matrix circuit. Finally the data are reconstructed 
into a 2-dimensional (2D) image by a computer. 
1.10.2 Planar Imaging 
For this application the camera remains stationary over the patient and 
acquires data from only one angle. In oncology this is commonly used to diagnose 
bone metastases. Dynamic planar imaging refers to the situation where a series of 
images is acquired over time, thereby allowing the motion of the radiotracer through 
the body to be detected; this technique is used to measure the glomerular filtration rate 
in the kidneys(Delpassand et al. 2000). 
1.10.3 SPECT 
In single photon emission computed tomography (SPECT) the gamma camera 
is rotated around the body on a gantry, so that a variety of different angles can be 
observed and then reconstructed into a 3-dimensional (3D) image. In oncology it is 
used for the detection of bone metastases and neuroendocrine tumours. Compared to 
planar imaging, the images are susceptible to artifacts, attenuation, and poor 
resolution (Kjaer 2006). Mathematical algorithms are used to compensate for 
attenuation. 
PET and SPECT can detect picomolar concentrations of radiotracers, however 
PET is more sensitive. SPECT is less expensive and does not require the presence of 
an on-site cyclotron. The tracers used in SPECT have longer half-lives than those 
used in PET. Typical SPECT radionuclides include ^^'"Tc (6 h), "^In (2.8 days), ' " l 
(13.2 h) and (59.5 days). Recently, preclinical studies of apoptosis have utilised 
[®®"'Tc ]-annexin-V SPECT to monitor response to radiotherapy in patients with 
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lymphoma (Haas et al. 2004). Other uses for this technique include the diagnosis of 
cerebrovascular disease, Alzheimer's disease, and determining the origin of infection. 
1.11 Basic Principles of PET 
Positron emission tomography (PET) differs from SPECT in that two gamma 
rays 180° apart are detected simultaneously. The first PET camera for human studies 
was built for by Hoffman, Ter-Pogossian, and Phelps in 1973 at Washington 
University, USA. The original tracers at that time were used to image regional blood 
flow in the lungs. 
The radiotracers used in PET are isotopes of carbon, nitrogen, oxygen, and 
fluorine (also used as a substitute for hydrogen), which have a closer resemblance to 
naturally occurring compounds within the body than those used for SPECT (e.g. 
Xenon-133, Technetium-99, lodine-123), therefore they are less likely to alter the 
biochemical properties of the compound which has been labelled. Positron emitting 
compounds do not normally exist in nature, and are produced by a cyclotron which 
uses powerful electric and magnetic fields to accelerate charged particles to high 
energies. These then bombard stable atoms in a target to produce proton-rich 
radioactive isotopes. Generators can also be used to produce positron emitting 
isotopes, such as [68Ga]. As the half-lives of the radionuclides used in PET are shorter 
than SPECT, production of radioactive isotopes such as [11C] generally requires the 
presence of an on-site cyclotron; however these properties of PET radiotracers do 
allow patients and normal volunteers to be studied with acceptable low doses of 
radiation. The reactions used to produce the radioisotopes in this thesis are shown in 
Table 1. Another advantage of PET over SPECT is that the collimation is electronic in 
PET (compared to SPECT where physical collimation is used) resulting in increased 
sensitivity and uniformity of the point source response function. 
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The basic principle of gamma decay is the same in PET as for SPECT; 
however in PET gamma decay is preceded by beta decay as the radionuclides used 
are positron (positive electron) emitters. After administration, a positron is emitted by 
the radionuclide to reduce the excess positive charge of the nucleus and render it 
more stable. 
After travelling a short distance the positron collides w/ith an electron in tissue 
to form a positronium that annihilates into two gamma rays of equal energy shown in 
Figure 1.7 (511 keV), along a line 180° apart known as the line of response (LOR), 
which are detected and used to quantify and localise the position of the positron 
emitter. This final process is known as simultaneous coincidence detection, and 
allows the annihilation event to be placed in the centre of a line between the two 
detectors on opposite sides of the object (Figure 1.8). 
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Figure 1.7 Positron decay 
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Figure 1.8: Annihilation detection 
The characteristics of the radioisotopes used in this thesis are shown in Table 1.5 
below. 
Table 1.5. PET radioisotopes: Characteristics and Production. 
Positron Stable Nuclear Number of Half-life (ty, of 
Emitter Element Reaction protons(p) and product) in 
neutrons (n) in min 
product nucleus 
''C 
18p 
15, o 
Nitrogen (^"N) 
Oxygen C^O) 
Nitrogen (^ '^ N) 
'"N (p,a)"C 
'=0(p,n)'»F 
14 N(d,n)'"0 
6p,5n 
9p,9n 
8p,7n 
20.4 
109.8 
2.03 
1.11.1 Coincidence detection 
PET is significantly more (approximately 100 x) efficient and provides better 
spatial resolution than SPECT, as two gamma rays are detected simultaneously 
compared to SPECT where only one ray is detected at a time. Modern PET detectors 
consist of thousands of coincidence detectors. If annihilation occurs outside the 
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volume between the detectors, only one gamma ray will be recorded and since this is 
not a coincidence event the event will be rejected. 
Figure 1.9. Coincidence and Scatter Detection 
1. True Coincidence 
• Annihilation event 
— G a m m a rays 
Assigned 
coincidence 
2. Scatter 
3. Random Coincidence 
1.11.2 Scatter and Attenuation 
Scatter occurs when the gamma rays change direction without (coherent) or 
with (incoherent) energy loss. The incoherent form of scattering is known as Compton 
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scattering. This is predominant at 511keV in the body and is thus totally responsible 
for the removal of a gamma ray/photon from a line of response (the line along which 
two coincident photons travel), and is referred to as attenuation. Correction for 
attenuation is used to obtain an accurate measurement of the regional distribution of 
radioisotope within the field of view of the scanner. The inclusion of scatter within 
reconstructed data lessens the contrast between different regions and can cause 
inaccuracies in measurement of activity concentration. 
Four alternative scatter correction techniques have been proposed for PET: i) 
empiric approaches, ii) methods based on two or more energy windows, iii) convolution 
(or equivalently, deconvolution), and iv) methods which model the scatter distribution 
on an initial estimate of the scatter-free image. Empiric approaches are based on 
observations that coincidences recorded outside the boundary of an object are entirely 
due to scatter (with randoms previously subtracted) and that the scatter distribution 
contains mainly low spatial frequencies. This method employs an analytic function (e.g. 
a one-dimensional Gaussian) to fit the scatter tails, and is well suited to neurological 
studies. However, in areas such as the thorax, the scatter distribution may not always 
be smooth as the tissue density is heterogeneous and secondly the object of interest 
occupies a large portion of the field of view - leading to over- or under-subtraction and 
small scatter tails to fit, respectively. 
Techniques involving multiple energy windows rely on i) a greater proportion of 
scatter in the region of the single photon energy spectrum below the photopeak, 
compared to those recorded near the photopeak (i.e. the characteristic energy emitted 
by a radionuclide), and ii) there is an energy threshold above which only unscattered 
photons are recorded. Therefore data recorded in energy windows below or above the 
photopeak can be used to estimate the amount of scatter within the photopeak 
window. 
In contrast to energy-based methods, the convolution methods for scatter 
correction employ an integral transformation of the projections recorded in the 
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photopeak window. Originally developed for 2D scanners, this method consisted of 
convolving the measured projection data line by line with an experimentally determined 
scatter function and then subtracting the resulting scatter estimate from the measured 
projections, and has since been modified for crosslane scattering for large area PET 
scanners and multi-ring scanners with the septa retracted. The advantage of these 
techniques is their low noise scatter estimates. As with the previous method, this is 
reliable for neurological studies, but is less robust for the thorax. Another limitation of 
this method is that it fails to account for scatter arising from activity outside the 
scanner's field of view(Baiiey 1998). 
The final method involves modelling photon interactions in matter and estimate 
the scatter contribution to projections given an accurate map of attenuation coefficients 
in the scattering medium and initial estimate of the scatter-free radioactivity 
distribution. Whilst this method is potentially more accurate than the others above as 
they use well understood physical principles to produce precise scatter estimates, it is 
complex to implement, computationally demanding, and requires assumptions to 
model scatter arising from activity outside the axial field of view. 
1.11.3 Dead Time 
During the time that the detector electronics connected to the photomultiplier 
tubes take to process each event they are unable to record any other events within 
that period, meaning that some may be missed - this is known as dead time. Data 
must be corrected for dead time to obtain accurate quantification. The fundamental 
determinant of dead time is the rate of single events that are striking the detectors. 
Tomographs continuously record this rate and use it as a basis of the calculation of 
dead time correction factors. For in vivo studies dead time correction is thought to be 
accurate to within 5% of the range of counting rates, however the magnitude of the 
correction factor should not be too large, and scanning should not be carried out near 
to or beyond the peak of the trues curve. 
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1.11.4 Random Events 
A true or real event is a detection of two photons (within the coincidence timing 
window) originating from one annihilation. A random event is a detection of two 
photons within the coincidence timing window which did not originate from one single 
annihilation event. Prompts are all detected coincidences. By having a delayed circuit 
where one detector is delayed by e.g. 100ns relative to the other it is possible to 
calculate the number of randoms, as any coincidence events recorded in the delay 
circuit cannot be true. Then by assuming that the number of delayed events is equal to 
the number of randoms in the primary circuit, the number of true events can therefore 
be determined by subtracting the calculated number of randoms from prompts in the 
primary circuit. 
1.11.5 Detector efficiency 
The detector efficiency is defined as the probability of a detector registering an 
event when a gamma ray intersects with it. In the scanner used in this study the 
scintillator detector is made from bismuth germinate oxide (BGO) crystal. The typical 
efficiency of BGO arranged in blocks is 64% for 511 KeV gamma rays(Townsend et al. 
1993). For each detector this is liable to change over time. To monitor detector 
efficiency, weekly tests using uniform phantoms are performed in the PET scanner. 
The results are then applied as a correction factor to the reconstructed PET data. 
Another correction factor, termed "z-scaling" allows for non-uniformity of detector 
efficiency along the longitudinal axis (z axis) in the field of view, this is also applied 
post-reconstruction. The process by which data is corrected for efficiency is known as 
normalisation. 
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1.11.6 Attenuation 
This describes the loss of detection of true coincidences due to their 
attenuation within body tissues. Without attenuation correction, significant artifacts 
which may occur on PET include: (1) pronninent activity at body surface edges due to 
relative lack of attenuation at the surfaces compared to deeper structures, (2) distorted 
appearance of areas of intense activity (e.g. urinary bladder) due to variable degrees 
of attenuation in different directions of activity originating from these areas, and (3) 
diffuse, relatively increased activity in tissues of relatively low attenuation (e.g. lungs). 
To correct for attenuation a transmission scan is performed with the patient in the 
scanner prior to injection of the radiotracer. In this study, rotating ®®Ge rods (t% of 
270.82 days) were used as the positron emitting source for the transmission scan 
which lasted 20 minutes. The count rate is measured for all possible lines of response 
(LOR), the line along which the coincidence event occurred. A blank scan is performed 
on a daily basis prior to any patient scans, and the ratio of blank counts to the 
transmission counts yields a correction factor which can be applied to each line of 
response. 
Figure 1.10 below, represents one of the unique features of PET, i.e. that for a 
given coincidence line, the probability of attenuation is the same for any source, 
independent of its location along the line, even if the source is external to the object. 
Therefore by using a transmission source which is external, attenuation correction is 
straightforward. If we consider a point source located x cm inside a cylinder of 
diameter D, with a linear attenuation coefficient of the cylinder material p, then the 
proportion of emitted photons that reach the nearest detector is e '^'and the proportion 
of photons that reach the farthest detector is . For a certain initial count rate (No) 
the number of detected coincidences (N) is determined by combining these tow 
probability terms: 
N = No(e-^''e-^'°"') = Noe-^° 
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Thus, the probability of coincidence detection is independent of source depth, 
X. This is true even if the source is positioned outside the body. In this case the 
probability terms are e° and e"^° for the nearest and farthest detectors respectively and 
the number of detected coincidences is: 
N = No(e°e-^°) = Noe'^ ^ 
which is the same as that obtained for the internal source. Therefore the probability of 
attenuation for all sources can be determined by comparing the count rate from a 
transmission source, with the unattenuated count rate from the same source when the 
patient is not in the tomograph; this is referred to as a blank scan. 
Figure 1.10 Attenuation in PET 
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75 
A transmission scan lasts 20 minutes on average to acquire, and is normally 
performed prior to administration of the radiotracer, although it can be performed 
afterwards. The transmission count rate is measured for all possible lines of response 
using one or more rod or point sources that rotate around the patient, or alternatively, 
using a stationary ring source. Typically the transmission source contains a positron 
emitter with a long half-life, e.g. ®®Ge (t% 275 days), which is retracted behind lead 
shielding when not in use. An alternative, more efficient option, is to employ a high-
energy single photon emitter such as "^Cs (Ey = 667 keV) and acquire the data in 
"singles" mode. This latter approach is more suited to septaless 3D scanners where 
dead-time is a challenge for coincidence-based transmission scanning. Attenuation 
correction factors can also be derived from spatially co-registered X-ray CT data in 
combined PET/CT systems. 
1.11.7 Data reconstruction 
After annihilation detection data are reconstructed (using either filtered back 
projection or iterative methods) and binned into sinograms. During reconstruction, 
images are normalised to account for the current efficiency of the different detector 
blocks. Following reconstruction, the scans are "z-scaled' to correct for the varying 
efficiency along the longitudinal (z-) axis of the field of view (Grootoonk et al. 1996). 
The filtered back projection (FBP) algorithm is the standard algorithm of tomography 
and is equivalent to the direct Fourier reconstruction in the limit of continuous 
sampling. In comparison, iterative reconstruction algorithms are independent of 
detector geometry. 
1.11.8 Partial volume effect 
Partial volume effects encompass: i) poor spatial resolution due the constraints 
of the imaging system leading to spillover from surrounding structures, and ii) image 
sampling, resulting in altered intensity values for a particular region of interest(Soret et 
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al. 2007). The sensitive volume lias dimensions approximately equal to twice the 
FWHM resolution of the reconstructed image. The partial volume effect results in small 
objects (i.e. those smaller than twice the system resolution) having an apparent 
reduction in isotope concentration and overestimation in the size of the object. A 
number of methods have been proposed for partial volume correction. Resolution 
recovery techniques can be applied to the data prior to reconstruction, or by using an 
iterative reconstruction framework. However if the size of the object approaches the 
resolution of the imaging system then the measured dimensions are unreliable unless 
there are co-registered images from CT, MRI. Finally, spill-over and partial volume 
effects can be built into the kinetic model and their magnitude estimated along with the 
physiological parameters of interest. This technique does not require anatomical co-
registration but may reduce the accuracy of the modelled parameters, especially for 
noisy dynamic data. 
1.11.9 Noise 
Statistical noise in PET images results from the limited number of counts in 
each pixel, and the randomness of radioactive decay. Image noise (random variations 
in pixel intensity) is decreased with more counts, which in turn are obtained by 
scanning longer, injecting more radiotracer, or improving the efficiency of the scanner 
for detecting emitted radiation. The injected dose of radioactivity is limited by safety 
constraints including the potential for short-term and long-term damage to DNA, 
however generally the highest dose possible within the safety range should be 
administered. In some cases, the amount of tracer cannot be increased because of 
dead time and random event rate limits in the camera. 
The efficiency of the camera also limits the sensitivity of coincidence detection 
which is only 0.5% in 2-D mode, with a scintillation crystal efficiency of only 50-80%, 
depending on detector material and size. In 3D septa-less mode the PET scanner can 
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only detect 1-3% of the annihilation events; even when there are no photon attenuation 
effects (Bailey et al. 1991). 
Noise is also influenced by the reconstruction process, corrections for random 
and scatter coincidences, attenuation, detector non-uniformities, and the size and 
location of the region of interest (Carson et al. 1993). The duration of the scan is 
dependent on the physical and biological half-lives of the radiotracer, and is influenced 
by patient comfort, as longer scan times lead to potentially more errors due to motion. 
The design of the scan protocol has therefore to be optomised to allow a 
balance between the permissible dose of radiation to the patient, tracer characteristics, 
camera sensitivity, and the type of study required. 
1.11.10 Resolution 
Resolution in PET is defined by the minimum distance between two point 
sources to be interpreted as separate, and is known as the full width at half maximum 
(FWHM). The FWHM is variable for different types of scanners, but at present varies 
between 4 - 8mm for clinical scanners. The type of acquisition i.e. two-dimensional, 
2D, or three-dimensional, 3D, can also affect resolution. The resolution of a PET scan 
can be affected by several factors including the physical dimensions of the detector 
elements, the distance the positron travels in tissue before annihilation and the 
deviation from strict co-linearity between emitted annihilation photons. The in plane 
spatial resolution is characterised by the spread of a point or line source in the 
reconstructed image along a line from the centre of the gantry to the source position 
(radial) and perpendicular to that line (tangential); producing the line spread function 
(LSF). The LSF is the commonest measurement of spatial accuracy in PET and also 
defines the limit of spatial resolution for the PET image. The shape of the LSF is 
dependent on the width of the detectors, the type of reconstruction method, and the 
precision with which the tomograph has been reconstructed. The FWHM is equal to 
the LSF at its widest value divided in two. The most constant region for LSF 
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measurements is the central third of the region between coincidence detectors, and 
therefore that region constitutes the most useful field of view for accurate 
measurements in PET. 
The accuracy of localisation by PET is physically dependent on the energy of 
positron emission, which is related to the individual isotope. The point of interest is the 
position of the positron emitting nuclide; however the inaccuracy of localisation 
increases with increasing kinetic energies which is reflected by an increase in FWHM. 
The accuracy of annihilation coincidence detection is limited by the intrinsic 
motion of the electrons and positrons at the time of capture, as they are not completely 
at rest there is deviation of the annihilation photons from the normal 180° angle to each 
other. The angular distribution of this non-colinearity has been described as +/- 0.3° 
(Hoffman 1986). However, in a tomograph with 6mm resolution (FWHM), the above 
two effects contribute less than 1 mm with the commonly used positron emitters. 
Loss of resolution can also occur due to patient motion during the scan. To 
prevent this happening patient comfort is made a priority and scan times are minimised 
as much as possible. In the case of brain studies, a head holder can be used. Patients 
are constantly observed during the scanning period, and if any movement occurs the 
time is recorded. Diaphragmatic motion during respiration is particularly relevant in 
scans of the thorax, and if the scan is not long enough to allow time averaging over 
enough breaths the data will be inconsistent and subject to artefacts. A technique 
known as gating has been developed for use in respiratory and cardiac imaging which 
freezes the motion of the lungs or heart relative to the respiratory and cardiac cycles 
respectively(Saab et al. 2003; Livieratos et al. 2006). 
1.11.11 Two dimensional (2D) and three dimensional (3D)PET 
The images acquired during a PET scan provide information about the 3D 
distribution of radioactivity within the subject. 2D PET and 3D PET relate to the physics 
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of acquisition, i.e. in 2D PET septae made from lead or tungsten are present between 
the detector rings, whereas in 3D PET acquisition is without septa. The purpose of the 
septa is to reduce the registration of random and scattered events. 2D PET acquires 
data in a number of contiguous planes or slices, with each plane consisting of data 
from coincidences either within an individual ring or in closely adjacent rings. The 
disadvantage of using septa is that it also reduces the efficiency of the scanner by 
reducing the number of counted true coincidence events, therefore increasing noise 
(see above). 3D PET allows all possible lines of response (LORS) to be recorded and 
results in a 10-fold increase in efficiency of the PET scanner. 3D PET is now used 
routinely in all brain scans. However 3D PET results in increased scatter detection, 
and estimates of 45% of all measured coincidences due to scatter compare 
unfavorably with that of 15% in 2D PET(Bailey et al. 1998). 
1.11.12 Calibration 
For most clinical applications of PET, the above corrections can be applied to 
produce images that are free from artefacts and reflect regional concentration of 
radiotracer in the body. However, for most kinetic study protocols as discussed in this 
thesis, the PET images need to be calibrated in terms of absolute units of tracer 
concentration. Calibration is the process by which the relationship between the 
measured count rate per unit volume and true activity concentration is 
established(Geworski et al. 2002). Accurate calibration between the well counter 
(which measures tracer concentrations in blood samples withdrawn from patients) and 
the scanner is performed by scanning a phantom source with uniform radioactivity 
concentration and then counting an aliquot removed from the phantom in a well 
counter. Images obtained from the phantom are then reconstructed using the same 
corrections as for the research studies, and the voxel values are directly compared 
with the counted aliquot to determine the calibration factor. 
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1.11.13 PET/CT 
Combined PET/CT systems are now widely available, and are particularly 
useful in oncology, where they can be used to co-register data from both scans 
thereby providing precise tumour location. This can enhance radiotherapy treatment 
planning by providing a more precise tumour volume (known as the planned target 
volume). A PET/CT consists of a full ring PET gantry abutted to a single- or multi-slice 
CT gantry with a common patient couch and aperture and integrated computer system. 
One of the main advantages is shorter scanning time, as a whole-body CT scan can 
be acquired in 2 minutes compared to a conventional PET transmission scan, which 
lasts 20 minutes. At present the main role for PET/CT is in staging and restaging of 
disease; though the technology may also be of benefit in drug development by 
combining the superior spatial resolution of CT with the sensitivity of PET in measuring 
drug pharmacokinetics(Boss et al. 2008). 
1.11.14 Arterial Blood Sampling 
To perform the tracer kinetic models in this thesis, measurements of the tracer 
concentration in tissue (provided by the PET scanner) and arterial plasma were 
required. The localisation of the radiotracer in the region of interest (in this case 
tumour) is affected by its biochemical properties such as plasma protein binding, 
lipophilic and hydrophilic attributes and polarity. The concentration of the radiotracer in 
blood, partitioning between plasma and blood cells, and metabolism are also 
important. PET is unable to distinguish between radioactivity from the parent 
radiotracer and that due to a radiolabeiled metabolite present in the same region of 
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interest. For that reason the total amount of radioactivity in arterial blood is sampled 
continuously for a defined interval at the start of the scan, and discrete aliquots are 
taken at pre-defined time points to measure the relative proportions of the parent 
radiotracer and its respective metabolite(s). By subtracting the fraction of radioactivity 
concentration due to the metabolite in arterial plasma, the true concentration due to 
the parent compound is derived throughout the dynamic imaging period; this is the 
gold standard for kinetic modelling of PET data (Wells et al. 2005). 
The alternatives to arterial blood sampling include arterialised venous blood 
sampling (Eberi et al. 1997) and image-based methods i.e. using a visible arterial 
blood area (left ventricle, or large artery) to provide an input function(lida et al. 1992). 
The first method involves heating the hand to approximately 45°C using a water bath 
or electric blanket, causing arterial blood to be shunted into the venous circulation. 
Arterialised venous blood samples are then withdrawn (usually from a vein in the 
antecubital fossa). The second method is used where a pool of arterial blood is within 
the field of view of the scanner, e.g. the left ventricular chamber of the heart which is 
used in cardiac studies. 
1.11.15 Mathematical models 
To analyse the data, hypothesis-led mathematical models which explain tracer 
kinetic behaviour are employed. Hence the relative rate of biological processes can be 
determined. Examples of the possible measurements include tracer delivery, washout, 
and retention. Mathematical models used in this thesis include: compartmental, 
spectral, and Patlak. 
The models used can have fixed assumptions about tracer behaviour based on 
previously obtained biological information e.g. the Sokoloff model for FDG, a two-
compartmental model assumes one reversible compartment, and a second inner 
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irreversible compartment (Sokoloff L 1977).. K1 is the unidirectional clearance of the 
tracer from arterial plasma to tissue, kg is the clearance in the opposite direction, ks is 
the rate of association of the radiotracer in the irreversible compartment, k^ is the 
dissociation rate constant of the radiotracer in the fixed compartment (see Figure 1.11 
below). 
Figure 1.11 The Sokoloff compartmental model for FDG uptake 
Plasma K i Tissue 
ks 
R ^ R-T 
4 
k4 
(where R- radiotracer, K1 is the unidirectional clearance of the tracer from arterial 
plasma to tissue, l<2 is the clearance in the opposite direction, kj is the rate of 
association of the radiotracer in the irreversible compartment, k4 is the dissociation rate 
constant of the radiotracer in the fixed compartment). 
For a tracer with metabolites, there may also be transfer of the radiolabelled metabolite 
from the plasma into the tissue, as shown below in Figure 1.12. The rate constants 
describing this are labelled KI ' and kz, the degree of binding affinity depends upon the 
chemical properties of the metabolite; i.e. some possess strong affinity within tissue, 
but for others such as [18F]FLT and [11C]choline the metabolites are assumed to be 
free and non-specifically bound within the tissue compartment. 
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Figure 1.12. Compartmental model for radiolabelled metabolites 
Plasnm ^ Tissue 
(where R-M- radiolabelled metabolite, K/ = transport into tissue, Acg' = transport back 
into plasma). 
The Patlak-Rutland method assumes irreversible binding of the tracer within 
the region of interest(Patlak at al. 1985). 
R(t) - K c{t)dt + Voc(t) 
(where R(t) is the amount of tracer in the region of interest, c(t) is the 
concentration of the tracer in arterial blood, K is the constant describing the rate of 
entry into the peripheral compartment, Vo is the distribution volume of the tracer in the 
central compartment)..The model assumes a single source for the radiotracer, the 
plasma, and rapid first-order exchange between compartments. 
A modified version of the Patlak plot (shown below) which takes account of the 
presence of tracer metabolites in the tissue of interest was initially developed by 
Mankoff et al for [11C]thymidine-PET studies was used in this thesis and applied to the 
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tissue data. The results were compared to the classical Patlak model described 
above(Mankoff et al. 1996) 
^Tot ^Tot 
(where A = Total tissue radioactivity (parent tracer and metabolites), CTOT= total blood 
radioactivity, Cx= Radioactivity of parent tracer by metabolite analysis of blood data 
(HPLC), V= Combination of volumes of distribution for parent tracer and metabolites). 
On the other hand, spectral analysis is a data-led approach and makes no a 
priori assumptions about tracer behaviour(Cunningham et al. 1993; Meikle et al. 1998). 
Spectral analysis operates by creating a series of exponentials which relate the 
measured concentration of the radiotracer in tissue from the PET data and relate them 
to arterial plasma data, using the equations below: 
1 ''V ^ e , > 0 
(t) = : GC exp(-j3 t)dt 
- f , r 1^1 
where Ctiss = concentration of the radiotracer in tissue, t is time, ® denotes the 
convolution operator , A, = decay constant for the radioisotope, N = number of basis 
functions in the model, p values are chosen to describe the entire spectrum of 
expected kinetic behaviour from the slowest possible clearance X , to the fastest 
measurable dynamic, a is the intensity of the component at P). 
The impulse response function (IRF) is calculated for the entire scan duration shown 
below; 
hit) = ^ a J exp(-(j3j - X)t) 
j=i 
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{h(t) = IRF). The fractional retention of tracer at various intervals (FRT ratios) can be 
calculated by dividing the IRF values for e.g. 60 minutes, and 90 minutes by the IRF 
for 1 minute, to obtain the FRT at 60min and FRT at 90 min respectively. 
The IRF can then be used to calculate the following parameters: 
I) The rate constant for the transport from plasma to tissue for the radiotracer, K j (sec" 
(equivalent to regional flow x extraction) 
h(0) = 
II) The apparent volume of distribution, VD, i.e. the partitioning between blood and 
tissue (i.e. the steady-state ratio of tracer concentrations in tissue and plasma). 
VD' 
An explanation of how radiotracer uptake is routinely measured in the clinical 
setting now presented. 
1.11.13 Semi-quantitative methods 
Standardised uptake value 
The standardised uptake value (SUV) is the most commonly used parameter in 
clinical PET practice. It provides a measure of uptake within a defined region of 
interest at a specified mid-frame time which is corrected for the dose of injected 
radioactivity and either weight or body surface area (BSA). 
i) 
Suy ^ WeightjKg) 
Qv 
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or 
sUV = —xQ 
Qinj 
The correction of SUV for body weight is the most common version used in 
clinical studies. However, this value can be subject to increases as high as two-fold in 
normal tissues when heavier-weight patients are studied in comparison to lighter 
ones, hence the use of SUV corrected for lean body mass has been suggested as an 
alternative method in FDG-PET scans(Zasadny et al. 1993). As yet, no information has 
been published regarding weight-dependence and the tracers that will be presented in 
this thesis, therefore it was elected to employ the SUV corrected for BSA method, as a 
previous FDG-PET study of breast cancer has shown that this method is does not 
correlate with body weight (Sugawara et al. 1999). 
The time when tracer uptake is measured post-injection is an important 
determinant of reliability of SUV values, which is of particular relevance to tumours with 
slow metabolism (Keyes 1995). In oncology, recent studies have suggested that 
measuring SUVs at later time-points post-injection in FDG-PET scans can help 
differentiate tumour from inflammatory lesions (Nishiyama et al. 2005). The 
advantages of using SUV are that its calculation is relatively straightforward to perform, 
and does not require blood sampling. 
Area under the curve 
The area under the curve (AUG) provides an integral measure of the summated 
activity over time also corrected for dose and body surface area. As activity is 
nominally measured at mid-frame time, then it follows that AUG is calculated by the 
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sum of the product of corrected activity at time (t) (i.e. SUV) by the duration of the 
frames. 
AUC= Z Frame duration(s) x Corrected activity (t) [m''/ml] 
For AUG to be accurate, it follows that more than one frame needs to be 
acquired, as the total area under the curve is obviously dependent on the slopes either 
side of the peak activity. 
The tracers used in oncology and this thesis will now be discussed. 
1.12 FDG 
2-[18F]fluorodeoxyglucose, FDG is the most commonly used PET tracer in 
oncology. It was originally labelled with [18F] in Brookhaven in the 1970's and used for 
preclinical imaging of regional myocardial glucose metabolism (Gallagher et al. 1977). 
The use of FDG in oncology is dependent on Warburg's observations in the 1920's 
that cancer cells display an increased rate of glycolysis compared to normal 
cells(Warburg O 1924). Typically normal cells rely on oxidative phosphorylation for 
energy production rather than glycolysis which is energy inefficient. 
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Figure 1.13: Cellular uptake and metabolism of FDG. 
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The transmembrane transporters Glut 1-5 are responsible for the transport of 
glucose intracellularly. Various cancers (breast, lung, colon, oesophagus) have shown 
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over expression of the Glut 1 transporter (Smith 1998). Other changes associated with 
the transformed phenotype are increased expression of the enzyme hexokinase which 
catalyses the formation of glucose 6-phosphate from glucose, redistribution of 
hexokinase to the outer mitochondrial surface, alteration of the glycolytic enzymes 
aldolase and enolase (although the latter will have no effect on FDG uptake)(Pauwels 
et al. 2000). Weber et al have shown that hepatic glucose-6-phosphatase activity is 
reduced during carcinogenesis, in adenocarcinoma bearing mice compared to normal 
controls, and absent in hepatomas in a preclinical study (Weber et al. 1955). 
Transfection with the oncogenes src, ras and c-myc and stimulation by growth 
factors such as EOF results in upregulation of the genes which encode hexokinase 
and glucose transporters(Scimeca et al. 1989). In response to certain grov\/th factors, 
PIS kinase activates the serine/threonine kinase Akt which leads to overexpression of 
Glut 1 and increased activity of hexokinase (Barthel et al. 1999; Plas et al. 2001; 
Elstrom et al. 2004). Drug-induced inhibition of PIS kinase in glioblastoma cells blocks 
the activation of glycolysis by Akt (Elstrom, Bauer et al. 2004). Downstream from Akt, 
regulation of glycolysis is mediated by, amongst other factors, hypoxia inducible facor-
1a (HIF la ) . In a recent study in breast carcinoma, absence of Akt phosphorylation 
was associated with low levels of HIF l a (Gort et al. 2006). 
Originally deoxyglucose was developed as a chemotherapeutic agent to block 
accelerated glycolysis in cancer cells, but was abandoned due to neurological toxicity. 
2-deoxyglucose is transported intracellularly in a similar fashion to glucose by Glut 
transporters, and phosphorylated by hexokinase. Further progression of 2-
deoxyglucose-6-phosphate down the glycolytic pathway does not occur as the 
compound lacks an oxygen atom at the C2 position. 2-deoxyglucose-6-phosphate is 
trapped intracellularly as it cannot diffuse back out of the cells, and the 
dephosphorylation reaction catalysed by glucose-6-phosphatase occurs 
slowly(Sokoloff L 1977). 
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Some of the limitations of using FDG as an imaging tracer include its lack of 
specificity (i.e. any tissue which has a high rate of glycolysis will show increased 
uptake), therefore discrimination between tumour tissue and inflammation may 
become difficult. Most clinical scans utilise static imaging rather than dynamic studies. 
Differences in uptake kinetics between tumour and inflammation have been observed 
using dynamic imaging in a study of thoracic lesions. Tumour uptake of FDG increases 
to a plateau over time compared to inflammatory lesions where after an initial rise the 
uptake tapers off (Zhuang et al. 2001). Serum glucose levels are known to have an 
effect on FDG uptake (Wahl et al. 1992). It has also been reported that elevated serum 
glucose results in increased uptake of FDG in inflammatory lesions, compared to 
tumours where a negative effect is seen (Zhuang et al. 2001). 
1.13 PET radiotracers for studying proliferation 
Investigators have recently sought alternatives to FDG which are more specific 
for studying selected molecular processes such as proliferation. Glycolysis is not 
limited to tumour tissues and may occur in areas of inflammation, leading to increased 
uptake of FDG in benign processes. Most of the proliferation markers being developed 
are thymidine analogues, their structures are shown in Figure 1.14. 
1.13.1 Thymidine 
The basis for using thymidine as a PET radiotracer for studying proliferation 
originated from the use of tritiated thymidine in autoradiography and flow cytometry. 
Thymidine is the only base which is incorporated into DNA and not RNA (where it is 
replaced by uracil), making it appropriate for studying DNA metabolism. It is 
transported intracellularly using a facilitated non-energy dependent transporter which 
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produces equilibration in seconds (Wohlhueter et al. 1979). Thymidine nucleotides are 
unsuitable for growth measurements as they are unable to cross the cell membrane. 
The rate of proliferation is dependent on the rate of DNA synthesis of the tissue of 
interest, provided that there is no shortage of DNA nucleosides(Cleaver 1967). 
Therefore, as 50% of base pairs contain thymidine the synthetic rate of DNA ( S R d n a ) 
has been defined as: 
SRDNA=2X 1 x f l u x T d R 
f. ext 
where fext is the flux of thymidine via the exogenous pathway and fluxTdR is the flux of 
thymidine nucleotides from the precursor pool into DNA (ijmol/min/g)(Mankoff et al. 
1999). 
Thymidine labelled with carbon-11 in the methyl position was first produced by 
Christman (Christman et al. 1972). Labelling in this position produced a complex set of 
metabolites, making modelling difficult(Shields et al. 1987). Investigators then tried 
labelling in the ring-2 position (Vander Borght et al. 1991), which led to rapid 
degradation into carbon dioxide and metabolites(Shields et al. 1992). 
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Figure 1.14: Pyrimidine Nucleosides in Development as PET radiotracers 
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Clinical studies of methyl-labelled thymidine have been performed in non-Hodgkin's 
lymphoma (Martiat et al. 1988), neuroendocrine tumours, and head and neck 
cancer(van Eijkeren et al. 1992). The investigators found higher uptake in high grade 
tumours compared to low grade ones. Increased uptake was also noticed in the 
myocardium, kidney, and liver (which was attributed to blood pooling). Activity seen in 
the gut wall could have been due to the normal proliferation of bowel mucosa. 2-[11C] 
thymidine has been used to image brain tumours (Vander Borght et al. 1994; Eary et 
al. 1999), sarcomas, and lung cancers, with mixed results. In Vander Borght's study, 
an increased thymidine uptake (tumor-to-cortex ratio > 1.2) in 11 of 14 untreated 
tumours and in 5 of 6 recurrent tumours was found. However, there was no correlation 
between thymidine uptake and tumour grade. 
The study by Eary et al compared 2-[11C] thymidine with FDG PET and 
magnetic resonance imaging (MRI) in 13 patients with brain tumours (Eary et al. 1999). 
In two cases where lower 2-[11C] thymidine uptake than FDG, tumour progression was 
slower compared to tumours in 3 patients with high uptake of both tracers. For brain 
imaging the blood brain barrier is much more permeable to [11C]C02 than 
[11C]thymidine, necessitating data correction for high background activity (Wells et al. 
2002). 
2-[11C]thymidine-PET has also been used to image response to treatment. 
Shields et al studied the effect of chemotherapy on 2-[1 ICJthymidine and FDG uptake 
in 4 patients with small cell lung cancer and 2 with sarcoma(Shields et al. 1998). In the 
4 responding patients decreases in uptake of both tracers were seen. In the 2 patients 
with progressive disease (1 metastatic small cell lung cancer, and 1 abdominal 
sarcoma) only small decreases (<10%) in KTdR (thymidine flux constant) were 
observed, the latter patient actually had a 69% increase in FDG SUV. 
Drugs which target incorporation of deoxythymidinetriphosphate (dTTP) into 
DNA result in decreased DNA biosynthesis and repair. For many agents this is 
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mediated by inhibition of the enzyme thymidylate synthase (TS). TS is a key target in 
cancer therapeutics. It is a catalyst for the methylation of 2'-deoxyuridine-5'-
monophosphate (UMP) into 2'-deoxythymidine-5'-monophosphate (TMP) in the de 
novo synthetic pathway of thymidine nucleotides. Drugs such as 5-fluorouracil (5-FU) 
inhibit this pathway resulting in depletion of intracellular thymidine pools. As a 
consequence of the decreased availability of intracellular thymidine, cells employ the 
salvage pathway where more thymidine is imported from the extracellular space and 
then phosphorylated by TK to form TMP. Increased extracellular thymidine leads to 
reduced activity of TS inhibitors, and conversely inhibition of thymidine transport 
results in enhanced activity of these agents. 
In the first study of its kind. Wells et al employed 2-[11C]thymidine PET to 
measure TS inhibition in patients with advanced gastrointestinal cancer before and 1 
hour after treatment with a novel TS inhibitor, nolatrexed hydrochloride (AG337, 
THYMITAQ, Aguoron Pharmaceuticals, San Diego, CA, USA) (Wells et al. 2003). Five 
patients treated with the agent together with 7 untreated controls were scanned. 
Treatment was associated with increased fractional retention (FRT) and standardised 
uptake value (SUV, corrected for body weight) of 2-[11C]thymidine compared to the 
control group where no significant changes in uptake were seen. Plasma AG337 AUG 
measurements correlated with both plasma deoxyuridine levels (a pharmacodynamic 
marker of TS inhibition due to increased intracellular levels of uridine 
monophosphate)(Jackman et al. 1984) and 2-[11C]thymidine uptake in four and three 
patients respectively (r=1, p=0.01 for the two parameters). 
The need for correction of metabolites in 2-[11C]thymidine studies was 
previously demonstrated by Wells et al in patients with advanced gastrointestinal 
cancer where it was found that semi-quantitative m eta bo I ite- u n corrected parameters 
SUV and AUG failed to correlate with Ki-67 labelling index, in contrast to FRT (Wells et 
al. 2002). The lack of correlation with the SUV method was later attributed to the 
presence of labeled metabolites and unincorporated thymidine(Wells et al. 2005). A 
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study comparing FDG and 2-[11C]thymidine - P E T with computed tomograpiiy (CT) for 
response in metastatic renal cancer treated with interleul<in 2 for 6 weeks found that 
responding tumors had decreases in both FDG and thymidine uptal<e, however, there 
were discrepancies in several tumour sites which showed an increase in thymidine 
uptake despite decreases in FDG and this correlated with ultimate tumor progression 
in these areas (Eary et al. 1999). This suggests that changes in [11C]thymidine uptake 
may be an earlier predictor of drug resistance than FDG. 
One of the major metabolites of 2-[11C]thymidine is [HCjCOz. The distribution 
of radiolabelled carbon dioxide [11C]C02 is pH dependent, therefore the contribution of 
[11C]C02 to the PET signal and pH of the blood are important when interpreting 2-
[11C]thymidine-PET studies (Shields et al. 1992). For data analysis, a 5-tissue 
compartment model with 8 rate constants (see Figure 4) has been developed by 
Mankoff et al (Mankoff et al. 1998). The complexity of the analysis together with the 
short half-life of 20.4 min of [11C] present challenges for the widespread use of 2-
[11C]thymidine-PET . Currently, clinical studies of 2-[11C]thymidine-PET are restricted 
to dedicated PET research centres with a cyclotron on-site. Most PET research 
centres have now switched from using [11C]thymidine to newer [18F]-radiolabelled 
pyrimidine analogues, which aim to be less complex in terms of analysis. The main 
advantage for [11C]-thymidine compared to some of these newer compounds is that it 
bears the most similarity to the target nucleoside substrate and thus should provide a 
more reliable estimate of the salvage pathway for DMA synthesis. 
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Figure 1.15: Tissue compartmental model for thymidine 
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(where K1t= transfer of thymidine from blood to tissue, k2t= transfer of thymidine from 
tissue to blood, k3t= incorporation of thymdine into DNA, kmet= rate of metabolism of 
intracellular thymidine, K1m= transfer of thymidine metabolites from blood to tissue, 
k2m= transfer of metabolites from tissue to blood, k1c= transfer of C02 from blood to 
tissue, k2c= transfer of C02 from tissue to blood, k3c= irreversible trapping of C02 
within tissue). 
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1.13.2 [18F]Fluorothymidine (FLT) 
3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a thymidine analogue. 
Compared to 2-[11C]thymidine, the main advantages of [18F]FLT are its longer half-life 
of 109.8 minutes and resistance to degradation. FLT is transported intracellularly via 
an equilibrative nucleoside transport mechanism, after v/hich it becomes 
phosphorylated by TK1 and trapped as the phosphate. Another set of sodium-
dependent concentrative transporters also exists in normal tissues which mediate 
influx only(Belt et al. 1993). The transport of [18F]FLT follows biphasic kinetics, with 
rapid initial accumulation followed by a slower rate of accumulation. Unlike thymidine 
only minimal amounts of [18F]FLT are incorporated into DNA as it lacks the 3'-hydroxyl 
moiety(Lu et al. 2002; Krohn et al. 2005). 
The rate of uptake of FLT into cells and phosphorylation by TK1 is 
approximately 30% of that of thymidine(Munch-Petersen et al. 1991). The expression 
of TK1 is tightly regulated with the cell cycle(Adler et al. 1974; Sherley et al. 1988; 
Sherley et al. 1988; Roehl et al. 1990) it increases in S phase(Toyohara et al. 2002);, 
and is targeted for degradation in M phase, such that newly divided cells have low 
levels of TK1. Unlike thymidine, and FMAU (discussed below) FLT is not a substrate 
for mitochondrial TK2 which is constitutively expressed throughout the cell cycle. 
Rasey et al showed that [18F]FLT measures TK1 activity in A549 lung 
carcinoma cells in vitro (Rasey et al. 2002). High levels of TK is associated with an 
increased risk of relapse and reduced survival in patients with node-positive breast 
cancer(Romain et al. 1997). A preclinical study from our group has shown that 
[18F]FLT uptake decreases as early as 24hrs post cisplatin treatment in RlF-1 
sarcoma bearing mice, and these changes correlated with decreases in proliferation 
cell nuclear antigen (PCNA), and preceded changes in tumour size(Leyton et al. 2005). 
Similar decreases were seen at 48hr in the same model treated with 5-
fluorouracil(Barthel et al. 2003). Preclinical comparison of [3H]thymidine, [18F]FLT 
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and FDG-PET for monitoring response to radiotlierapy in C3H/He mice bearing 
SCCVII tumours showed that the reduction in [18F]FLT uptake correlated with that of 
[3H]thymidine and Ki-67 LI. [18F]FLT uptake declined rapidly (6 hours) post-irradiation, 
whereas a significant decrease in FDG uptake was only noted at day 3, which may 
have reflected local radiation induced inflammatory changes (Sugiyama et al. 2004). 
The first human study of [18F]FLT-PET was performed by Shields et al in a 
patient with sarcoma: high tumour localization was seen as well as high uptake in the 
bone marrow, liver, bowel, kidneys and the bladder(Shields et al. 1998). Low uptake 
was noted in the normal brain, muscle, heart, and lungs. In humans, FLT is 
metabolised by glucuronidation in the liver and excreted via the kidneys(Shields et al. 
2005). FLT was originally used for the treatment of HIV, but stopped due to toxicities 
such as peripheral neuropathy, myelosuppression and hepatic failure (Kong et al. 
1992; Flexner et al. 1994). Due to the above toxicities however, although typically only 
lOjjg of FLT is injected for a single PET scan it is recommended that patients have 
adequate haematological and hepatic function prior to scanning(Been et al. 2004). 
[18F]FLT can be produced with high specific activity, the production method 
and radiation dosimetry have been established (Grierson et al. 2000; Vesselle et al. 
2003). Two different strategies have been developed for [18F] labeling of FLT(Been et 
al. 2004). The method of Grierson and Shields utilizes nosylate derivatives of 
thymidine (Grierson et al. 2000), and that of Machulla employs anhydrothymidine 
derivatives(Machulla 2000). The second method is easier to perform, but has low 
radiochemical yields of 5-14%. Cleij et al have further improved the yield by adding 
dimethyl sulphoxide to the precursor(Cleij 2001). 
Prior to commencement of work reported in this thesis, [18F]FLT-PET had not 
been studied previously in breast cancer. The optimal parameter for describing 
[18F]FLT uptake had not been established. Although repeatability studies have been 
determined for [11C]thymidine(Wells et al. 2005) no studies have evaluated the 
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repeatibility within tumours of [18F]FLT, nor described the pharmacokinetic parameter 
which correlates best with tissue proliferation. 
Buck et al compared the uptake of FDG and [18F]FLT in 26 patients with 
solitary lung nodules. The results showed that tumour uptake of FDG was higher than 
that of [18F]FLT, but that correlation of [18F]FLT SUV with proliferation was 
significantly better for FLT which was entirely specific for malignant tumours. There 
were two false negative cases for [18F]FLT, one in a metastatic colorectal lesion and 
the other in a non-small cell lung cancer with a low proliferation index(Buck et al. 
2003). A second study which compared [18F]FLT uptake with proliferation in ten 
patients with non-small cell lung cancer found that the correlation was better for Patlak 
analysis of [18FJFLT retention than SUV, and a superior correlation for [18F]FLT 
uptake with Ki-67 labelling index than S-phase fraction (Vesselle et al. 2002). Dittman 
et al compared [18F]FLT and FDG-PET in sixteen patients with primary and metastatic 
thoracic tumours (non-small cell lung cancer, oesophageal carcinoma, sarcoma, 
Hodgkin's lymphoma, and renal carcinoma)(Dittmann et al. 2003). Whole-body 
imaging was performed QOminutes post tracer injection. There was no correlation with 
Ki-67 labelling index (LI) and [18F]FLT-PET, which the authors attributed to the 
diversity of tumour types which were imaged. The interval between biopsy and PET 
scans and method of calculating the Ki-67 LI was not stated. The [18F]FLT and FDG-
PET results were similar, with one bone metastasis being missed due to high 
physiological FLT uptake. 
[18F]FLT-PET has been shown to be inferior to FDG-PET for imaging liver 
metastases from colorectal tumours which is likely to be due to the high physiological 
background signal due to glucuronidation(Francis et al. 2003). Imaging of extrahepatic 
colorectal cancer metastases in the same study did have more promising results. 
Another study of colorectal tumours (primary and metastatic) by the same group 
demonstrated good correlation (r=0.8, p<0.01) between [18F]FLT SUV and 
corresponding MlB-1 proliferation indices(Francis et al. 2003). 
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[18F]FLT-PET has also been used to evaluate tumourous and non-tumourous 
cerebral lesions using static imaging one hour after injection. The results were 
compared to FDG uptake in the same patients. [18F]FLT-PET was superior to FDG in 
distinguishing tumours from grey matter (presumably due to the high rate of glycolysis 
in normal brain tissue causing an intense FDG signal). The sensitivity and specificity of 
[18F]FLT for diagnosing brain tumours was 79% and 63% respectively: there were 
three false negatives in grade II astrocytomas (Choi et al. 2005). 
A study by Cobben et al evaluated the utility of [18F]FLT-PET for studying soft-
tissue sarcoma in 19 patients, who had static imaging performed 1hr post-injection of 
[18F]FLT. The MIB-1 score (an antibody which recognises Ki-67) correlated with 
[18F]FLT uptake as measured by SUV(Cobben et al. 2004), however [18F]FLT-PET 
missed a 0.5cm diameter metastatic lymph node. Equivalent results for [18F]FLT and 
FDG have been reported for laryngeal cancer (Cobben et al. 2004), though as 
expected the tumour uptake of FDG was higher than that of [18F]FLT. In stage III 
melanoma, [18F]FLT-PET scans upstaged two out of ten patients with therapeutic 
consequences. The authors found [18F]FLT-PET had a threshold diameter of 6mm for 
detecting lymph node metastases and had a region based sensitivity of 88%(Cobben 
et al. 2003). 
1.13.3 FMAU 
2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) can be 
labeled with [11C] or [18F] (Conti et al. 1995; Wang et al. 2002; Sun et al. 2003). 
FMAU resists degradation and is incorporated into DNA but not RNA or protein. It has 
been previously used as an antiviral agent and an anti-neoplastic agent as at high 
concentrations it acts to inhibit DNA synthesis. FMAU is a substrate for TK1 and TK2 
and is incorporated into DNA by DNA polymerase. The level of uptake of FMAU in vitro 
is proportional to the rate of DNA synthesis and proliferation (Collins et al. 1999). 
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Studies in normal dogs show that there is increased uptake in proliferating tissues 
such as the bone marrow and intestine where 87% and 64% of the radioactivity was 
located in the DNA. In contrast, the radioactivity in non-proliferating tissues and organs 
such as the heart and kidneys was in the supernatant (Sun et al. 2005). 
Sun et al studied the dosimetry of [18F]FMAU in 14 patients with a variety of 
cancers (prostate, glioma, metastatic colorectal, renal, breast, lung, and sarcoma) 
using PET(Sun et al. 2005). All tumours were visualised. At 60 min post-injection 70% 
of the administered radioactivity in the urine was due to intact [18F]FMAU. There was 
physiological uptake in the heart, liver and kidneys. Due to high uptake in the latter two 
regions two regions were visible as areas of decreased signal intensity (i.e. cold 
spots). Low uptake in the bone marrow may allow further study of this agent for 
imaging bone metastases. The elevated physiological uptake in the liver and renal 
regions in humans compared to dogs could be attributed to interspecies differences in 
nucleoside transporters and tracer metabolism. 
1.13.4 Bromodeoxyuridine 
[76Br]Bromodeoxyuridine, [76Br]Du has also been suggested as an alternative 
to FDG. For years BrDu has been used in immunohistochemistry to assess 
proliferation in tissue sections. However despite encouraging results from preclinical 
studies with up to 70% of administered tracer detectable in tissue/tumour DNA, clinical 
evaluation of the tracer has proved disappointing. The main problems appear to be 
dehalogenation, resulting in high levels of [76Br] in plasma and non-proliferating 
tissues. Techniques in preclinical studies including forced diuresis with loop diuretics 
have been employed to circumvent this problem, but this would be an added burden 
for patients undergoing [76Br]Du scans(Lu et al. 1999). Data would require to be 
corrected for this high background activity as it needs to be distinguished from that of 
[76Br]Du. In a study of 8 patients with brain tumours on average only 9% of 
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radioactivity was found in tumour DNA (Gudjonssona et al. 2001). Cimetidine has also 
been used to decrease elimination and increase bioavailability of [76Br]Du (Borbath et 
al. 2002).[76Br] has a long VA of 16 hours, which increases the dose of radiation to the 
patient. 
1.14 Choline 
Choline is a quaternary saturated amine, an essential nutrient, and a precursor 
of i) phosphatidylcholine the major phospholipid component of cell membranes, ii) the 
neurotransmitter acetylcholine. The structure is shown below in Figure 1.16. 
Figure 1.16 Structure of choline 
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Choline is transported intracellularly in human breast cancer cells by a Michaelis-
Menten like mechanism, see Figure 1.17 (Katz-Brull et al. 1996). 
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Figure 1.17. Michaelis-Menten equation for enzyme catalysis 
ki 
kz 
A + E , B • E + C 
k-i 
(where ki is the rate constant for the combination of the enzyme E with the substrate 
A, to form the enzyme subtrate complex, B, l<-1 is the rate constant for the dissociation 
of the E and the unaltered substrate A and B (i.e. altered substrate), k2 is the rate 
constant for formation of the product C and enzyme E). 
Formation of phosphocholine results from the phosphorylation of choline by the 
enzyme choline kinase (CK) in the presence of ATP and This reaction effectively 
commits choline to the Kennedy pathway for the formation of phosphatidylcholine 
(PtC), see Figure 1.18. Hydrolysis of PtC is effected by three major PtC-specific 
enzymes, phospholipase C (PLC), phospholipase D {PLD), and phospholipase Ai and 
Az (PLAi and PLA2). The rate of choline phosphorylation by CK has been found to be 
twice that of its transport across the cell membrane(Katz-Brull et al. 1996). Three 
isoforms of CK have been elucidated in mammalian cells(Aoyama et al. 2004). The a 
isoforms of the enzyme (CKa1, CKa2) contain 453 amino acids, and CK(3 contains 394 
amino acids. Studies in mouse liver have shown that most (60%) of active CK exists as 
the 0/(3 heterodimer with the remainder as the homodimeric form (a/o or (3/ (3), this 
configuration changes to a/a as the predominating isoform when the cells are treated 
with the hepatotoxin CC14. The relative roles each of the isoforms plays in 
tumorigenesis and response to grov/th factors requires further evaluation. 
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Figure 1.18: Biosynthesis and hydrolysis of PtC. 
(where cytidylyltriphosphate=CTP, phosphocholine cytidyltransferase=(CT), 
phosphocholine transferase (PCT), phospholipase C = PLC, phospholipase D (PLD), 
and phospholipase A1, A2 =PLA land PLA2, and FFA, free fatty acid) Figure talon 
from Aboagye and Bhujwalla (Aboagye et al. 1999). 
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PtC is the major phospholipid constituent in cell membranes, and also acts as a source 
of lipid second messengers e.g diacylglycerol and lyso-phosphatidic acid. The rate-
limiting step in PtC formation is the cytidylyltriphosphate(CTP):phosphocholine 
cytidylyltransferase reaction. CK is also thought to play a regulatory function in PtC 
synthesis as increased CK activity results in an increased rate of PtC synthesis. 
However, induction of CK by ras oncogene transfection, growth factors (eg PDGF-AA, 
basic FGF, EGF and phorbol esters) and chemical carcinogens can result in increased 
formation of phosphocholine which is independent of PtC synthesis(Cuadrado et al. 
1993). Alterations in membrane choline phospholipid metabolism (MCPM) are evident 
in breast cancer tumorigenesis (Aboagye et al. 1999). In normal human mammary 
epithelial cells low levels of choline metabolites are present at steady state, with 
glycerophosphocholine (GPC) predominating, with benzo(a)pyrene-induced 
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immortialisation of the cells an early switch occurs such that the major metabolite 
changes to phosphocholine. Oncogenic transfection of erbB2 resulted in both an 
increase in the overall GPC:phosphocholine ratio and the total level of choline 
metabolites compared to the immortalised cells(Aboagye et al. 1999). 
The change in MCPM induced by erbB2 is thought to be due to activation of the 
erb2 receptor tyrosine kinase and hence stimulation of the ras/raf/MAPK pathway (see 
Figure 6). The increased rate of growth and proliferation has been attributed as the 
cause of altered MPCM in tumour cells, however in normal proliferating mammary 
epithelial cells the level of choline metabolites remains low and MPCM is unaltered; 
suggesting that the change in MPCM is being driven by another mechanism such as 
enhanced receptor tyrosine kinase cascade, amplification of CK, phospholipase C/D/A 
genes during carcinogeneis, or differential induction of different CK isozymes. 
In comparison with normal cells human breast tumour cells have been found to 
have an increase of CK activity of 38.5%(Ramirez de Molina et al. 2002). Inhibition of 
CK by RNA-interference (RNAi) mediated down-regulation of in nonmalignant and 
malignant human breast epithelial cell lines resulted in decreased proliferation 
(measured by PCNA and Ki-67) and formation of phosphocholine (measured by 
magnetic resonance spectroscopy spectroscopy (MRS)) and promoted cell 
differentiation (Glunde et al. 2005). The recently developed CK inhibitor, MN58b, also 
results in reduced formation of phosphocholine in breast cancer cells, with a 
decreased number of cells observed 48hrs after dosing (Al-Saffar et al. 2006). 
The cytokine tumour necrosis factor alpha (TNFa) induces cell cycle arrest in 
Go and Gi/S phases of the cell cycle. When a human breast cancer cell line (MCF7) 
were treated with TNFa there was a resultant decrease in phosphocholine production, 
which was found to be due to decreased choline transport into the cell and an 
accompanying 2-fold increase in the activity of the enzyme cytidine triphosphate 
cytidylyltransferase (Bogin et al. 1998). These cellular changes in choline metabolism 
are thought to be a prelude to apoptosis. 
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Radiolabelled choline has been used to study the effect of inhibition of the Raf-
I/IVIAP kinase pathway in a cell culture study using HT29 colon carcinoma cells. 
Geldanamycin, a benzoquinoid ansamycine antibiotic related to herbimycin A, binds to 
heat shock protein 90 (hspQO) in complex with co-chaperones, leading to degradation 
of Raf-1 and other oncogenic client proteins. When treated with geldanamycin, a 
decrease in methyl-[14C]choline uptake and phosphocholine production was 
observed, which was associated with a decrease in extracellular signal regulated 
kinase 1 and 2 phosphorylation (Liu et al. 2002). This effect was independent of PIS 
kinase. 
1.15[18F]-AH111585 
The focus of the final study in this thesis concerns a new [18F]-labelled RGD 
peptide,which is proposed to measure avps integrin levels. The first synthetic RGD 
peptide developed for imaging by Haubner et al [125i]-c(RGDyV) in mouse models of 
melanoma and osteosarcoma also had high liver signal due to hepatobiliary 
clearance(Haubner et al. 1999). To try and circumvent this problem van Hagen et al 
then coupled an RGD analogue to diethyleletriamepentaacetic acid (DTPA) which 
when labelled with [1111n] resulted in renal clearance in a rat model, further advances 
of this compound were limited as the uptake and retention in the kidneys was 4-8 times 
that of any other tissue(van Hagen et al. 2000). Several RGD-based peptides have 
now been evaluated as imaging agents with both PET and SPECT. Studies focusing 
on the RGD binding site of the integrin receptor have utilised a peptide combined to a 
galacotose ring, which enables rapid uptake, distribution and excretion of the tracer. 
Coupling of a sugar amino acid moiety (SAA) to a second generation derivative 
of the compound used by Haubner, [125l]-c[RGDyK(SAA)] yielded further 
improvements in tumour retention, tumour to blood ratios, decreased liver signal, and 
similar renal and blood clearance in murine models of melanoma and osteosarcoma. 
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Glycosylation resulted in the pentapeptide becoming more hydrophilic, which explains 
the alteration in pharmacokinetics (i.e. preferred renal to hepatobiliary excretion). 
However this modification also results in increased activity in lung, mycocardium, and 
liver compared to the non-glycosylated peptide(Haubner et al. 2001). 
[18F]Galacto-RGD PET uptake measured by SUV in a variety of human 
malignant tumors correlated with tissue expression of avps measured by 
immunohistochemistry using the LM609 antibody and MVD(Beer et al. 2006). The 
alpha V integrins recognise Arginine-Glycine-Aspartate (RGD) as a determinant factor 
for binding to their cognate ligands. Pasqualini et al have shown that RGD-based 
peptides displayed on a probe designed to target alpha v integrins bind to those 
expressed on tumor neovasculature (Pasqualini et al. 1997) rather than that on tumor 
cells in a breast cancer model, using MDA-MB-435. The ratio of avp3/5 integrin 
expression on endothelial cells compared to human breast carcinoma cells in vivo in 
patients remains unknown. 
Expression of membrane-type 1 matrix metalloproteinase in MCF-7 cells is 
associated by functional association of avpS which initiates the first step in activation 
of the pro-angiogenic matrix metalloproteinase 2 (MMP2)(Deryugina et al. 2000). avp3 
experession in a breast cancer cell line has also been shown to accelerate the 
development of osteolytic bone metastases(Pecheur et al. 2002). Abdollahi et al 
studied the effect of an av integrin inhibitor, S247, combined with external beam 
radiotherapy in prostate cancer cells and human umbilical vascular endothelial cells 
(HUVEC) and found that the combination enhanced the anti-angiogenic effects of 
radiation by inhibiting the radiation induced up-regulation of avp3 expression and Akt 
activation (Abdollahi et al. 2005). Non-invasive imaging of avp3 status in the future 
could act as a predictive factor for choosing therapy. 
In the clinical setting several av integrin antagonists are in phase 1/2 trials, and 
can be classified into antibodies, endogenous peptides, synthetic peptides and 
peptidomimetics (Alghisi et al. 2006). Cilengitide is a cyclic RGD peptide which acts as 
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an avp3 and avps antagonist and is now undergoing Phase 2 clinical trials in patients 
with hormone-refractory prostate cancer, non-small cell lung cancer and pancreatic 
cancer. A Phase 1 study of cilengitide in patients with advanced solid tumors did not 
reach dose limiting toxicity, therefore the optimum dose for this agent remains to be 
determined (Eskens et al. 2003). Vitaxin is a humanised form of LM609, has also 
entered early stage clinical trials(Gutheil et al. 2000). Treatment with the anti-
angiogenic agent AG-013736 (a small molecule inhibitor of VEGF/PDGF receptor 
kinases) has been shown to result in decreased integrin expression measured by an 
RGD-phage displayed peptide in a preclinical model (Yao et al. 2006). 
The final study is a first-in-man study of [18F]-AH111585 to determine its 
pharmacokinetics and utility as a radiotracer in patients with advanced breast cancer. 
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Thesis Outline 
This thesis describes the biological processes which lead to tumour 
proliferation in cancer, the current methods for measuring response to treatment, 
theory and principles of PET, and rationale for new radiotracers (Chapter 1). The next 
chapter focuses on clinical studies of [18F]FLT-PET, including correlation of its 
retention and delivery with immunohistochemical markers of proliferation, generation of 
a cardiac input function for use as an alternative to sampling blood from the radial 
artery, repeatability in the absence of treatment, and examination of its potential as an 
early response marker in response to cytotoxic chemotherapy. The roles of different 
analysis techniques are compared, and tracer uptake in normal tissues is assessed. 
Finally the value of using [18F]FLT as a pharmacodynamic marker to thymidylate 
synthase by capecitabine is presented. Chapter 3 focuses on [11C]choline-PET, 
correlation with histological parameters of MAPK activity, repeatability of uptake, and 
early changes in response to HER2/neu inhibition by trastuzumab. The final chapter 
describes a phase 1 study of a new tracer ([18F]-AH111585) used to image tumour 
angiogenesis in metastatic breast cancer by detecting the av(33 integrin. 
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CHAPTER 2: [18F]Fluorothymidine ([18F]FLT) 
2.0 Outline of [18F]FLT Projects 
The first project examines how the uptal<e and retention of [18F]FLT correlates 
with Ki-67 LI, a commonly used immunohistochemical marl<er of cell proliferation, in a 
group of patients with primary and metastatic breast cancer. Previous studies have 
shown a correlation between [18F]FLT uptake and KI-67 LI in non-small cell lung 
cancer(Vesselle et al. 2002; Buck et al. 2003), but this is the first time that 1) the value 
of mathematically-modelled kinetic parameters and 2) the utility of [18F]FLT-PET in 
breast cancer will be studied. The use of the cardiac blood pool to derive a suitable 
arterial input function for [18F]FLT is then explored. 
One of the essential characteristics of any test is that it lacks significant test-
retest variability in the absence of any intervention. The same is true for the 
development of new radiotracers(Aboagye et al. 2003). The second study evaluates 
the repeatability of [18F]FLT and the pharmacokinetic parameters SUV, Ki, and FRT. 
The data will then be used to determine significance levels after intervention with FEC 
chemotherapy. This third study (response to treatment) will compare pre- and post-
treatment [18F]FLT uptake and retention at one week to clinical response at 60 days 
post first treatment as is normal with clinical evaluation to chemotherapy. In responding 
tumour lesions it is expected that at one week a decrease in [18F]FLT uptake will be 
seen due to decreased tumour proliferation. The potential of [18F]FLT-PET for use as 
a pharmacodynamic marker to study the activity of the thymidine salvage pathway an 
early increase in [18F]FLT uptake is expected in response to successful inhibition of 
thymidylate synthase. The initial results of this [18F]FLT-PET study are presented at 
the end of this chapter. 
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2.1 [18F]FLT-PET Correlation with Proliferation in Breast Cancer 
2.1.1 HYPOTHESIS 
[18F]FLT uptake measured by PET corresponds with proliferation in breast cancer 
Non-invasive left ventricular sampling provides a suitable surrogate arterial input 
function for [18F]FLT-PET to that obtained from radial artery sampling 
2.1.2 AIMS 
• To assess pharmacokinetic parameters which describe [18F]FLT 
uptake in breast cancer lesions in vivo using PET 
• To determine if the parameters differ significantly from those in 
corresponding normal tissue 
• To measure the correlation between [18F]FLT-PET in vivo and 
proliferation in the same tumours using the Ki-67 LI in tumour biopsies 
• In patients where the heart is in the field of view of the PET scanner, to 
correlate the results derived from radial arterial sampling with non-
invasive cardiac sampling. 
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2.1.3 INTRODUCTION 
Tumour proliferation is a key target for modern cancer therapeutics. Breast 
cancer was chosen as a model system as i) there is an opportunity to correlate 
imaging findings in tumours in situ prior to surgery or treatment with biopsy findings, ii) 
outcomes for the treatment of breast cancer need to be improved, and iii) a successful, 
non-invasive marl<er of breast tumour proliferation could potentially be extrapolated to 
a large population of patients resulting in widespread diagnostic and therapeutic 
applications as there is a high incidence of breast cancer in the Western world. 
Patients with larger breast tumours are increasingly being treated with 
neoadjuvant chemotherapy in an attempt to downstage the size of the tumour and 
make limited surgery a viable option(Buzdar 2007; Mieog et al. 2007). Despite any 
clear survival benefit from neoadjuvant treatment, the opportunity to test 
chemosensitivity in vivo and kill occult micrometastases remains attractive: however 
novel early predictors of response are required to validate this approach. Patients with 
relapsed and metastatic disease were included in the study to enable the utility for 
[18F]FLT-PET in these situations to be discovered. Primary tumours less than 2.5 cm 
were not included in this study, as currently there is no role for neoadjuvant treatment 
in this patient group and the standard initial treatment is surgical excision (except if the 
patient is medically unfit for surgery, or as part of a clinical trial). 
Tumour expression of the Ki-67 antigen, an immunohistochemical marker of 
proliferation, is widely used to assess prognosis. In patients with breast cancer treated 
with neoadjuvant endocrine therapy changes in expression of Ki-67 after only 2 weeks 
of therapy were predictive of relapse free survival(Dowsett et al. 2007). Interestingly 
this study found that the baseline proliferation level did not affect prognosis, whereas if 
the level remained elevated at 2 weeks then prognosis was adversely affected. Rather 
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than performing repeat biopsies, [18F]FLT-PET has the potential to offer a non-
invasive method of measuring tumour proliferation in serial studies. 
For [18F]FLT to be a viable radiotracer for use in breast cancer, it is imperative 
that tumour uptake is significantly different from corresponding normal tissue. In 
planning this study the region of interest (ROI) analysis was for complete tumour 
ROIs in breast or metastatic regions to be compared with normal breast or (if normal 
breast was not in the field of view) lung on the contralateral side. The kinetics of the 
radiotracer in blood and tissue need to be ascertained, as it is unlikely that a tracer 
which is rapidly metabolised into multiple metabolites, or has a rapid washout from 
tissues is going to gain widespread acceptance outside research centres. The 
optimum time for PET scanning post intravenous injection for [18F]FLT is not known, 
therefore dynamic imaging over a reasonable time window should allow the optimal 
period of tumour uptake from the injection time point to be detected. 
Radiotracer uptake and retention can be described by a variety of 
pharmacokinetic parameters - described in Chapter 1. Analytic methods used to 
describe "proliferation-related" PET parameters measured the kinetics of [18F]FLT 
simultaneously in arterial blood and tissues using dynamic PET scanning, such a 
protocol has not been reported previously. In planning this study, the PET parameters 
were compared in terms of correlation with Ki-67 LI in tumour samples. 
To determine if arterial sampling was required for future studies, in patients 
where the heart was in the field of view of the PET scan, a region of interest was 
drawn manually on the cardiac blood pool and compared to the measured data 
obtained from the online blood sampling from the radial artery. This would facilitate 
future studies without the need for radial artery sampling, whilst not limiting the 
availability of measuring multiple pharmacokinetic parameters. The kinetic analysis 
presented in the [18F]FLT studies in this chapter relies upon continuous radial artery 
sampling to provide an accurate estimate of radiotracer concentration in plasma over 
time i.e. a dynamic arterial plasma input function; this is viewed as the gold standard 
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for PET imaging. Most PET centres do not have this facility, and are therefore 
restricted to semiquantitative parameters. Alternatives to arterial sampling do exist, 
such as arterialised-venous sampling which requires hand warming and continuous 
venous sampling. A less invasive option is the use of the cardiac blood pool drawn as 
an ROI over the left ventricle, which was explored in the patients in this study. 
Compared to FDG, there should be little myocardial uptake of [18F]FLT as 
myocardial expression of TK1 is intrinsically low(Toyohara et al. 2002). Previous 
studies have employed the alternatives described above for FDG (Weinberg et al. 
1988; Choi et al. 1991; Choi et al. 1993; Chen et al. 1994), but the use of alternatives 
for [18F]FLT has yet to be evaluated. 
2.1.4 METHODOLOGY 
2.1.4.1 Eligibility criteria and recruitment 
Patients were recruited from medical oncology clinics in Charing Cross 
Hospital, London. The inclusion criteria for patients were as follows: 1) age > 18 years 
and < 80 years, 2) histologically or cytologically proven breast cancer, 3) at least one 
site of measurable disease > 2.5cm (n.b. patients with liver and/or bone metastases 
were allowed to participate in the study provided the measurable lesion was not 
located at these sites as previous studies suggested high normal uptake in these 
regions(Shields et al. 1998)), 4) have a treatment-free interval of > 3 weeks (for 
cytotoxic chemotherapy, hormonal therapy, or cytostatic agents), nb 4 weeks applied 
for radiotherapy to the imaging site - to give a satisfactory washout period and prevent 
measurement of an effect related to previous treatment, 5) life expectancy of > 3 
months, 6) haemoglobin of > lOg/dL, granulocyte count of > 1.5 x 10^/L, platelet count 
of > 100 X 10®/L, 7) adequate creatinine clearance (calculated > 50ml/min), 8) 
adequate hepatic function (bilirubin < 1.5 ULN, serum transaminases < 2.5 x the upper 
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limit of normal) 9)EC0G performance status 0 - 2 inclusive(Oken et al. 1982) - see 
Appendix 1, 10) be able to give fully informed consent and comply with the protocol. 
The exclusion criteria were; 1) pregnant or lactating patients, 2) sexually active 
patients who were not employing adequate contraception (pregnancy tests were 
performed in all women of childbearing potential, this population was strongly advised 
to avoid pregnancy in this study), 3) patients with uncontrolled medical conditions, 4) 
patients unable to lie flat, 5) patients with evidence or previous diagnosis of cerebral 
metastases. 
Eligible patients were approached and given a study information leaflet to 
consider at their leisure. All research was performed according to the Declaration of 
Helsinki guidelines. Ethical approval for the studies was granted by the Hammersmith 
Hospitals NHS Trust Ethics Committee. 
The plan was to recruit 10 patients, allowing for a dropout rate of 20% for a 
target of 8 patients. However, if after 3 patients it became apparent that with 3 scans 
there was excessive bruising, or the scans were not well tolerated, it was proposed to 
recruit 14 patients in total, allowing for a dropout rate of 21% for a target of 11 patients. 
The plan of the study would have been changed such that each of the further 8 
patients would have 2 scans each, either baseline + repeatability, or baseline + post-
treatment (there would be 4 patients in each of these groups). As the initial protocol 
was well tolerated in the first 3 patients, the study continued with 3 scans planned for 
each subject. A decision was made to study 15 patients in total to improve the 
robustness of the data, ethics and ARSAC appoved this amendment. 
Fifteen patients with 13 primary tumour areas, 6 nodal metastatic regions, and 
1 pulmonary metastasis were included. The histological types were as follows: 11 
tumours were invasive ductal carcinomas, 3 were lobular carcinomas, and one was an 
inflammatory carcinoma. 
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For the cardiac blood pool analysis, eleven patients who participated in the 
[18F]FLT proliferation, repeatability and response to FEC chemotherapy studies were 
included as the heart was in the field of view. 
2.1.4.2 Scanning procedure and [18F]FLT synthesis 
An arterial cannula was inserted in the radial artery prior to the start of the scan 
(after an Allen's test to ensure satisfactory ulnar circulation) under local anaesthetic 
(2% bupivicaine) to allow arterial blood sampling during the scan. A second cannula 
was inserted into a suitable upper limb vein to allow intravenous administration of the 
radiotracer. Two transmission scans ( -20 min) were performed to ensure that the 
patients were positioned correctly, i.e. the field of view was centred on the tumour of 
interest, and to facilitate attenuation correction. 
Patients were scanned for 95 minutes following a bolus intravenous injection of 
a tracer dose of [18F]FLT over 30 seconds. Radiochemical purity and specific activity 
was determined by the quality control laboratory staff in Hammersmith Imanet® prior to 
injection. The dose injected ranged from 153 to 380MBq (specific activity 25-465 
GBq/jjmol, measured using high performance liquid chromatography (HPLC)). PET 
scans were performed using an ECAT962 HR+ tomograph (CTI/Siemens Knoxville, 
TN) within Hammersmith Imanet (GE Healthcare®) which allows simultaneous data 
acquisition to form 63 transaxial planes (axial field of view 15.7 cm). Images were 
reconstructed using 20 filtered back projection (FBP). In two patients reconstruction 
was performed using an iterative ordered subset expected maximisation algorithm to 
identify the tumour regions, the object maps drawn using this method were then 
applied to the images obtained by the filtered back projection method. This was 
attributed to the presence of high noise in the background region (due to the liver 
being in the field of view in 1 case, and the intravenous injection site in the second). 
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Data were binned into 31 discrete time intervals (referred to as frames) of 
varying length (30s x 10; 60s x 5; 120s x 5; 180s x 5; 600s x 6). The scanner 
dimensions are shown below in Table 2.1. The raw data count was transferred onto 
SPARC Ultra workstations (Sun Microsystems Inc., Mountain View, California, USA). 
Reconstruction into 3D images of radioactivity concentration was performed using CTI 
(Siemens, Knoxville) software. 
Table 2.1: Dimensions of the ECAT 962 HR+ Tomograph 
Scanner 962 
Reconstruction method 2D FBP 
Zoom 1.00 2.5 
Pixel size (x-y) mm 5.23 2.09 
Slice thickness 2.42 
Transaxial resolution (x-y) mm 8.5 ramp, brain mode off 
Axial resolution (z) mm 5.0 
All radiochemical synthesis of [18F]FLT was performed by the chemistry 
department within Hammersmith Imanet®. [18F]FLT was synthesised by a method 
which involves radioflorination of the 2,3'-anhydro-5'-0-(4,4'-dimethoxytrityl)-thymidine 
precursor described previously by Cleij et al (Cleij 2001). The maximum permissible 
cold activity was <10 micrograms per preparation. Radiochemical purity was > 95%. 
The pH range of the injectate was restricted to between 5.5 and 7.5. 
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2.1.4.3 Determination of Radioactivity in Blood and Plasma after Injection of 
[18F]FLT 
In addition to the PET scanning, arterial blood sampling was performed 
continuously for tine first 10 minutes post-injection; discrete arterial samples were taken 
at baseline, 2.5, 5, 10, 20, 30, 45, 60, 75, and 90 min. Total blood radioactivity was 
measured from the continuous sampling in an on-line radioactivity detector. The 
activity was compared to that in the discrete samples which was monitored by gamma 
counting; [18F]FLT plasma parent fraction (and metabolite, [18F]FLT-
glucuronide)(Muzi et al. 2005) was determined by HPLC (Barthel et al. 2003). 
The radioactivity in an aliquot of blood and plasma (1ml) was measured using a 
sodium iodide well counter. The remainder of blood (7ml) was centrifuged at 14,000 
rpm to obtain plasma. The plasma samples (2ml) were deproteinised by solvent 
extraction (using 5 fold ice-cold acetonitrile. Fisher Scientific, Leicestershire UK) 
analysed using a reverse-phase HPLC. The column (CI 8, p Bodapak, 30 x 0.78 cm id; 
10 pm particle size) was washed with the mobile phase: a mixture of potassium di-
hydrogen phosphate, pH 4.5 (lOmM) and acetonitrile (85:15, v/v) at a flow rate of 3ml 
per min. The eluate was monitored for radioactivity. Both detectors were linked to a PC 
based integrator which recorded the radioactivity profile and enabled the correction for 
[18F]-radioactivity decay and background and integration of radioactive components. 
The amount of [18F]FLT and other radioactive components at each sample time was 
calculated as a percentage of each radioactive component in each analyte. 
The [18F]-radioactivity profile in plasma showed parent [18F]FLT and another 
more polar radioactive component than [18F]FLT. [18F]FLT decreased slowly with 
time, whereas the polar radioactive component was observed to increase with time 
(see figure 2.2). 
To assess the metabolism of [18F]FLT, 5 arterial plasma samples taken at 60 
min were treated with ^-glucuronidase (5000U/ml) for 30 min at 37 °C, or (3-
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glucuronidase (5000U/ml) and a ^-glucuronidase inhibitor (saccharic acid -1,4,lactone 
(0.5M)) for 30min at 37 °C and analysed by HPLC using the method of Barthel et 
al(Barthel et al. 2003). The results of the metabolite analysis from this technique are 
shown in Table 2.1. The metabolite analysis was performed by Hammersmith Imanet 
staff under the supervision of Ms S Osman. 
2.1.4.4 Pharmacokinetics and Data Analysis 
Following reconstruction, the kinetic image data were analysed with the aid of 
Analyze® image analysis software (Biomedical Imaging Resource, Mayo Foundation 
Rochester, MN, USA). Images from the final 5 time frames were combined to form an 
"add image" on which an object map was defined. Regions of interest (ROIs) were 
drawn manually on tumour, normal breast, lung, and vertebral tissue. The object map 
was then applied to the complete dynamic image data set to derive tissue activity time 
curves (TACs). From these TACs, together with the blood data, the following methods 
of analysis were used to generate parameters, which describe delivery, washout, 
uptake and retention of the tracer. 
SUV and AUG 
The semiquantitative parameters SUV and AUG were calculated for each 
region from the TACs after correction for the injected dose of radioactivity and [18F] 
decay. The average (as opposed to peak) activity during specific time frames was 
used for calculation of both parameters. Weight and height were measured for each 
patient immediately prior to scanning. 
Corrected activity (t) [m^/ml] = Measured activity at time (t) [kBq/mll x e^' 
Injected dose [kBq] / BSA 
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A, = decay constant for [^ ®F] (1.053 x 10"^) 
t = time in minutes 
BSA = Body surface area (m^) - this was calculated for each patient visit. 
NB Corrected activity is equivalent to standardised uptal<e value (SUV). 
SUV was corrected for body surface area (BSA) using the formula below: 
BSA (m=^ ) = 0.20247 x Height(m)°^^® x Weight(l(g)°^^^(DuBois D 1916) 
For AUG the integral of each SUV value multiplied by the duration of the time frame in 
seconds for the 31 time frames was calculated. 
Plasma Input Functions 
The ratio of radioactivity in whole blood to plasma measured in the discrete 
blood samples (described above) was fitted to a linear function and plotted against 
time. The proportion of radioactivity in plasma recovered in the non-metabolised, i.e. 
parent fraction, was fitted to a function describing an exponential approach to a 
constant. These two functions were then applied to the continuous on-line and discrete 
arterial data, which after cross-calibration with the camera gives a parent plasma input 
function for subsequent kinetic analyses (i.e. compartmental, spectral, and Patlak). 
The plasma input functions were generated using IVIatlab versions® with in-house 
software. Modifications of the arterial plasma input function were used for Patlak 
analysis and are described in the Patlak and spectral analysis section below. 
Compartmental Modelling 
A two tissue compartmental model, similar to the one described by Sokoloff for 
FDG, was used to derive the unidirectional delivery macro parameter Ki(Sokoloff L 
1977)..This was possible for [18F]FLT as the proportion of metabolites in the delivery 
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phase is negligible (see chromatogram at 2 minutes shown in Figure 2.2A below). The 
proposed model for [18F]FLT is shown below in Figure 2.1. The process of 
glucuronidation of FLT blocks phosphorylation, as phosphorylation and glucuronidation 
occur at the same position. 
Figure 2.1: Two Tissue Compartment Model for MSHFLT 
metabolic 
compartment 
free 
space 
vascular 
compartment 
free 
space 
vascular 
compartment 
(where K1= unidirectional delivery of [18FJFLT from plasma to tissue, k2 = 
transfer back from tissue to plasma, k3 = trapping of [18F]FLT as the phosphorylated 
form within tissue by TK1, k4 = dephosphorylation of [18FJFLT within tissue, K1' = 
delivery of [18F]FLT-glucuronide into tissue, and k2'=transport of [18F]FLT-glucuronide 
back to plasma). 
The time delay between tissue uptake and measurement of on-line blood radio 
activity of the tracer was chosen initially depending on the best fit of the mathematical 
model to the raw tissue data and selecting the delay with the lowest residual sum of 
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squares. During the project, an automated method of delay detection became 
available using Matlab® and the compartmental model shown above. This method for 
computing delay detection was then applied to all data in this thesis. 
Patlak and Spectral Modelling 
Three forms of Patlak analysis were undertaken in this study by using three 
different arterial input functions: i) classical Patlak using the parent plasma input 
function in which there is correction for the presence of metabolites in arterial plasma, 
ii) total Patlak in which there is no correction for metabolites in the plasma input 
function and iii) modified Patlak in which there was correction for metabolites in both 
tissue and plasma, see Chapter 1 for equations (Patlak et al. 1985; Mankoff et al. 
1996). 
Whilst Patlak analysis measures irreversible retention, the exact 
pharmacokinetics of [18F]FLT have not yet been described; therefore spectral analysis 
- a data-led approach with no a priori assumptions about radiotracer behaviour was 
undertaken. Spectral analysis was used to calculate the ratio of tracer uptake at sixty 
minutes and ninety minutes compared to that at 1 minute (FRT60:1 and FRT90;1). 
Cardiac Blood Pool Analysis 
The early time frames (2 to 5) were used to form a composite image from 
which the cardiac blood pool was identified as an ROI to minimise any possible spill 
over from myocardial uptake which should be minimal. The periphery of this was 
drawn manually to form an object map, which was then applied to the dynamic 
[18F]FLT image to generate TACs, and the area under the time activity curve (AUG 
kBq.sec.ml"') determined as an integral of the midframe uptake multiplied by the frame 
duration in seconds. The AUG of the total blood input function curve was also 
calculated for comparison, as in the heart ROI the measured activity was from total 
blood - i.e. it was not possible to separate arterial plasma for region analysis. The 
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peak activities for tlie heart ROI and total blood input functions, AUG at 60 minutes 
(AUC60), AUG at 90 minutes (AUG90), and total blood activity at 60 minutes vjere 
compared. 
2.1.4.5 Ki-67 Immunohistochemistry 
To determine the relationship between [^®F]FLT uptake and histological 
markers of proliferation patients with a suitable core biopsy taken within 3 months of 
the scan (median 18 days) were studied. Formalin fixed sections were sectioned and 
stained with an anti-Ki-67 monoclonal antibody, NGL-Ki-67-MM1 (Novocastra 
Laboratories, Newcastle Upon Tyne, UK). All staining was performed by David Peston, 
of the immunohistochemistry laboratory. Department of Histopathology, Gharing Gross 
Hospital London. 
The numbers of total and Ki-67 positive tumour cells were manually counted in 
8 randomly selected fields of view using a BX51 microscope (Olympus Optical, Tokyo, 
Japan) at 400 X magnification with the aid of Sigma Scan Pro 5 (Aspire Software 
International, Leesburg, VA). The ratio of Ki-67-positive stained cells to the total 
number of tumour cells was then used to calculate the Ki-67 labelling index (LI). 
2.1.4.6 Statistical Analysis 
A paired t-test was used to assess the difference between tumour and normal 
tissue data (breast, or if normal breast tissue was not in the field of view normal lung 
tissue was used). The association between PET parameters and Ki-67 LI was 
determined using the Pearson correlation coefficient (95% confident, two-tailed). A p-
value of < 0.05 was considered significant. All statistical analysis in this thesis was 
performed using the aid of Graph Pad Prism ® version 3 (Graph Pad Software, San 
Diego, Galifornia, USA). 
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2.1.5 RESULTS 
2.1.5.1 Patients 
Fifteen female patients aged between 37 and 79 years participated in the 
study. The scans were well tolerated. The tumour phenotypes, regions studied, and 
results of the semi-quantitative analysis and modelled parameters are shown in Table 
2.2 and Table 2.3 respectively. The majority of the patients had ductal carcinoma 
(73.3%), followed by lobular carcinoma (20%); inflammatory carcinoma was the least 
common (6.7%). This is in keeping with findings in the general population where ductal 
carcinoma represents the most common histological subtype of breast cancer affecting 
75% of breast cancer patients (Veronesi et al. 2005). 
Uptake was studied on a lesion by lesion basis - in large tumours (i.e. greater 
than 5cm) the ROls covered a proportion of the tumour area as there was significant 
heterogeneity in uptake of [18F]FLT over large tumour areas. Regions which were 
obviously necrotic were not included within the tumour ROls. In total, twenty nine 
tumour regions comprising of 22 primary tumours and 7 metastatic lesions were 
studied. 
2.1.5.2 Metabolism of [18F]FLT and effect of p-glucuronidase 
The results shown in Figure 2.2 and Table 2.1 (below) indicated that during the 
scanning period, [18F]FLT was metabolised into a single metabolite -
[18F]glucuronide. This reaction was inhibited by the addition of ^-glucuronidase 
leading to an increase in [18F]FLT, and the action of ^-glucuronidase was 
subsequently inhibited by the addition of saccharic acid-1,4-lactone leading to a 
decrease in the percentage fraction of [18F]FLT detected in arterial plasma. 
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Figure 2.2: HPLC Chromatoqrams from arterial plasma showing MSFIFLT and 
metabolite 
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where A) 2 min arterial plasma sample showing a parent [^®F]FLT peak, B) 60 min 
arterial plasma (control) sample in which both [^®F]FLT and [^®F]FLT-glucuronide peaks 
are seen, C) 60 min arterial plasma sample incubated with ^-glucuronidase, D) 60 min 
arterial plasma sample incubated with ^-glucuronidase and (saccharic acid-1,4-
lactone). 
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Table 2.1: Metabolism of [18F]FLT and effect of p-glucuronidase 
Percentage Radioactivity due to [18F]FLT 
60 min plasma 
Sample 
60 min plasma sample 
+ ^-glucuronidase* 
60 min plasma sample 
+ ^-glucuronidase 
+ saccharic acid 1,4 lactone® 
Sample 1 80.61 93.59 88.97 
Sample 2 80.05 94.55 77.16 
Sample 3 76.85 93.78 77.12 
Sample 4 84.80 90.39 ND 
Sample 5 74.00 88.00 80 
Tables 2.2 and 2.3: Kinetic parameters for primary tumours, metastatic tumours, 
and normal tissue (breast or lung). 
* Intraductal carcinoma is represented by the letter D, invasive lobular carcinoma by 
the letter L, and inflammatory carcinoma by the letter I; the histological types are 
suffixed with the tumour grade (1-3). Ki, rate constant measured by the modified Patlak 
technique (ml plasma.ml tissue'^ s"^) x 10^. K1 - delivery constant (microL.s"\mL'^). 
Larger tumours (> 5cm) were subdivided into separate regions for analysis. SUVA = 
SUV at 21.5 min, and SUVG = SUV at 90 min (m^ml"^) x 10'^ AUG - AUG measured at 
90 minutes (m^.ml.s"^). 
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Table 2.2: Semiquantitative parameters of [18]FLT uptake 
Patient# Region, Type and Grade* SUVA SUVB AUG 90 
1 Tumou L2 5.767 6.308 0.353 
3 Tumou D3 5.418 3.795 0.269 
4 Tumou A, D2 7.868 9.164 0.467 
4 Tumou B, D2 5.989 7.189 0.365 
4 Tumou C, D2 9.515 10.749 0.571 
4 Tumou D, D2 8.736 10.293 0.528 
5 Tumou , L3 4.134 3.676 0.208 
6 Tumou A, D3 9.286 11.189 0.560 
6 Tumou B, D3 8.002 9.912 0.498 
7 Tumou , D2 5.118 4.999 0.273 
8 Tumou A, D2 5.863 6.296 0.348 
8 Tumou B, D2 4.541 5.384 0.286 
8 Tumou C, D2 5.030 5.736 0.314 
8 Tumou D, D2 6.721 8.510 0.443 
9 Tumou , D2 4.335 4.827 0.259 
11 Tumou A, 13 5.063 4.373 0.280 
11 Tumou B, 13 4.188 3.726 0.228 
12 Tumou . L2 3.039 2.368 0.160 
13 Tumou , D2 13.128 14.415 0.751 
14 Tumou , D2 7.824 8.324 0.469 
15 Tumou A, D2 6.929 7.583 0.401 
15 Tumou B, D2 5.366 6.349 0.332 
2 Lung metastasis, D3 5.721 6.369 0.353 
5 Mammary node 7.171 7.232 0.387 
5 Axillary node 3.950 6.188 0.299 
6 Axillary node 8.076 9.159 0.479 
10 Axillary node 13.728 19.983 0.927 
10 Pretracheal node 10.124 12.184 0.621 
13 Axilla 9.349 14.211 0.646 
1 Normal breast 2.252 1.748 0.115 
2 Normal lung 1.583 0.922 0.075 
3 Normal breast 1.010 0.664 0.044 
4 Normal breast 0.456 0.046 0.019 
5 Normal breast 1.096 0.469 0.047 
6 Normal breast 2.792 2.220 0.137 
7 Normal breast 1.329 0.769 0.055 
8 Normal breast 1.203 0.867 0.061 
9 Normal breast 2.039 1.445 0.080 
10 Normal lung 2.241 1.152 0.106 
11 Normal breast 1.639 1.246 0.089 
12 Normal breast 1.854 1.259 0.095 
13 Normal breast 0.771 0.557 0.042 
14 Normal breast 1.295 1.109 0.071 
15 Normal breast 0.314 0.471 0.071 
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Table 2.3: Modelled pharmacokinetic parameters of [18]FLT uptake 
Patient* 
Region, Type and 
Grade 
Ki FRT 90:1 
Ki 
1 Tumour, L2 2.987 0.192 1.815 
3 Tumour, D3 1.953 0.120 2.051 
4 Tumour A, D2 6.717 0.524 1.455 
4 Tumour B, D2 5.462 0.536 1.237 
4 Tumour C, D2 7.018 0.413 2.404 
4 Tumour D, D2 7.895 0.444 2.021 
5 Tumour, L3 2.269 0.179 2.051 
6 Tumour A, D3 5.390 0.264 2.301 
6 Tumour B, D3 5.362 0.305 1.887 
7 Tumour, D2 1.767 0.194 1.314 
8 Tumour A, D2 3.603 0.213 2.048 
8 Tumour B, D2 3.135 0.231 1.641 
8 Tumour C, D2 3.560 0.238 1.769 
8 Tumour D, D2 5.476 0.324 1.982 
9 Tumour, D2 2.233 0.183 1.518 
11 Tumour A, 13 1.958 0.097 2.515 
11 Tumour B, 13 1.615 0.113 1.978 
12 Tumour, L2 0.627 0.098 0.964 
13 Tumour, D2 3.581 0.367 3.820 
14 Tumour, D2 3.534 0.322 1.639 
15 Tumour A, D2 1.818 0.202 1.792 
15 Tumour B, D2 1.550 0.209 1.399 
2 Lung metastasis, D3 3.978 0.252 1.920 
5 Mammary node 5.276 0.373 1.215 
5 Axillary node 3.759 0.182 2.825 
6 Axillary node 4.570 0.267 1.895 
10 Axillary node 10.379 0.594 2.072 
10 Pretracheal node 6.509 0.380 3.528 
13 Axilla 10.311 0.467 2.266 
1 Normal breast 0.448 0.087 0.374 
2 Normal lung 0.408 0.089 0.659 
3 Normal breast 0.468 0.178 0.245 
4 Normal breast < 0.03 0.005 0.448 
5 Normal breast 0.000 0.001 1.184 
6 Normal breast 0.570 0.151 0.514 
7 Normal breast 0.190 0.081 0.397 
8 Normal breast 0.226 0.096 0.539 
9 Normal breast 0.514 0.222 0.290 
10 Normal lung 0.549 0.053 0.625 
11 Normal breast 0.348 0.084 0.571 
12 Normal breast 0.235 0.099 0.369 
13 Normal breast 0.472 0.019 0.315 
14 Normal breast 0.484 0.213 0.272 
15 Normal breast 0.010 0.033 0.355 
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2.1.5.3 [18F]FLT uptake in tumour and normal lesions 
Twenty nine distinct tumour areas in the 15 patients were detected using 
[18F]FLT-PET. [18F]FLT-PET was able to visualise all of the breast tumour lesions in 
the study. All of the patients had measurable disease in the breast or axilla except for 
patient 2 who had a secondary lung metastasis (from breast cancer). 
The mean activity injected was 302 MBq (range 153-381 MBq, radiochemical 
purity 100%). [18F]FLT localised mainly in tumour, liver and vertebrae - see Figure 
2.3. The uptake of [18F]FLT-PET was not reversible within the duration of the 
scanning period. [18F]FLT-PET images showed high tumour-to-background contrast. 
Uptake was also seen in the liver and bone marrow due to catabolism of the 
radiotracer, as well as its uptake by the proliferating bone marrow cells(Shields et al. 
1998; Shields et al. 2002). 
Figure 2.3 Sagittal view of ri8FIFLT-PET image showing high uptake in a primary 
breast tumour, normal liver, and vertebrae. 
P^FJFLT uptake 
1 0 0 % -
0% 
vertebra 
tumour 
The high physiological uptake in liver, bone, and the primary breast tumour 
compared to normal tissue depicted in the PET image above is further demonstrated 
by the SUV curve of the same patient shown below in Figure 2.4. 
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Figure 2.4: MSFIFLT-SUV in tumour and normal tissues 
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Figure 2.4 above shows the decay and BSA-corrected uptake for [18FJFLT in tumour 
and normal tissues, note the high uptal<e in normal vertebra and tumour regions (A,B, 
and axilla) compared to normal tissues such as breast and lung. 
[18F]FLT-PET retention in larger tumours was heterogeneous; this could be due to 
differing proliferation rates within the same tumour and areas of tumour necrosis, 
possibly as a result from an altered blood supply in different regions. An example of 
heterogeneity is shown in Figure 2.5. 
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Figure 2.5: Heterogeneous uptake of ri8F1FLT in a patient with a large primary 
tumour. 
The slices labelled A, B, C, and D respectively, depict transverse sections moving from 
the superior to the inferior aspect of the tumour 
B 
% 
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There was a significant difference in [18F]FLT kinetic parameters in tumour 
lesions compared to the corresponding normal tissue (breast or lung) for all of the 
tumour ROIs that were analysed. SUV was measured at 21.5 mins and 90 mins to 
determine if early measurement had any difference in correlation with Ki-67 LI. The 
latter time point was chosen as the transport of [18F]FLT should be at steady state, 
and the signal was due to the phosphorylated radiolabel, and not unphosphorylated 
[18F]FLT. 
Measurement of the SUV at an early or late time point had no effect on this 
significance (p<0.0001 for both). Modelled parameters were equally effective as 
semiquantitative parameters for discriminating tumour lesions from normal tissue (p < 
0.0001 for Ki, FRT, K1, and AUG). In patient 4 a hotspot of [18F]FLT uptake was 
clearly visible in a rib posteriorly on the PET scan, this corresponded with a hotspot in 
the same location on a Technetium ([99mTc]) bone scan (see Figure 2.5b above). 
There was a trend for [18F]FLT uptake to be higher in ductal tumours (mean SUV90 = 
8.287 ± 0.997 x 10 ® m^.ml'^) than lobular tumours (mean SUV90 = 5.514±0.913 x 10'® 
m^.mM) though this was not statistically significant (Mann-Whitney p=0.08); the uptake 
was lowest in an inflammatory carcinoma (patient 11). 
In large tumours (> 5 cm), there was marked heterogeneity (see Figure 2.5); 
regions of obvious necrosis were excluded from the analysis. Radiotracer localisation 
also differed between primary tumours and metastases from the same patient. 
Localisation of radioactivity in normal tissues such as breast and lung was generally 
low. 
The proposed compartmental model for [18F]FLT is shown in Figure 2.1. In this 
model, [18F]FLT-glucuronide derived predominantly from the blood (transported from 
liver) can occupy an exchangeable space but does not contribute to the specific signal 
derived from the phosphorylation of [18F]FLT to [18F]FLT-phosphate. Determination of 
plasma-tissue exchange rate constants was made possible because of the ability to 
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perform online arterial sampling and HPLC profiling of parent [18F]FLT levels. 
[18F]FLT was slowly metabolised in all patients such that only 71.54±1.50 of f®F]FLT 
remained unmetabolised at 90 min post injection (coefficient of variation =8.09%) 
(Figure 2.6). 
Figure 2.6: Metabolism of MSFIFLT 
The percentage of parent compound [18F]FLT measured in arterial plasma for 
each of the patients during the scan is shown in Figure 2.6 below, with the mean value 
depicted by a trend line. At 90 minutes post-injection 71.54 ± 1.50% of [18F]FLT 
remained unmetabolised (coefficient of variation = 8.09%). 
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A non-decay corrected tumour activity (TAG) curve from patient 3 is shown 
below with the parent plasma input function (i.e. radioactivity present in arterial plasma 
due to unmetabolised [18F]FLT) in Figure 2.7. 
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Figure 2.7 Tumour TAG curve and arterial parent plasma input function 
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Using the modified Patlak approacfi, a linear phase of the curve was 
discernible indicating that there was unidirectional uptake of the radiotracer; the slope, 
Ki, was higher in tumour than in normal tissues. An example of this for patient 3 is 
shown below in Figure 2.8. 
Figure 2.8 Comparison of tumour and normal breast MSFIFLT retention using 
modified Patlak analvsis 
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The spectral model also fitted the data and showed that there was a retention 
component in tumour but less so in normal breast (asymptotic nature of the unit IRF in 
patient 4, Figure 2.9). Use of this data-led modeling approach showed the existence of 
predominantly reversible kinetic components (bars to the right in Figure 2.10; the bars 
to the left represent irreversible components). 
Figure 2.9 Comparison of the IRF for breast tumour and normal tissue 
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Figure 2.10 Spectrum of kinetic components in breast tumour 
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A summary of the parameters from all 29 individual tumour sites from 25 
patients is shown above in Tables 2.2 and 2.3. In all cases, the delivery and retention 
of FLT was higher in tumours than in normal tissues (Ki (p < 0.0001), SUV21.5 (p < 
0.0001), SUV90 (p <0.0001), AUG (p < 0.0001), FRT90 (p = 0.0001)), the delivery of 
FLT Ki, (p <0.0001). Ki values were low and similar to the low blood flow values seen 
previously in these tumours(Wilson et al. 1992). The results are depicted graphically in 
Figures 2.11. Overall, uptake was higher in nodal and metastatic regions in 
comparison with primary breast tumours. Retention of [18F]FLT was also lower in the 
inflammatory carcinoma in comparison with the other histological subtypes. There was 
a wider range for each parameter for tumour uptake in comparison with normal breast 
tissue. 
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Figure 2.11 Difference between tumour and normal tissue MSHFLT 
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2.1.5.4 Correlation between [18F]FLT uptake and Ki-67 LI 
Since [18F]FLT has tiie potential to be used as a surrogate marl<er of cell 
proliferation, it was important to examine tine association between its kinetic 
parameters and a standard measure of proliferation, LI. Of particular interest are 
associations with the kinetic parameters that describe retention as these are related to 
phosphorylation of the radiotracer by TK1. Suitable histology was available in 12 of the 
15 patients. An example of the difference in retention of [18F]FLT between tumours 
with low (patient 1 and 11) and high (patient 4) LI is shown in Figure 2.12. 
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Figure 2.12: nSFIFLT PET images and corresponding Ki-67 
immunohistochemistrv sections 
Where a) shows [18FJFLT retention in a lobular carcinoma and corresponding 
histological section stained for Ki-67 LI (4.9%), b) shows an [18FJFLT-PET image of a 
large primary ductal carcinoma with high uptake around the periphery of the tumour, 
central necrosis, and a hotspot on the sixth rib which was confirmed as a metastasis 
on a radioisotope bone scan; Ki-67 LI (45.2%) and c) an inflammatory breast 
carcinoma, and high uptake in the liver and the vertebra; Ki-67 LI (8.8%). 
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A strong correlation was found using Pearson's correlation coefficient between LI and 
Ki (r=0.92, p<0.0001), FRT (r=0.92. p<0.0001), SUV21.5 (r=0.71, p=0.0098), SUV90 
(r=0.79, p=0.002), and ADC (r=0.76, p=0.004) (Figure 2.13). There was a non-
significant correlation between LI and Ki(r=0.28, p=0.38). 
Figure 2.13 Correlation between Ki-67 LI and pharmacokinetic parameters 
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(where A is Modified Patlak Ki, B is FRT ratio (90:1 min), C is SUV corrected for BSA at 
90min, and D is AUC at 90min). 
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The results of the correlation and linear regression analysis for the various 
parameters and Ki67 LI are shown below in table 2.4. 
Table 2.4: [18F]FLT-PET correlation with Ki-67 LI 
Parameter Pearson r P r* 
Patlak Ki (modified) 0.9195 <0.0001 0.8455 
Patlak Ki (parent) 0.9413 <0.0001 0.8860 
Patlak Ki (total) 0.9388 <0.0001 0.8813 
FRT90:1 0.9149 <0.0001 0.8371 
KI 0.2804 0.3773 0.0786 
SUV 21.5 min 0.7094 0.0098 0.5032 
SUV 90 min 0.7912 0.0022 0.6260 
AUG 90 min 0.7626 0.0039 0.5815 
The kinetics support a simple model of intracellular retention of the radiotracer 
by phosphorylation (Figure 2.1) (Barthel et al. 2003; Wagner et al. 2003; Barthel et al. 
2004). The Ki for [18F]FLT was of the same order of magnitude as blood flow in breast 
tumours and normal breast previously reported by Wilson et a/(Wilson et al. 1992); the 
Ki values were in general higher for tumour (range: 0.964 -3.82 ml plasma.s"\mr^ 
tissue) than normal breast or lung (range; 0.315-1.18 x 10"^ ml plasma.s^'.ml"' tissue) 
but this did not reach statistical significance. 
Since the proliferation-specific signal for [18F]FLT is the formation of [18F]FLT-
phosphate, we hypothesised that retention of [18F]FLT will correlate with proliferation. 
Both reversible and irreversible kinetic components were observed in the [18F]FLT-
derived spectrum of kinetic components. In this study irreversible uptake kinetics were 
demonstrated by graphical analysis. Spectral analysis of the data showed that there 
are both reversible and irreversible components. These two findings are not mutually 
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exclusive as the reversible component could be due to influx/efflux of FLT, as well as 
dephosphorylation of FLT. Another reversible component is the blood volume 
component that is seen as a large peak in the higher end of the spectrum (Figure 
2.10).The Patlak model can determine the net irreversible transfer constant (Ki) in the 
presence of reversible components. Muzi et al suggest that use of a 3 parameter 
compartmental model leads to underestimation of KI by 47%, as there is a significant 
k4 with [18F]FLT. 
All the retention parameters for [18F]FLT correlated with LI determined by Ki-67 
labelling. The correlations with Ki-67 increased in the order AUC< SUV<FRT, Ki. This 
is the first description of Ki for [18F]FLT calculated with full correction for plasma and 
tissue metabolites. The superior nature of this parameter may be due to 
implementation of these corrections. However correction for tissue metabolites may 
not be absolutely essential, correction for plasma metabolites did suffice, as witnessed 
by the higher correlation for Ki obtained using a parent plasma input function rather 
than the new modified Patlak analysis. There was no significant correlation between 
K1, tracer delivery, and Ki-67 which was to be expected as this parameter is largely 
dependent on tumour blood flow. An improvement in the estimation of K1 could have 
been obtained by using shorter time frames at the start of the scan; whether this would 
have affected the correlation is unknown. 
Visvikis et al. performed Ki calculations for [18F]FLT uptake in colorectal 
cancer without correction for the space of exchangeable region occupied by 
metabolites(Visvikis et al. 2003). In this breast cancer study, this leads to 
overestimation of Ki by 12.2%, although the correlation with LI (r=0.91, p<0.0001) does 
not change substantially. Ignoring any contribution of metabolites, underestimates Ki 
(by 16.5%: r=0.94, p<0.0001). SUV90 and AUG were also highly correlated with LI. 
SUV is the parameter which has been used by most investigators in other tumour 
types including lung and colorectal cancer, and in general, correlation coefficients of 
0.7 to 0.92 have been reported (Buck et al. 2002; Buck et al. 2003; Francis et al. 2003; 
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Wagner et al. 2003). In the only other breast tumour studies published so far, 
Smyczek-Gargya et al used [18F]FLT PET to image 12 patients with primary breast 
cancer (Smyczek-Gargya et al. 2004). In that study there was a lack of correlation 
between Ki-67 and [18F]FLT-derived SUV. However, in that study, the scanning 
protocol was different and the SUV value was not corrected for body surface area. 
Proliferation as determined by [18F]FLT-derived Ki was higher in tumours than 
in normal breast or lung. The values differed between primary tumours and 
corresponding metastases. This is important from both a prognostic viewpoint, as well 
as for therapy monitoring given that all tumour masses can be studied at once. Shields 
et al., have reported Ki values for a lymphoma and sarcoma in the dog (Shields et al. 
2002). Their tumour-derived Ki values in the dog, where metabolism of [18F]FLT is 
lower, are in agreement with the metabolite-corrected Ki values in humans found in 
this study. 
2.1.5.5 Results of cardiac blood pool analysis 
The results for undecay corrected activity measured using both techniques are 
shown below in table 2.5, and results of Pearson's correlation and linear regression 
are shown in table 2.6. An example of the activity curve obtained by using the heart 
ROI and the total blood input curve from patient 6 are shown in Figure 2.13. 
In general, there was a significant correlation between the cardiac blood pool 
ROI and that obtained from dynamic arterial sampling. As can be seen from the table 
2.5 and Figure 2.14, the peak activity in the heart was significantly less than that in the 
total blood curve (p<0.0001 by paired t-test). This is likely to be due to the activity in 
the heart ROI being taken at a mid-frame timepoint and average counts rather than 
peak counts being used. The use of shorter time frames at the start of the scan could 
help to overcome this problem in the future. 
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Table 2.5 Results obtained using the cardiac blood pool ROI and dynamic radial 
artery sampling 
Patient Activity 
injected 
(MBq) 
AUC60 
heart 
ROt 
AUC60 
total 
blooct 
AUC90 
heart 
R o r 
AUC90 
total 
bloocf 
peak 
activity 
blood* 
peak 
activity 
heart* 
Activity 
at 
60min 
blood* 
1 
o 
296.30 23062.01 23443.95 26664.50 27669.10 100.42 66.14 2.56 
369.63 23945.07 27628.05 27621.99 31934.41 197.44 84.44 2.53 
3 
271.03 20220.79 15821.67 23152.55 17713.08 91.53 60.91 1.18 
4 
246.64 14417.38 13151.28 16503.29 14807.32 71.12 33.04 0.98 
5 
188.70 14500.52 11820.67 16794.26 13677.29 124.74 59.06 1.06 
6 
343.25 24879.13 22227.51 28983.71 25807.66 167.99 92.82 2.11 
7 
8 
296.30 26745.99 26562.81 31380.20 30590.30 169.61 73.06 2.37 
368.96 34760.56 25209.71 45010.74 29108.75 133.90 13.65 2.26 
9 
370.62 31686.27 25851.33 36932.66 29934.66 204.13 97.95 2.38 
10 
11 
380.73 29227.03 22642.66 34387.48 26641.32 188.50 74.35 2.28 
248.57 24044.85 20851.06 28012.93 24388.17 118.47 59.16 2.13 
(•"AUG in kBq.sec.mr , *activity measured in kBq.ml') 
One otiier factor wliicfi could be important for improving the correlations 
is the ability to sample only arterial blood from the cardiac ROI, as there may have 
been some spill over from the right ventricle. Smaller ROIs using an ellipse of 6 x 6 
pixels may be suitable for this purpose rather than a larger, manually drawn ROI. 
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Table 2.6 Correlation between cardiac AUG and radial artery total blood AUG 
Pearson r r* 
AUC60 heart ROI and total blood 0.82, p=0.0019 0.67 
AUC90 heart and total blood 0.78, p=0.0049 0.60 
AUC60 heart and total blood activity at 0.77, p=0.0057 0.59 
60min 
Peak heart and total blood activity 0.67, p= 0.0234 0.45 
Figure 2.14 Relationship between cardiac ROI and total blood arterial input 
function 
—tota l blood 
=• 120 
E 
m 100 
u 
< 60 
40 60 
Time (min) 
100 
The correlation between the heart AUC60 and measured total blood activity at 
60 min, and the correlation between AUC60 for both input functions are shown below 
in Figure 2.15 A) and B), respectively. 
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Figure 2.15 Correlation between two forms of input function 
A) Relationship between radial artery total blood activity at 60 min and heart ROI 
AUC60. 
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This demonstrates that it is possible to use a dynamic input function derived 
non-invasively from a cardiac ROI for [18F]FLT. Other alternatives to a cardiac ROI 
which have been investigated previously for FDG include use of the abdominal aorta, 
but this is prone to problems such as partial volume effects and spill over(Germano at 
al. 1992). The linear regression analysis of the peak activity in the heart and total 
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blood shows that it would be feasible to calculate a correction factor to the cardiac data 
in order that values closer to dynamic arterial sampling are obtained. 
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2.1.6 CONCLUSIONS 
• At 60 mins post injection approximately 70% of [18F]FLT remained as 
the parent compound in humans, with the remainder metabolised to a 
single metabolite [18F]FLT-glucuronide. 
• Both semiquantitative and modelled kinetic parameters describing 
uptake and retention of [18F]FLT correlated with tumour proliferation 
measured by Ki-67; though the correlation is superior for Ki and FRT 
than SUV or AUG 
• There was a significant difference between breast tumour and normal 
tissue delivery, uptake, and retention of [18F]FLT for all parameters -
SUV, AUG, Ki, FRT, K1 (P<0.0001) 
• There was a wide intratumoural variation in [18F]FLT uptake in primary 
tumours and metastases illustrating a broad spectrum of tumour 
proliferative capacity 
• Early (at 21.5 minutes post-injection of [18F]FLT) and late measurement 
of SUV (at 90 minutes) are equally useful 
• [18F]FLT derived activity measurements in cardiac ROIs and total blood 
do correlate; the best correlation is for AUG60. 
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2.2 Repeatability of [18F]FLT Pharmacokinetic Parameters 
2.2.1 HYPOTHESIS 
Tumour uptake and retention of [18F]FLT is repeatable in tfie absence of 
treatment or other intervention 
2.2.2 AIMS 
To compare ttie repeatability of [18F]FLT measurements in breast 
tumours in serial scans amongst patients with breast cancer 
To determine significant changes in [18F]FLT uptake which equate to a 
significant response 
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2.2.3 Introduction 
For a novel tracer to be validated it is crucial that the intrinsic variability of 
tracer uptake in the absence of an intervention is established. This is a prerequisite for 
reliable response detection; i.e. it will enable significant levels of change in [18F]FLT 
uptake to be defined for the parameter under investigation. 
Despite the considerable amount of papers citing the use of [18F]FDG for 
diagnosis and treatment response monitoring, only two relatively small studies have 
been produced concerning the repeatability of uptake of FDG in tumours (Minn et al. 
1995; Weber et al. 1999). One study focused on lung cancer(Minn et al. 1995), and the 
other had a variety of tumour types and anatomical locations(Weber et al. 1999). 
Whilst the early clinical [18F]FLT papers show promising results in terms of its 
correlation with tumour proliferation(Dittmann et al. 2003; Buck et al. 2005), and 
tumour specificity, the most robust pharmacokinetic parameter describing [18F]FLT 
uptake/retention remains to be defined. Standard semiquantitative measures (SUV and 
AUG) need to be compared with modelled parameters, for if [18F]FLT is to be widely 
utilised outside a research institution it is likely that semiquantitative parameters would 
be more pertinent in a clinical environment. 
One could predict that a model with no inherent assumptions that includes both 
irreversible and reversible tracer kinetics i.e. spectral analysis is likely to be more 
susceptible to variation than the Patlak technique which assumes tracer uptake is 
irreversible. Therefore, repeatability analysis was performed for both techniques. 
Radiotracer delivery, K1, is subject to changes in tumour perfusion, which in turn is 
affected by factors such as blood flow, intracapillary pressure, tumour angiogenesis, 
and blood volume. Consequently, it is probable that K1 is not reproducible - but prior 
to making any such assumptions, the repeatability of this parameter was also 
assessed. 
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2.2.4 Methods 
Nine of the patients entered in study 2.1 were able to have repeatability scans 
after an initial baseline scan. The entrance criteria, tumour demographics and 
scanning techniques were all as for study 2.1. The remainder of the patients did not 
have [18F]FLT repeatability scans due to failure of radiochemical synthesis, scanner 
breakdown, need to start treatment urgently, or, in the case of one patient, poor 
medical fitness. Every attempt was made to reposition the patient for the second scan 
in exactly the same position as the baseline one by measuring the distance from the 
top of the scanner field of view to an appropriate bony landmark. Patient rotation made 
placement of the baseline object map on the repeatability scan invalid, therefore the a 
new object map was drawn on each repeatability scan using the baseline object map 
as a reference guide. 
Analysis of repeatability of SUV60, SUV90, Ki, K1, FRT ratio at 60 and 90 mins 
(FRT60 and FRT90), and AUC at 60 and 90 mins (AUC60 and AUC90) was performed 
on a lesion-by-lesion basis. Patient weight was recorded prior to each scan, and 
together with height, enabled SUV correction for BSA for each scan data set. 
The coefficient of variation (cov) for each parameter was calculated as 
described previously and is shown below (Bland et al. 1995): 
i) = Within subject variance = (measurement A - measurement Bf 
2 
ii) m = Mean value of 2 observations for each patient = (A+B) 
2 _ 2 iii) x= mean (for all patients) of s m 
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v) Coefficient of variation (cov) = square root of x = V x 
For repeatability measurements individual parameter values for the two pre-
treatment scans were plotted against each other; high repeatability was represented by 
all data distributed along a line of unity. A Pearson's correlation coefficient and 
Wilcoxon signed rank test were used to assess correlation and significant differences 
between the two scans, respectively. The normality of the data was also assessed as a 
probability plot of the ordered relative differences versus the normal probability 
(cumulative frequency of ranks) for each lesion; a curved line indicates deviation from 
normality. Relative differences in parameter estimates were defined as 2 x (Scan A -
Scan B)/ (Scan A + Scan B). 
To compare the repeatability of the various pharmacokinetic parameters, an 
intraclass correlation coefficient (IC) that describes the correlation between the two 
measurements of a parameter was calculated using SPSS® for Windows® version 
12.0; if the two measurements were identical the IC will be 1. Random or systematic 
differences between the two measurements reduce the value of the IC. A 2 way 
random mixed model with absolute agreement was used. The difference in the 
variance of the relative difference for the different parameters was tested using the F-
test that compares the standard deviations (SDs) of two normally distributed data sets. 
The 95% normal ranges for spontaneous fluctuations in the parameters was 
calculated as 1.96 x SD of the relative difference in the two pre-treatment scans. 
[18F]FLT response was the relative difference between post-treatment and mean pre-
treatment measurement parameters, i.e., (Scanpre - Scanpost)/(Scanpre), where the pre-
treatment scan is the mean of the two pre-treatment scans in the case of patients who 
completed the repeatability phase of the study. 
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2.2.5 Results 
Ki obtained by using the modified PaMak method, FRT ratio at 60:1 min and 
90:1 min (FRT60, FRT90), K1, SUV and AUG at 60 and 90 minutes (SUV60, SUV90, 
AUC60, AUC90) were used to assess repeatability of [18F]FLT uptal<e in 9 tumour 
lesions from 8 patients. The repeatability analysis was also assessed for the impulse 
response function values at 60 and 90 minutes, as there was a possibility that the FRT 
ratios were influenced by the presence of a blood volume component at 1 minute. The 
results are shown below in Table 2.7. One other patient's data was excluded from this 
analysis due to an anomaly in tissue radioactivity data (scanner head counts) 
compared to the administered dose. 
The time between baseline scan and the repeatability scan ranged from 2-10 
(median=4.5) days. There was no significant difference between the two scans for all 
of the imaging parameters (range p =0.13 (for FRT60) to p = 1.06 (for AUC60)). 
Regression analysis of the line of unity indicated good test-retest correlation for all the 
parameters studied, excluding KI . The standard deviations of the mean relative 
difference were 10.5 and 15.1% for SUV90 and Ki, respectively. This measure was 
much lower for IRF60 and IRF90 in comparison to the relevant FRT values (SD of 
mean relative difference = 12.6 and 24.6 for IRF60 for FRT60, respectively). 
F-test values were 0.97 for SUV90 and 0.99 for Ki. These results indicate that 
both parameters (SUV90 and Ki) can be used repeatedly in serial scans. The 95% 
normal values for spontaneous fluctuations were determined from the SD of the 
relative difference are shown in table 2.7 below. AUC60 and AUC90 were slightly 
superior to SUV60 and SUV90. This was predictable as the AUG is a measure of 
uptake throughout the scan, as opposed to SUV which defines uptake at a single 
midframe timepoint and is subject to more noise. The timing of measurement of the 
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semiquantitative parameters (i.e. sixty minutes opposed to ninety minutes) liad little 
effect on tlieir repeatability - they were both equally good. 
FRT 90:1 and 60:1 appeared less reproducible than the other parameters (but 
were superior to the relative IRFs by the F-test, see table 2.7 below), this was 
attributed to the presence of a blood volume component present causing intrinsic 
variability of the IRF in some of the lesions at 1 minute. For that reason the 
repeatability of the impulse response function at 60 and 90 minutes was calculated, as 
at that stage the tracer uptake has approached steady state. The IRF values proved to 
be more reliable, for example the SD of the mean relative difference was much lower 
for IRF60 and 1RF90 were 12.65 and 15.29, respectively, compared to the relevant 
FRT60 and FRT90 values (24.6 and 32.7). 
As expected K1, which represents unidirectional tracer delivery to the tumour, 
obtained by compartmental analysis was not reproducible and therefore would not be 
suitable for measuring response. This parameter is largely flow dependent, and this 
may be a major contributing factor for its lack of robustness in this study. This may not 
signify an adverse event, as the previous study (section 2.2) showed no correlation 
between K1 and Ki-67 LI, therefore it is unlikely that K1 would be an appropriate 
measure of tumour proliferative response to treatment. 
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Table 2.7 Repeatability of semi-quantitative and modelled parameters in tumour 
lesions 
Parameter GOV 
Pearson 
Correlation 
coefficient 
rz Wilcoxon 
p value ICC 
SD of mean 
relative 
difference 
{%) 
F-
test 
SUV 60 7.019 0.974 0.948 0.910 0.986 10.49 0.94 
SUV 90 7.380 0.986 0.973 0.950 0.993 10.52 0.97 
AUC60 5.990 0.987 0.975 1.055 0.994 8.98 0.97 
AUC90 5.228 0.992 0.984 1.000 0.996 8.37 0.99 
Ki 10.146 0.969 0.939 1.050 0.990 15.14 0.99 
FRT60 17.278 0.905 0.819 0.129 0.948 24.56 0.80 
FRT90 18.876 0.963 0.928 0.203 0.946 32.71 0.79 
IRF60 9.577 0.965 0.932 0.203 0.977 12.65 0.68 
IRF90 11.697 0.963 0.928 0.250 0.977 15.29 0.72 
K1 31.564 -0.197 0.039 0.301 0,250 43.61 0.08 
(where ICC = interclass correlation coefficient) 
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Table 2.8: Spontaneous fluctuation range for each [18F]FLT pharmacokinetic 
parameter 
Parameter 95% Confidence Interval 
SUV 60 ±0.2056 X 10 " m'.mr' 
SUV 90 ±0.2063 X 10 ® m .^mM 
AUC60 ±0.1761 m .^s.mM 
AUC90 ±0.1536 m^s.mi"^  
Ki ± 0.2968 X 10^ ml plasma, ml"^  tissue, s"^  
FRT60 ±0.4810 
FRT90 ±0.5399 
IRF60 ±0.2479 s"" 
IRF90 ±0.2998 s^ 
K1 ±0.8547 pl.s-\mr^ 
The results of Pearson's correlation coefficient for each parameter are depicted 
graphically in Figure 2.16 below. 
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Figure 2.16 Correlation of Baseline and Repeatability Scan Parameters for 
ri8FIFLT uptake in breast tumour lesions. 
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Figure 2.16 Correlation of Baseline and Repeatability Scan Parameters for 
nSFIFLT uptake in breast tumour lesions. 
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Figure 2.16 above shows the correlation between values for the baseline (scan 1) and 
repeatability scan (scan 2) plotted for each pharmacokinetic parameter along a 
superimposed line of unity; n=9 lesions.. 
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2.2.6 Discussion 
This study has shown that [18F]FLT uptake and retention is repeatable when 
measured by semiquantitative and metabolite-corrected modelling techniques. 
Spectral analysis data, in particular FRT60 and FRT90, is subject to noise thus it may 
be more appropriate to use the IRF values at these time points. This study provides 
objective criteria for determining true changes in [18F]FLT-PET imaging parameters 
during serial measurements. The data can also be used to define the sample size for 
larger [18F]FLT-PET trials. 
The previous repeatability studies for FDG looked at SUV and Ki in ten and 
sixteen patients respectively(Minn et al. 1995; Weber et al. 1999). This is the first time 
that repeatability of human tumour [IBFjFLT kinetics has been evaluated. The 
repeatability for spectral analysis and compartmental analysis for FDG in tumours has 
not been reported previously. It would be interesting to study the repeatability of FRT 
and KI parameters for FDG to determine if they are as liable to fluctuation to the same 
degree as was observed in this study with [IBFjFLT. However, as stated at the outset 
of this study, it was inherent in the spectral analysis model that there would be more 
noise in the data as a result of its intrinsic nature of calculation. The two tissue 
compartmental method chosen for calculation of KI may be inappropriate for [IBFjFLT 
due the presence of a significant k4 (i.e. dephosphorylation of FLT-
monophosphate)(Muzi et al. 2005). 
Repeatability studies are demanding on patients; ideally all the patients would 
have had the same tumour histological type, similar stage of disease, anatomical 
location, and preferably no previous treatment. Three of the eight patients had 
received previous chemotherapy or hormonal treatment; none had received 
radiotherapy to the imaging site. This repeatability study is exploratory by nature, 
perhaps in the future larger studies can be performed which can evaluate such factors 
more closely. 
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2.2.7 Conclusion 
• [18F]FLT uptake and retention in breast cancer is repeatable when 
measured by PET using SUV, AUG, modified Patlak Ki, FRT, and 
IRF. 
• Measurement of radiotracer uptake at 60 or 90 minutes post-
injection are equally repeatable for SUV and AUG 
• Response criteria have been derived for each parameter (i.e. 
significant changes in [18F]FLT are those which lie outside the 95% 
confidence interval listed in table 2.8). 
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2.3 [18F]FLT-PET Prediction of Early Response to Treatment in Breast Cancer 
2.3.1 Hypothesis 
[18F]FLT-PET will provide an accurate measure of the effect of anti-
proliferative chemotherapy on breast cancer in vivo 
2.3.2 Aims 
• To assess the early changes in [18F]FLT-PET pharmacokinetic 
parameters in response to a commonly used cytotoxic chemotherapy 
regimen in patients with locally advanced and metastatic breast cancer 
• To correlate the [18F]FLT-PET response at day 8 with clinical response 
to chemotherapy at 60 days 
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2.3.3 Introduction 
Anti-cancer therapies work by disrupting the balance between tumour cell 
proliferation and cell death. Response assessment using the RECIST criteria relies 
upon detection of a decrease in physical tumour volume as a result of reduced cell 
proliferation or increased cell death due to necrosis or apoptosis(Therasse et al. 2000). 
However changes in tumour dimensions may take a long time to develop, and provide 
little information about cell viability. Consequently, some authors believe that the 
RECIST criteria are altogether inappropriate for monitoring response to novel 
cytostatic agents which may have minimal effect on tumour size (Korn et al. 2001; 
Michaelis et al. 2006). 
The early detection of tumour chemosensitivity or chemoresistance has 
obvious advantages in terms of maximising patients' treatment response benefit i.e. by 
continuing with successful therapies, whilst simultaneously minimising patient 
exposure to ineffective and potentially toxic treatment regimens. A quantitative 
proliferative index measurement could provide a mechanism for chemosensitivity or 
chemoresistance to be detected in vivo. Histological Ki-67 immunostaining and 
analysis of cell cycle genes have shown changes in breast tumour proliferation status 
as early as 24h and certainly at 1-4 weeks after chemotherapy or hormone therapy; in 
some cases the early changes in proliferation were predictive of pathological response 
(Dowsett et al. 1999; Ellis et al. 2003; Ellis et al. 2003; van Diest et al. 2004; Vincent-
Salomon et al. 2004). 
Non-invasive molecular imaging technologies including FDG-PET have 
been explored as surrogates to the anatomical and histological or molecular 
approaches mentioned above due to a combination of factors including their ability to 
detect changes in tumour biochemistry in all tumour regions and good repeatability 
(Wahl et al. 1993; Weber et al. 1999). Decreases in FDG uptake as early as one week 
after starting chemohormonotherapy treatment have previously been reported in 
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breast tumours(Wahl et al. 1993). FDG uptake may, however, increase within the early 
period after treatment through mechanisms involving enhanced inflammatory 
response, making it unpredictable as a response marker (Dehdashti et al. 1999; 
Spaepen et al. 2003). Proliferation markers like [18F]FLT, are not susceptible to such 
inflammatory changes(van Waarde et al. 2004) and can potentially be used to 
measure early changes in response. 
[18F]FLT can be used to measure proliferation in tumours of breast cancer 
patients (Kenny et al. 2005). This current study examines the role of [18F]FLT for 
determining response to therapy in breast cancer; in this specific instance a standard 
chemotherapy regime (5-fluorouracil, epirubicin, and cyclophosphamide (FEC)) was 
used. To ascertain if the reductions in [18F]FLT uptake post-treatment are significant, 
knowledge of the intrinsic variability of [18FJFLT-PET reported in the previous study 
above (section 2.2), was used to provide the objective criteria for early response 
assessment. 
A previous [18F]FLT-PET study evaluated response of breast tumours to a 
variety of treatments (chemotherapy and endocrine therapy) at 5.5 weeks. (Pio et al. 
2006). The timescale for post-treatment scans in that study were similar to that for 
RECIST(Therasse et al. 2000). We rationalised that, like the early FDG studies (Wahl 
et al. 1993), oncologists may benefit more from an earlier indication of response. Thus, 
this study investigated whether [18F]FLT-PET could be used to measure response as 
early as 1 week after initiation of FEC chemotherapy and compared the PET results 
with clinical response measured at 60 days. 
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2.3.4 Methods 
The patients were those entered into study 2.1; eligibility criteria were as 
described previously. After at least one pre-treatment scan (two in the case of the nine 
patients who entered the repeatability study, 2.2) patients were treated with 
combination intravenous 5-fluorouracil (600mg/m^), epirubicin (60 mg/m^), and 
cyclophosphamide (600mg/m^) (FEC) chemotherapy. The post-treatment PET scan 
was performed approximately 1 week later. Patients received FEC chemotherapy 
every 21 days up to a maximum of 8 cycles until surgery or disease progression. 
Patients received a single bolus intravenous injection of [18F]FLT (153-
381 MBq, specific activity 15-227 GBq.jjmol'^) over 30 seconds. The scanning 
protocol, reconstruction, and arterial blood sampling were as described previously in 
study 2.1. The parameters SUV90, Ki (obtained by modified Patlak analysis), AUC90, 
and FRT90:1 were used to quantify [18F]FLT uptake and retention, respectively, in the 
pre- and post-treatment scans. In the nine patients who participated in the repeatability 
study, the mean of each parameter for the two scans was used as a baseline value. 
Tumour response was defined using the RECIST criteria, see section 1.7, table 
2 (Therasse et al. 2000). Tumours were measured using electronic callipers (AR/2001, 
Camlab Laboratory products, Cambridge, UK) on each of the PET scanning visits and 
at day 60 post-treatment by the same investigator. Radiological investigations 
(ultrasound, computed tomography) were used where clinically appropriate. 
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2.3.5 Results 
15 patients with 19 discrete lesions due to breast cancer (all histological types; 
see study 2.1 for demographics) were entered into the study. Of these, 13 patients with 
a total of 17 lesions had at least one pre-treatment and a post-treatment scan (one 
patient withdrew from the study due to a viral illness and the other patient could not be 
scanned at 1 week). All of the patients tolerated the PET scanning protocol, and none 
suffered complications due to the study. With the exception of 3 patients (2 of whom 
had metastatic disease, and one locally advanced) who had received prior treatment 
for breast cancer, all patients were newly diagnosed. 
Clinical and [18F]FLT-PET response 
Thirteen patients completed both pre-treatment and post-treatment scans at the 
required study time. Clinical response (CR/PR) was evident in 6 patients at 60 days, 
the remaining 6 had stable disease, and one patient died from cerebral metastases. 
Therefore, no patient could be classified as having had progressive disease within the 
imaging region. In responding lesions the average decrease in FLT-PET was 41.3% 
for SUV90, and 52.9% for Ki; in non-responding lesions the average increase in FLT-
PET was 3.1% for SUV90and 1.9% for Ki. 
The interval between commencement of chemotherapy and the post-treatment 
[18F]FLT-PET scanning ranged from 6 to 12 (median 8) days. Figures 2.17A and B 
show typical transverse PET images through the chest of patient 1 before and after 
receiving FEC chemotherapy; a reduction in [18F]FLT uptake was seen at 1 week 
post-treatment. This patient showed the most significant [18F]FLT-PET response with 
an 83% decrease in [18F]FLT uptake. Figures 2.17C and D are images of patient 8 
who did not show a reduction in [18F]FLT uptake. 
The average SUV90 and Ki from multiple slices of entire lesions were 
compared. Figure 2.18 shows the [18F]FLT-PET response pattern for all lesions. 
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Objective [18F]FLT response was defined as relative differences in imaging 
parameters that were below the normal ranges of spontaneous fluctuation; values 
higher than the range will constitute significantly increased proliferation. The normal 
ranges are the two solid lines on either side of the mean (bold solid line) in Figure 2.18. 
[18F]FLT-PET response (< 95% range) was seen in 12 of 17 (SUV90) and 11 of 17 (Ki 
and AUC90) lesions, but in only 2 of 17 lesions when assessed by FRT90. As there 
were no changes in tumour size at 1 week (Table 2.9), with the exception of the 
axillary metastasis in patient 6, we can state that the [18F]FLT-PET responses 
preceded tumour size changes. 
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Figure 2.17 Comparison of r i81FLT-PET response and non-response 
p®F]FLT uptake A. Patient 1 Baseline B. Patient 1 Day 8 Post FEC 
100% 
tumour 
vertebra 
C. Patient 8 Baseline D. Patient 8 Day 8 Post FEC 
tumour tumour 
Figure 2.17 above shows [18FJFLT-PET images in transverse section of a breast 
tumour which was associated with both a clinical and [18FJFLT response (A and B), 
and a tumour which did not respond clinically or by [18F]FLT-PET criteria (C and D). 
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Figure 2.18 ri81FLT-PET response for all tumour lesions 
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(where values above the upper bold line represent significant increases in proliferation 
post-treatment, values below the lower bold line represent significant decreases in 
proliferation, and those between the two bold lines were associated with no significant 
change). 
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Table 2.9 Clinical response to FEC chemotherapy 
Patient Tumour 
Region 
Imaged 
Baseline 
Dimensions 
(cm^) 
Day 8 Dimensions 
(cm*) 
Day 60 
Dimensions 
(cm') 
1 
2 
3 
4 
5* 
5 
6 
6 
7 
8 
9 
10+ 
11 
12 
13 
14 
15 
Breast 
Lung met 
Breast 
Breast 
Breast 
Axilla 
Breast 
Axilla 
Breast 
Breast 
Breast 
Axilla 
Breast 
Breast 
Breast 
Breast 
Breast 
8.0 X 6.4 
3 . 0 x 3 . 0 
7.7 X 10.1 
2 6 x 1 8 
1 9 x 1 8 
3 x 4 
10 .5X 10 
4 .5 X 4 .5 
4x4 
1 0 x 1 3 
3 .7x3 .4 
3 x 2 . 9 
9 .0x7 .8 
6 x 3 
2 .7x3 .5 
5 .8x7 .8 
3.1 x 3 . 2 
7.5 X 6.7 
ND 
6.7 X 10.7 
ND 
19 X 18 
3 x 4 
8 . 5 x 9 
2 . 5 x 3 
4 x 4 
1 0 x 1 3 
3 .5x2 .8 
3 x 2 . 9 
8 .9x7 .9 
ND 
2 .6x2 .9 
5 .7x7 .7 
3.1 x2 .4 
1 X 1 
ND 
6.5x 8.6 
16x 13 
1 9 x 1 8 
2 x 2 
5 x 4 
CR 
3 x 1 
1 2 x 1 3 
3 .5x3 .2 
3 x 3 
8 x 8 
ND 
2 .2x2 .2 
3 .5x3 .5 
ND 
(5*: This patient also had an internal mammary node lesion which had not been 
detected by other imaging investigations, 10+: This patient also had a pretracheal node 
lesion which had not been detected previously. ND: Patient 2 developed brain 
metastases, Patient 4 could not attend at day 8, Patient 12 withdrew from study due to 
a viral illness, and Patient 15 proceeded to surgery due to an abscess). 
All 6 patients who had a clinical response also had a significant reduction in 
[18F]FLT uptake as measured by Ki and SUV. Figure 2.18 (below) shows the 
relationship between [18F]FLT response and clinical response of individual lesions. 
Pre-treatment tumour size and tumour sizes at days 8 and 60 post-chemotherapy are 
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recorded in Table 2.9 (above). Only one of the patients (patient 2) in this study 
developed progressive disease after the first cycle of treatment days in the form of 
previously undiagnosed cerebral metastases and died as a result of this before day 60; 
the metastases were outside the field of view of the PET scanner used in this study. 
Patient 12 withdrew from study due to a viral illness, and patient 14 developed a breast 
abscess after the f * cycle of chemotherapy and proceeded to mastectomy. These 
patients could not be assessed for clinical response to FEC at day 60. Patient 3 had a 
significant increase in Ki and SUV90 by 92.3 and 69.2%, respectively; this patient 
failed to achieve a partial response, and has had disease progression within 18 
months following completion of chemotherapy. 
Changes in [18F]FLT uptake were not always similar for different lesions in 
patients with more than one lesion, i.e. there was intra-patient variability in [18F]FLT 
response. This was evident in patients 5, 6, and 10 for both Ki and SUV90. For 
instance, patient 5 had a primary lobular carcinoma with axillary nodal and internal 
mammary metastasis (the internal mammary metastasis had not been detected on 
prior screening investigations, including computed tomography). Clinically the patient 
was classified as a non-responder due to lack of response in the primary tumour 
(although the axillary node showed a reduction in size) after two cycles of FEC and her 
treatment was changed to combination docetaxel-trastuzumab. With regard to 
[18F]FLT response, the primary tumour did not show a significant reduction in Ki or 
SUV90, whereas there was a significant reduction in SUV90 and Ki in the internal 
mammary node and the axillary nodal metastasis. Similarly, patient 6 had a reduction 
in both SUV90 and Ki in the axilla but not in the breast; this patient had a clinical 
response in both areas. The patient has subsequently relapsed in the breast despite 
completing 6 cycles of chemotherapy plus surgery and radiotherapy. It was interesting 
to note at the time of surgery that this patient had a pathological complete response in 
the axilla. 
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To evaluate the early predictive value of [18F]FLT-PET in breast cancer 
patients in this pilot study, i.e. the ability of PET at 1 week post-treatment to predict 
response at 60 days, the lesions were classified in this pilot study into CR/PR (n=7 
lesions) and those with stable disease (n= 6 lesions), and compared with [18F]FLT-
PET response. Figure 2.19 shows that there was a significant difference between the 
two groups for changes in [18F]FLT uptake for Ki ,SUV90, FRT90 and AUC90 (Mann-
Whitney p=0.022 for both Ki and SUV90, p=0.026 for FRT90). The difference was not 
significant for AUC90 (p=0.366) which may reflect that changes in the total area under 
the curve at 90 minutes were relatively small and non-discriminatory for detecting 
response in this particular study. 
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Figure 2.19 Relationship between clinical response and changes in MSFIFLT-
PET parameters. 
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Figure 2.19 above shows the response pattern for modified Patlak Ki and SUV90 for 
responders (A and C), and lesions with stable disease (B and D), there ivas a 
significant difference between the 2 groups in tenvs of [18F]FLT-PET response, Mann-
Whitney p=0.022. 
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2.3.6 Discussion 
Data from the repeatability study iiad shown that a decrease in tumour 
[18F]FLT of >18% for SUV90, and/or s 31% for Ki is required for a significant 
response. In this study, objective changes in [18F]FLT-PET were seen at 1 week after 
FEC chemotherapy. Given that [18F]FLT uptake highly correlated with proliferation in 
breast cancer in the previous study (Kenny et al. 2005) these present findings indicate 
that [18F]FLT-PET can be used to measure changes in proliferation as early as 1 week 
post-treatment. Since tumours can acquire drug resistance after 1 week of treatment, 
this time-point is not necessarily optimal for imaging but allows for early monitoring of 
chemosensitivity. 
[18F]FLT-PET response was seen in a high proportion of tumours at this early 
time point (12 of 17 or 11 of 17 when assessed by SUV90/AUC90 or Ki) and 
importantly preceded tumour size changes. The results with FRT90 suggested only 2 
patients had achieved a significant response, however the value of the IRF at 1 minute 
used to calculate the FRT90 may have been affected by fluctuations due to blood flow 
at the early part of the scan (as evidenced by the lack of repeatability of KI) . The 30 
second time frames used at the beginning of the dynamic imaging may have been 
suboptimal in this current study. The basis for choosing the selected time bins was 
based on our group's previous experience with [11C]thymidine(Wells et al. 2002; Wells 
et al. 2002; Wells et al. 2003), and is also backed by Mazoyer et al (Mazoyer et al. 
1986) who showed that for FDG, differences in rate constants obtained from dynamic 
PET scanning are insignificant when the initial scan duration was <30 seconds. 
Although this is a pilot study we sought to compare the [18F]FLT-PET lesion 
response to the patient's clinical response at 60 days. In general the patients who 
showed CR/PR had a change in SUV90 and Ki of -63.4 to -15.6 and -83.0 to -20.4% 
respectively. Early Ki-67-based proliferation studies have been performed in breast 
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cancer patients and in some cases predicted for pathologic response (Dowsett et al. 
1999; Archer et al. 2003; Ellis et al. 2003; Ellis et al. 2003; van Diest et al. 2004; 
Vincent-Salomon et al. 2004). Studies by Dowsett et al. (1999) suggested that in 
breast cancer patients treated with tamoxifen, even to achieve disease stabilisation, a 
reduction in proliferation index of 50% and a 2-3-fold increase in apoptotic index will be 
required (Dowsett et al. 1999), i.e. some of the changes in proliferation below the lower 
limit of spontaneous fluctuation seen in our studies may be insufficient to cause clinical 
regression. If we had set >50% decrease in [18F]FLT uptake as necessary for 
significant response, 3 lesions out of 6 which showed a clinical response would have 
been detected. On the other hand, patients who failed to show changes in [18F]FLT-
PET parameters or had an increase are less likely to show a clinical response. This is 
in keeping with one of the reports of [18F]FDG-PET in breast cancer(Wahl et al. 1993). 
In that study, Wahl and co-workers demonstrated that non-responding patients failed 
to show a decrease in [18F]FDG uptake at day 63 (Wahl et al. 1993). The ability to 
distinguish between patients that had stable disease and those that had complete or 
partial response by using SUV90 is encouraging. Future studies using [18F]FLT-PET 
could be enhanced by measuring other factors such as apoptosis that influence tumour 
regression(Dowsett et al. 1999). 
The range of spontaneous fluctuations for Ki is slightly higher than that of 
SUV90. However, Ki is the more accurate parameter when correlated with Ki-67 
labelling index(Kenny et al. 2005). Factors that can affect the SUV90 parameter 
include changes in radiotracer delivery and dephosphorylation within the tumour, as 
well as changes in systemic clearance after treatment. Hence, the more clinically 
applicable method, SUV, is robust but knowledge of the aforementioned factors needs 
to be obtained to justify its use. 
In general, [18F]FLT-PET is likely to be more specific for measuring changes in 
proliferation than FDG, which can show an increased uptake in inflammatory regions 
(Buck et al. 2003; van Waarde et al. 2004). Pio et al have recently reported the 
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advantage of [18F]FLT-PET over FDG-PET for measuring treatment response in 14 
patients with breast cancer including those with liver metastases(Pio et al. 2006). 
There are a number of differences between that study and this one. In their study, 
response assessment was done at - 5 weeks after treatment initiation. Also different 
treatment regimes were used; one-third of the patients were treated with hormonal 
therapy and the remaining with a variety of cytotoxic chemotherapy regimes. Of 
interest, the authors showed that the 10- or 45-min [18F]FLT SUV correlated with 
CA27.29 and late changes in tumour size. These studies did not, however, examine 
other kinetic parameters or the repeatability of the measurement parameters. 
This pilot study is important in many respects. The response studies 
demonstrate that [18F]FLT-PET measurements can be done early, i.e., studies of the 
time course of drug effect can be performed with [18F]FLT-PET commencing at 1 
week post treatment. The optimal time for predicting long term clinical response will 
depend on the dosing regime, pharmacokinetics and mechanism of action of the agent 
of interest. Of note in this study is the fact that some lesions which showed an early 
[18F]FLT-PET response failed to have a significant clinical response, which may be 
attributed to initial chemosensitivity followed by the development of tumour 
chemoresistance. This study may be important in the clinical trial of novel mechanism-
based, relatively non-toxic, molecular therapeutics. The clinical trial evaluation of such 
agents is still based on maximum tolerated dose and tumour volume 
measurements(Parulekar et al. 2004). Maximum biological activity could occur at a 
lower dose than the maximum tolerated dose and using the RECIST criteria to define 
response may be inappropriate for some agents that are unlikely to cause early overt 
changes in tumour volume (Ratain et al. 2004). Imaging studies of the type reported 
here could shorten Phase 1 and 11 trials and provide important information on 
mechanism of action. 
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2.3.7 Conclusion 
• [18F]FLT-PET can detect changes in proliferation at 1 week post 
treatment after FEC ctiemottierapy. 
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2.4 [18F]FLT-PET As A Pharmacodynamic Marker In Vivo 
2.4.1 Hypothesis 
Membrane nucleoside transport is enhanced following TS inhibition, 
therefore [18F]FLT-PET should be a suitable marker for monitoring the 
pharmacodynamics of tumour TS inhibition. 
2.4.2 Aims 
• To determine if [18F]FLT-PET can be used as a pharmacodynamic 
marker of early response of breast cancer to treatment with a 
thymidylate synthase inhibitor, capecitabine 
» To study the pharmacokinetics of [18F]FLT by PET in tumour lesions 
before and after the f * dose of capecitabine 
. To examine the effect of blood flow on changes in [18F]FLT kinetic 
parameters by performing [150]-labelled water scans 
• To compare the changes in [18F]FLT-PET parameters to with clinical 
response 
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2.4.3 Introduction 
Capecitabine is a fluoropyrimidine, and acts as a pro-drug of the commonly 
used anti-cancer drug 5-fluorouracil (5-FU). It is thought to be preferentially activated in 
tumour tissue, leading to improved intratumoural drug concentrations and less 
systemic toxicity than 5-FU. The tumour selectivity is due to the higher expression of 
thymidine phosphorylase (TP) in tumour tissue compared to normal tissue (Miwa et al. 
1998). The active agent, 5-FU inhibits TS and, thus, DNA synthesis (it is also 
incorporated into RNA)(Miwa et al. 1998). The mechanism of action of capecitabine is 
depicted below in Figure 2.19. 
Figure 2.20 Mechanism of action of Capecitabine 
(where DFCR = deoxyfluorocytidine and DFUR = deoxyfluorouridine) 
Tumour/Normal Tissue Intestine Liver 
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Cytidine 
deaminase 
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As shown in Figure 2.20 above, capecitabine is metabolised to 5-FU via 3 
metabolic steps. After absorption in the intestine, carboxyl esterase converts it to 5'-
deoxyfluorocytidine (DFCR). DFCR is then metabolised to deoxyfluorouridine (DFUR) 
by cytidine deaminase. The third and final steps involves conversion of DFUR to 5-FU 
by thymidine phosphorylase (TP) which is expressed in solid tumours at levels 3-10 
times that of surrounding normal tissue(Schuller et al. 2000; Yarden et al. 2004). 
Intratumoural expression of TP has shown to be a predictive marker of 5-DFUR activity 
in breast cancer(Tominaga et al. 2002). 
The structure of capecitabine and 5-FU are shown below in Figure 2.21. 5-FU 
either undergoes catabolism by dihydropyrimidine dehydrogenase (DPD) forming 
dihydrofluorouracil, which is subsequently metabolised to fluoro-p-alanine (FBAL) 
before urinary elimination, or anabolism by TP to form compounds responsible for its 
cytotoxic activity. Fluorodeoxyuridine monophosphate (FdUMP) is a product of 
phosphorylation of FU by thymidine kinase. FdUMP subsequently competes with 
uridine monophosphate to form a ternary complex with thymidylate synthase (TS) and 
folic acid, inhibiting TS in the rate limiting step of de novo thymidine synthesis. In the 
absence of thymidine, DNA synthesis is reduced and cell death occurs. 
One of the main advantages of capecitabine is that due to its 100% 
bioavailability it can be given orally, unlike 5-FU which requires intravenous 
administration due to its variable absorption from the gastrointestinal tract and rapid 
degradation. The high first pass metabolism of 5-FU have resulted in patients receiving 
protracted infusions at home. Capecitabine has shown activity against a variety of 
tumour xenografts including colon, gastric, breast, cervical, bladder, ovarian, and 
prostate cancer; however the largest experience to date and current clinical indications 
are for metastatic breast and colorectal cancer. 
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Figure 2.21 Structures of Capecitabine and 5-FU 
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This study will evaluate whether [18F]FLT-PET can be used as an early 
pharmacodynamic marker of capecitabine activity. In contrast to the previous study, 
2.3, where the antiproliferative effects of treatment led to a decrease in [18F]FLT, this 
study should show that early inhibition of the de novo thymidine synthesis pathway will 
lead to an early rise in [18F]FLT as the cells attempt to synthesize more thymidine 
monophosphate by the salvage pathway. 
As the activity of TP is critical for capecitabine activation, then it would be 
interesting to study the intratumoural expression of this enzyme. Therefore, in patients 
with suitable lesions, the plan was to study the relationship between TP expression 
(from fine needle aspirates), [18F]FLT uptake and radiological response. Fine 
needle aspiration will be used as core biopsies are invasive, and tissue 
proliferation due to the inflammatory response after a biopsy could theoretically 
alter [18F]FLT uptake. Factors that could affect the relationship between TP 
expression and [18F]FLT include the rate of catabolism of 5-FU to inactive 
metabolites, a process that is initially catalysed by DPD, as well as the levels of the 
target enzyme,TS. 
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In an additional pharmacodynamic study, the levels of capecitabine and 
metabolite, deoxyuridine, dUrd, in plasma will be assessed at selected time points as 
indices of drug exposure. dUrd levels are a surrogate for global TS inhibition largely 
resulting from TS inhibition in normal tissues (de Jonge et al. 2002; Benepal et al. 
2005). The PET scans will be commenced at 1 hour after the first oral dose of 
capecitabine. From the published plasma pharmacokinetics of capecitabine, it is 
expected that maximum tumour concentrations will be achieved within 1-2 hours after 
drug administration (Schuller et al. 2000). 
Patients will be assessed for radiological and clinical response by the RECIST 
criteria (Therasse et al. 2000) during routine follow-up at medical oncology clinics as 
they continue their treatment with capecitabine. To mitigate any effect of altered 
drug/radiotracer delivery on [18F]FLT pharmacokinetics, a surrogate measure for 
blood supply using H2[150]-PET will be used prior to each [18F]FLT-PET scan. The 
basis for this is outlined below. 
2.4.3.1 H2[150] 
Tumours have a heterogeneous vascular architecture characterised by areas of 
angiogenesis, leaky vasculature, and areas of necrosis. Measurement of tumour blood 
flow has implications for both diagnosis and pharmacokinetics. In the diagnostic 
setting, altered blood flow patterns measured by H2[150] are able to differentiate 
breast tumour tissue from surrounding normal tissue(Hentschel et al. 2007). Tumour 
blood flow rates can affect drug pharmacokinetics by impairing the delivery of 
anticancer drugs in underperfused areas. It is commonly acknowledged that tumour 
hypoxia in areas of reduced blood supply is associated with resistance to both chemo-
and radiotherapy via expression of a host of biological factors including HIF-1(Tredan 
et al. 2007). 
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Water is a chemically inert, freely diffusable tracer i.e. it has no net effect on 
tissue structure or function and is not modified or retained by tissue. This, together with 
its 100% first-pass extraction, makes it suitable for studying tumour blood supply. Most 
studies published using H2[150]-PET have been performed as part of neurological 
investigations of cerebral blood flow. Blood flow and the volume of distribution of water 
(Vd, the volume of water in tissue that exchanges with an equivalent volume of arterial 
blood during the time of the water scan) were studied in 20 patients with breast 
carcinoma and found to be significantly higher in tumour compared to normal breast 
tissue, the differences were explained in part by different tissue composition, i.e. the 
higher fat content of normal breast tissue (Wilson et al. 1992). Previously, Mankoff et al 
have shown that a low-ratio of glucose metabolism (measured by FDG) to blood flow 
is a positive predictive factor for complete response and disease free-survival in breast 
cancer patients treated with neoadjuvant chemotherapy(Mankoff et al. 2003), and that 
after 2 months of treatment in non-responding patients tumour blood flow increases by 
48%. 
In this study patients are planned to have a baseline water and [18F]FLT-PET 
scan on the same day, and then repeat scans on the day of starting capecitabine 
which is anticipated to be 2-10 days after the baseline scan. The [18F]FLT uptake will 
be corrected for changes in tumour blood flow (measured using H2[150]) to determine 
if changes in [18F]FLT signal reflect a genuine change in retention or are due to 
altered [18F]FLT delivery. The proposed method for measuring water flow and Vd is 
now outlined below. 
The one compartment model developed by Kety in 1951 is most commonly 
used for modelling H2[150] data, and has mainly been used for neurology and 
cardiology studies(Kety 1951). 
The behaviour of water within tissue is described by the following equation: 
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C{t) = / X [Ca{t) O exp( - / / Vd x f)] 
(where C(t) is the radioactivity concentration in tissue at time t, Ca(t) is the radioactivity 
concentration in arterial blood at time t, f is regional blood flow (per gram of perfused 
tissue) from plasma to tissue, Vd is the volume of distribution for water which is defined 
as the ratio of the water concentration in tissue to that in blood at equilibrium, and ® 
denotes the convolution operator.) 
One of the limitations of the water flow model is that assumes equivalent flow 
throughout the tumour - which may be inappropriate for larger lesions, especially 
those with areas of necrosis. For that reason, in this study, lesions larger than > 5cm 
will be subdivided into separate tumour areas, and necrotic areas will not be sampled. 
2.4.4 Methods 
Patients were recruited from the medical oncology clinics in Charing Cross 
Hospital, London. The inclusion criteria for this study were: age more than 18 years 
and less than or equal to 80 years, with a diagnosis of histologically or cytologically 
proven breast cancer, at least one site of measurable disease at least 2cm in diameter 
(nb patients with liver and/or bone metastases were allowed to participate in the study 
provided the measurable lesion is not located at these sites), a treatment-free interval 
of 3 weeks, nb 4 weeks applied for radiotherapy to the imaging site/1 week for patients 
previously on tamoxifen, a life expectancy of at least 3 months, a haemoglobin of at 
least lOg/dL, granulocyte count of at least 1.5 x 10®/L, platelet count of at least 100 x 
10®/L, have adequate creatinine clearance (calculated at least 50ml/min), have 
adequate hepatic function (bilirubin not greater than 1.5 ULN, serum transaminases 
not greater than 2.5ULN), be able to consent and comply fully with the study protocol. 
The exclusion criteria were: pregnant or lactating patients, sexually active patients who 
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are not employing adequate contraception, pregnancy were performed in all women of 
childbearing potential, (this population was also strongly advised to avoid pregnancy in 
this study), patients with uncontrolled medical conditions, patients unable to lie flat, 
patients with evidence or previous diagnosis of cerebral metastases, patients with 
excessive bruising from a previous scan on the same side as the position of the new 
arterial line. 
Eligible patients had a breast tumour or regional lymph node lesion or 
metastasis measuring > 2.0cm, for which they were to receive treatment with 
capecitabine chemotherapy. All patients had AJCC stage 11 I/I V breast cancer. 
Information sheets were given to all patients. All patients were given a minimum of 24 
hours to make a decision about participation in the study. Consenting patients with 
suitable lesions were to have fine needle aspirates prior to PET scanning to assess TP 
enzyme levels. Full information was available to all patients' general practioners, and 
carers who requested it, after the patients' consent had been obtained. 
Patients were scanned on two separate occasions, one baseline prior to 
treatment, and the second scanning session was within 1 hour of the first oral dose of 
capecitabine. Treatment was dosed at 1250mg/m^, which is the standard dose for 
capecitabine monotherapy in metastatic breast cancer. Plasma samples were taken at 
15 and 60 minutes post the 1®' dose of capecitabine and stored for future analysis of 
capecitabine, and metabolite, FBAL. 
Nine patients with locally advanced and metastatic breast cancer were 
recruited for the study, of whom 8 completed the two scanning sessions. The other 
patient could not be scanned due to radiochemistry failure to manufacture [18FJFLT on 
two occasions. 
Details of the patients and sites of disease are shown in Table 2.10. 
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Table 2.10 Patients in the [18F]FLT Pharmacodynamic study 
Patient Imaging site Sites of Disease Histology Response 
1 Pelvis Liver, 
bones, 
ovary 
Grade III IDC 
ER-ve, PR-ve, 
c-erbB2 +++ 
Partial 
2 Upper thorax Supraclavicular 
fossa 
Grade III IDC 
ER +, PR + 
c-erbB2 +++ 
Partial 
3 Chest wall Posterior thorax Grade III IDC 
c-erb B2-ve 
n/a 
4 Breast, axilla Bones, liver, 
lymph, breast 
Grade II IDC Partial 
5 Supraclavicular 
fossa 
Lymph nodes, 
liver 
Grade II 
Lobular 
carcinoma 
ER-ve, PR-ve, 
c-erb - ve 
n/a (RIP) 
6 Breast and 
contralateral 
axilla 
Breast, lymph 
nodes 
Grade III IDC 
ER +++/ 
PR+++ 
c-erbB2 -ve 
n/a (RIP) 
7 Lungs Lung, bones Grade III IDC 
ER+++, PR+, 
c-erbB2 
negative 
n/a 
8 Breast Breast, bones Grade III IDC Partial 
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Scans were acquired in tine following time frames for the dynamic water study: 
Table 2.11: Dynamic water scans 
No. Duration Type 
Accumulated 
Frames Time 
(min:sec) 
1 30s Background 1 0:30 
1 20s Frames 2 0:50 
22 5s Frames 24 2:40 
3 10s Frames 27 3:10 
5 30s Frames 32 5:40 
5 60s Frames 37 10:40 
For the [18F]FLT study the frames were acquired as follows; 
Table 2.12: Dynamic [18F]FLT Imaging 
No. Duration Type Accumulated 
Frames Time (min:sec) 
1 30s Background 1 00:30 
6 10s Frames 7 01:30 
4 15s Frames 11 02:30 
4 30s Frames 15 04:30 
5 120s Frames 20 14:30 
4 180s Frames 24 26:30 
4 600s Frames 28 66:30 
2.4.4.1 Radiotracer Synthesis and Scanning Procedure 
[150] was generated by the action of deuteron beams in the same cyclotron 
which produces [18F], and was then reacted with hydrogen (H2) to produce H2[150]. 
Due to the short half-life of 123 s, the gases are pumped directly to the scanner table 
to enable hydrogenation. [18F]FLT was manufactured as described previously in 
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section 2.1. The target radioactivity for injection was 600MBq for H2[150], and 222MBq 
for [18F]FLT. Prior to injection of both tracers a short, 2D, 2 minute transmission scan 
was performed: a second longer transmission scan lasting 20 minutes was performed 
for attenuation correction prior to injection of the H2[150] only. Both radiotracers were 
administered by bolus iv injection over 20-30 seconds. Patients were scanned for 
10min 40sec for the H2[150] scan, and for 66 min 30 sec for the [18F]FLT scan. 
Images were reconstructed using 2D filtered back projection; reconstructed images 
had a spatial resolution of (x,y,z): 8.5, 8.5, 5 mm. 
Arterial blood sampling was done from a cannula inserted into the radial artery 
(see section 2.2 for technique). Continuous sampling was performed at a rate of 
5ml/minute for 1 minute post-completion of the H2[150] scan and for the first 10 
minutes of the [18F]FLT scan. Samples were taken for cross-calibration for 
measurement of activity due to [18F]FLT at the following time-points: baseline, 2min 
30sec, 5min, lOmin, 20min, 30min, 45min, and 60min. Measurement of activity due to 
the [18F]FLT metabolite, [18F]FLT-glucuronide was undertaken at 2min 30sec, 5min, 
lOmin, 30min, and 60min to enable metabolite correction for mathematical modelling 
of [18F]FLT pharmacokinetics. Correction was made for delay and dispersion of the 
recorded arterial curve due to the time delay between the measured arterial input 
function and the imaging pixel, and dispersion due to the slower rate of flow through 
the edge of a laminar vessel. 
ROIs were defined manually on the [18F]FLT scans as previously outlined in 
section 2.1. Definition of the ROIs on water images was very difficult when they were 
used alone, this was worse for tumours located near a region of high blood flow such 
as the liver. To avoid sampling error between the [18F]FLT scans and the water scans, 
the ROIs were identified on the [18F]FLT scan, and the same object map was applied 
to the dynamic water datasets. 
Mathematical modelling and measurement of semiquantitative parameters for 
[18F]FLT was done as previously described in section 2.1. The following parameters 
were obtained: SUV and AUG at 60 minutes (SUV60, AUG), modified Patlak Ki, parent 
plasma PaWak Ki, and FRT60:1. 
The permeability surface area product (ps) for [18F]FLT was calculated as 
follows using K1 (delivery constant from compartmental analysis) and flow obtained 
from the water analysis: 
K1 = flow (f) X extraction 
K1/f = 1 - e-P^ 
e-P®'f= 1- K1/f 
-ps/f = In (1-K1/f) 
PS = -f X in (1-K1/f) 
2.4.4.3 Immunohistochemistry 
Two patients consented for FNA. One sample was analysed for TP using 100ul 
of Anti-Thymidine Phosphorylase (TP) Antibody, antigen retrieval system, Roche® 
Diagnostics, UK. Staining was performed by Mr D Peston, Histopathology Department, 
Charing Gross Hospital, London as reported previously (Tec et al. 2003). The second 
sample was found not to contain tumour cells. 
2.4.4.4 Statistics 
The results for Ki, FRT, SUV, and AUG of [18F]FLT were determined to be 
significant based upon the variability for each parameter as described in section 2.2. A 
Wllcoxon matched-pairs test was used to determine if there was a significant 
difference in tumour blood flow, Vd, K1, and PS product, using GraphPad Prism 
version 3. 
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2.4.5 Results 
The scans were well tolerated. The activity of [18F]FLT injected ranged from 
147-234MBq, and that of H2[150] was 566-777MBq. Of the eight patients who 
completed the study, suitable PET images were obtained in six. This is because one 
patient with small-volume metastatic disease present in the larynx which was outside 
the field of view of the PET scan had a lesion suitable for imaging which was 
presumed to be a metastatic lymph node. On [18F]FLT-PET scan images there was no 
significant uptake; further investigation by fine needle aspiration and MRl imaging 
showed that this was non-invasive and not a metastatic lymph node. The other patient 
who had widespread liver disease was initially thought to have a metastatic lung lesion 
in the right apex, however detailed radiological review concluded that this was benign; 
there was no significant uptake in this region compared to normal lung tissue on the 
[18F]FLT-PET scan. 
10 breast tumour lesions in total were imaged using [18F]FLT PET and 
H2[150]. The lesion with the maximal change in [18F]FLT-PET SUV60 was a primary 
breast tumour which showed a 50% increase in SUV60 (see Figure 2.22). The 
smallest change was seen in a cervical node which showed a 1.35% decrease in 
uptake. With the exception of this lesion, all other lesions showed an increase in 
uptake measured by SUV60 at 1 hour post-capecitabine. Of these increases, 4 were 
significant as defined by the repeatability study in section 2.2: one in an ovarian 
metastasis, one in a breast tumour, and 2 in distinct regions within patient 8 with a 
large breast tumour (i.e. an increase in (SUVpre-SUVpost-SUV)/SUVpre of >95% 
confidence interval for variability); all of these 4 lesions had a partial clinical response. 
The changes in SUV60, AUG, FRT60, 1RF60 and Ki are shown in Figure 2.23. The two 
lesions from patient 4 (breast and axilla) are depicted with white circles, and the four 
lesions from patient 8 are depicted with grey symbols and lines. 
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The significance of responses is shown in Figure 2.24 (significant response is 
above the upper solid line). Four lesions were deemed to have responded using 
SUV60 and AUC60 (identical lesions for both parameters). For modelled data, the 
changes in modified Patlak Ki and IRF60 were significant for all but 2 lesions. The 
significant changes matched those obtained by SUV60, in the additional 2 lesions one 
had a clinical response, and the other could not be assessed. 
In contrast, FRT60 suggested a significant response in an axillary lymph 
node which was deemed not to have responded by any of the other parameters; 
FRT60 showed no significant response for the remainder of the lesions. Although 
faster time frames at the start of this study compared to those in study 2.3 were used 
to improve the assessment of delivery of [18F]FLT, the difference in spectral analysis 
results suggest that the FRT60 is still influenced by blood flow at one minute. IRF60 
may be a more reliable parameter than FRT60 as suggested previously by the 
repeatability analysis in study 2.2. The lower response rate for FRT60 may be 
explained by its wider confidence interval for this parameter obtained using the 
repeatability data of 0.078±0.48, however there are no data for the repeatability of 
FRT60 with the new time frames used in this study. 
The mean blood flow before therapy (± SE) was 0.55±0.07 ml/min/ml, and 
post-capecitabine this increased to 0.76 ± 0.17 ml/min/ml. However this was not 
significant as would be expected as scans were performed on average 6 days apart 
(range = 3-13). 
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Figure 2.22 ri8F1FLT-PET Images Pre and Post Capecitabine 
A) B) 
tumour tumour 
c) 
Baseline Post-Capecitabine 
D) 
tumour 
Baseline 
umour 
Post-Capecitabine 
Figure 2.22. Images of the tumour with the maximum increase in [18FJFLT SUV post-
capecitabine are shown in above in a primary breast tumour, 2.22 a) and b), compared 
to the tumour with the minimal change which are shown in c) and d). 
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Figure 2.23 Changes in nSFIFLT Pharmacokinetic Parameters Post-Capecitabine 
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Figure 2.24 Significance of nSFIFLT response to capecitabine for all lesions 
A) SUV60 B) Modified Patlak Ki 
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Figure 2.24 above shows the response pattern for all lesions for each of the 
pharmacokinetic parameters, values within the shaded area show no significant 
change in [18FJFLT uptake compared to baseline, those above the upper border of the 
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area represent a significant increase, and those below the lower border represent a 
significant decrease). 
2.4.5.1 Tumour perfusion, Vd, and PS product 
This was assessed in 9 out of 10 lesions, the remainder could not be 
assessed as there was a delay in commencing continuous blood sampling with a result 
in loss of counting of the peak radioactivity due to Hall 50], The results are shown 
below in table 2.13. 
One case was excluded from the statistical analysis due to the data being 
subject to noise (line 3 in table 2.13 below), this occurred in a supraclavicular lymph 
node which resulted in a poor fit of the 2-tissue 3 compartmental model. 
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Table 2.13: Comparison of tumour Vd, K1, and PS product pre- and post-
capecitabine. 
Region 
Pre 
flow 
Post 
flow 
AUC 
pre 
AUC 
post Vd Vd 
K1 
xia^ 
K1 
x1ff' 
Prep 
s 
Post 
ps 
Tumour 0.52 0.52 0.076 0.090 0.93 0.97 2.60 2.62 3.10 2.62 
Tumour 0.98 0.34 0.036 0.050 0.32 0.47 1.14 2.55 1.18 2.56 
Tumour 0.31 0.26 0.056 0.054 0.54 0.60 1.71 6.13 2.07 6.17 
Tumour 0.25 0.14 0.050 0.038 0.57 0.59 1.53 1.30 1.91 1.30 
Axilla 0.069 0.064 0.64 0.57 7.08 0.92 10.64 0.92 
Tumour a 0.50 0.71 0.075 0.064 0.76 0.71 3.77 3.24 5.00 3.25 
Tumour b 0.44 1.46 0.049 0.067 0.46 0.65 2.33 2.98 2.81 2.99 
Tumour c 0.58 0.95 0.063 0.076 0.63 0.80 5.05 4.49 7.12 4.50 
Tumour d 0.61 0.90 0.075 0.071 0.75 0.74 4.05 4.86 5.16 4.87 
(where columns in grey represent values post-capecitabine and units are: flow 
ml/min/ml tissue, ADC m^sec/ml, Vd ml blood/ml tissue, K1 for [18F]FLT from 
compartmental analysis |jl/s/mi, ps product ml/s/m, ** was not included due to a poor fit 
of the model). 
Statistical analysis by the Wilcoxon matched-pairs test showed that there was 
no significant difference for tumour blood flow (p=0.25), ADC (p=0.16), Vd (p=0.16), K1 
(p=0.65), or ps product (p=0.74) between baseline and post-capecitabine scans. 
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Clinical Response 
This was assessed in 5 patients. Two patients died before response 
assessment could be performed (one due to brain metastases and the other had an 
unexplained death at home). In the remaining patients one was not assessed as the 
imaging site had not contained tumour due to the FNA findings. None of the patients 
had a complete response. 
Therefore, as there were a small number of patients in this study, and only 
one response category it is difficult to correlate the PET findings with clinical response. 
Immunohistochemlstry 
Only one sample was suitable for analysis, 100% of cells stained positive for 
thymidine phosphorylase at a 1:500 dilution. This patient also had a significant 
response as determined by Modified Patlak Ki and IRF60 but not by SUV60 or AUC60. 
The patient had a partial clinical response. 
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2.4.6 Discussion 
Drug metabolism is subject to a large interpatient variability: due to a 
combination of genetic e.g. allotypes of dihydropyrimidine dehydrogenase, 
environmental e.g. age, and disease factors e.g. reduced renal clearance. Whilst it is 
possible to measure some of these affects, most require invasive studies and some 
are difficult to quantify. Early pharmacodynamic monitoring with [18F]FLT could allow 
non-invasive individualisation of drug therapy. This small pilot study attempted to 
quantify early (mins to hours) changes in [18F]FLT-PET uptake post-treatment with the 
TS inhibitor, capecitabine. 
Previously, [18F]FLT has been used as a marker of the pharmacokinetics of 
cisplatin in a radiation-induced (RIF-1) fibrosarcoma model. In that study, decreased 
[18F]FLT at 24 hours was associated with cell cycle arrest, reduced TK-1 and co-factor 
ATP(Leyton et al. 2005). Another in vivo study has shown a decrease in [18F]FLT 
uptake in the same model in response to 5-FU treatment after an interval of 24 hours 
and 48 hours, reflecting decreased proliferation at these later timepoint (Barthel et al. 
2003). 
The early pharmacodynamic response to TS inhibition with 5-FU has also 
been measured preclinically using [18F]FLT-PET in the RIF-1 model. The early 
increases in [18F]FLT uptake at 1-2h hours post-dosing were due to an increased 
number of membrane equilibrative nucleoside transporter, ENT1. This was due to 
redistribution of the transporter from the cytoplasm to the cell membrane, induced by 
5-FU and surprisingly not due to increased TK1, the TK1 co-factor ATP, incorporation 
of [18F]FLT into DNA, or increased binding affinity of ENT1(Perumal et al. 2006). 
In this current study, although the patient numbers are small, the fact that 
there was no significant increase in PS product suggests that the effect was not due to 
increased permeability at the tumour cell membrane and/or increased numbers of the 
nucleoside transporter binding sites. The PS product is derived by from the delivery of 
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[18F]FLT, K1 obtained by compartmental analysis, and the blood flow (obtained by the 
water study). In the previous study, section 2.2, to assess repeatability of 
pharmacokinetic parameters, the repeatability of K1 was poor (r^= 0.039), however this 
is likely to have been optimised in this study due to an increased number of rapid time 
frames at the start of the dynamic imaging post [18F]FLT injection. One possible 
explanation for the increase in [18F]FLT uptake post-capecitabine is that the transport 
mechanism has not reached full saturation, and that there is an absolute increase in 
[18F]FLT extraction from the plasma into the tumour cells. The underlying process 
which drives the increased [18F]FLT extraction post TS inhibition remains to be 
verified in human breast tumour cells in vivo. 
The timing of [18F]FLT-scans is crucial and depends upon the 
pharmacokinetics of the drug involved, therefore pharmacodynamic studies with 5-FU 
should be performed early as later studies may result in decreased [18F]FLT uptake 
due to an anti-proliferative effect. Whilst the alternative pharmacodynamic marker, 2-
deoxyuridine, has been used as an index of 5-FU activity, its level is not tumour 
specific, and reflects the anti-proliferative of 5-FU in non-tumour cells as well as 
tumours. The action of capecitabine is however, thought to be more tumour specific 
than 5-FU due to the presence of TP, however systemic effects do occur such as 
palmar plantar erythema, so although 2-deoxyurdine levels in capecitabine treatment 
should be more predictive of intratumoural TS inhibition, they are likely not to be 100% 
specific. One of the future objectives from this study is to correlate the levels of 2-
deoxyuridine measured in plasma on the capecitabine treatment day with [18F]FLT. 
Mankoffs previous breast study showed a mean tumour blood flow of 0.3 ± 
0.14 ml/min/g of tissue, and a 2 month post-treatment value of 0.23 ± 0.19 ml/min/g of 
tissue(Mankoff et al. 2002). The timing of that study at 2 months makes comparison 
with the current one difficult, as at that time the changes are likely to be treatment 
related, whereas in this one the changes in blood flow were used as a correction factor 
for [18F]FLT uptake and are unlikely to be treatment related given that they were 
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measured within an hour of taking the first dose of treatment. The reported Vd for 
breast tumours has been reported previously as 0.56± 0.15 mlbiood-mltissue"\ which 
compares favorably to this study where the Vd was 0.622±0.06 mlbiood-mltissue'^  that of 
normal breast tissue has been established as 0.14±0.05 mlbiood mltissue"^  (Wilson et al. 
1992). The changes for Vd and blood flow were non-significant, suggesting that future 
pharmacodynamic studies with [18F]FLT-PET could be done without the need for prior 
scanning with [150] water. 
The major limitation with this study was the small number of patients which was 
contributed to by poor patient recruitment, radiochemical failure, and the limited 
number of imaging sites (i.e. exclusion of liver metastases). Despite this, the novel 
finding of increased [18F]FLT post-capecitabine at such an early time interval warrants 
further investigation. 
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CONCLUSION 
• [18F]FLT-PET in breast tumour lesions demonstrates early changes in 
response to treatment with the TS inhibitor capecitabine 
• The increases in tumour uptake of [18F]FLT are not due to increased blood 
flow or permeability surface product 
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CHAPTER 3: CHOLINE 
3.1 Hypothesis 
• The uptake of [11C]Choline will be significantly different in human 
breast cancer compared to normal tissue 
• [11C]Choline uptake measured by PET is repeatable in breast cancer 
• [11C]Choline-PET is a marker of MARK activity in vivo 
• Inhibition of MARK via a c-erb-b2 inhibitor will lead to a decrease in 
[11C]Choline signal 
3.2 Aims 
• To determine the difference in uptake in [11C]choline measured by RET 
in breast tumour lesions and metastases compared to normal tissue 
• To study the repeatability of [11C]choline-RET in breast tumour lesions 
and metastases 
• To study the relationship between [11C]choline and 
immunohistochemical markers of signal transduction in breast cancer 
biopsies 
• To determine the effect of a MARK inhibitor, trastuzumab, on 
[11C]choline pharmacokinetics 
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3.3 Introduction 
The focus of this chapter is another PET radiotracer, [11C]choline and its 
potential to characterise intracellular signalling events within breast tumours. In 
contrast to the previous studies where [18F]FLT focused on proliferation - a result of 
increased signalling through growth factor pathways, the aim with this study is to 
concentrate on events upstream within the cell signalling mechanism where 
upregulation of MARK acts as a precursor to cell proliferation. As cancer treatments 
become more target-specific, then a non-invasive method of detecting pathway 
activation and/or inhibition by treatment would have clear advantages and help to 
achieve individualisation of cancer therapy. 
To date there have been no published clinical studies investigating the potential 
of [11C]choline-PET in breast cancer. Most of the published PET studies using 
[11C]choline have focused on the diagnosis of primary and regional lymph node 
metastatic prostate cancer (Hara et al. 1998; de Jong et al. 2003; de Jong et al. 2003; 
Yamaguchi et al. 2005; Yoshida et al. 2005; Fanti et al. 2007). Although other tumours 
e.g. glioma and lung, have been studied to a lesser extent(Pieterman et al. 2002; Khan 
et al. 2003; Khan et al. 2004). 
Recently, the uptake of the PET tracers [18F]FLT, [11C]Choline, FDG, 
[11C]acetate, and [11C]methionine were compared in a preclinical study of treatment-
induced effects on a breast tumour model (multicellular tumour spheroids (MTS) 
produced from the MCF-T cell line of breast tumour cells). The level of reduction in 
choline uptake was insignificant for two cytotoxic agents - paclitaxel and docetaxel, 
inappropriately low for the degree of inhibition induced by doxorubicin, and gave a 
false index of efficacy with imatinib (i.e. decrease in uptake when an increase in 
tumour growth was observed)(Monazzam et al. 2007). [18F]FLT was the best tracer for 
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detecting growth related effects. These results may be partially explained by the fact 
that [11C]choline is not specific for proliferation, the use of a non-standard model 
(MTS) which may require further validation as there have only been a limited number 
of published reports (6) of its use to date, and timing of the experiments (3 or 5 days). 
Most previous studies analysing choline and choline related metabolites in 
breast cancer have utilised MR spectroscopy with either [31]P or [1]H. One such study 
found , increased phosphocholine levels in tumour xenografts of the MCF-7 and MDA-
mb-231 cell lines compared to normal tissue, which decreased post-treatment with the 
microtubule stabilising agent, docetaxel (Morse et al. 2007). The timing of imaging in 
relation to drug administration is crucial, as although a decrease in phosphocholine 
levels in breast carcinoma cells in response to choline kinase inhibition can be seen as 
early as 4 hours after dosing, (Al-Saffar et al. 2006). 
As with [18F]FLT in chapter 2, the validity of [11C]choline must be established 
by determining if there is a significant difference in breast tumour/metastases 
compared to the corresponding normal tissue in patients, which is expected given the 
low levels of membrane phosphocholine metabolites in normal mammary cells 
compared to breast tumour cells(Aboagye et al. 1999), and if the tracer 
pharmacokinetics are reproducible by performing serial scans in the absence of 
treatment. Trapping of choline within the cell is dependent on the phosphoryiating 
action of choline kinase (CK) forming phosphocholine. Malignant transformation in 
mammary cells has been shown preciinically to result in an altered phenotype with 
increased phosphocholine relative to glycerocholine(Aboagye et al. 1999). Therefore 
the first aspect of the study will be to detect if this is also true for human breast cancer 
in vivo, by seeking to establish a difference in tumour lesion uptake from normal tissue 
uptake. 
There is clearly a need to demonstrate repeatability of [11C]choline uptake in 
breast cancer as the normal variability of this radiotracer in the absence of treatment 
has not been previously determined. As with [18FJFLT, absolute quantification of the 
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repeatability of each pharmacokinetic parameter describing [11C]choline uptake and 
retention will allow accurate definition of treatment-induced PET response. 
The third aspect of the study will determine the correlation of [11C]choline with 
immunohistochemical testing of tumour biopsies for MARK, pMAPK, and proliferation 
(using Ki-67). [11C]Choline is not a proposed marker of cell proliferation, but of 
membrane phospholipid choline metabolism and MARK activation upstream of mitosis, 
therefore correlation with proliferation may be inferior to [18F]FLT. 
Finally, it seems appropriate to employ molecular imaging to determine if a 
molecular therapy is exerting its desired effect of MARK inhibition via the c-erbB2 
receptor. Thus, in the absence of a licensed mitogen activated protein kinase kinase 
(MEK) inhibitor, trastuzumab was used in a group of suitable patients with locally 
advanced and metastatic breast cancer. Measurement of [11C]choline uptake was 
performed at baseline and after treatment with trastuzumab which acts by inhibiting the 
the c-erbB2 receptor. 
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3.4 Methods 
3.4.1 Patients 
Ethical approval for the study was granted by the Hammersmith Hospitals 
NHS Trust Research Ethics Committee. The administration of radioactivity for the PET 
scans was approved by the Administration of Radioactive Substances Advisory 
Committee, UK. The patient recruitment for the study was divided into two arms: A) to 
determine the repeatability of [11C]choline, patients had a baseline scan followed by a 
second one within 1 week in the absence of treatment, and B) a treatment arm in 
which patients had a baseline scan followed by treatment with trastuzumab and a post-
treatment scan within 1 month of initiating treatment. 
Patients were recruited from the medical oncology clinics in Charing Cross 
Hospital, London. The inclusion criteria for the study were as follows: age > 18 years 
and < 80 years, histological or cytological evidence of breast cancer with at least one 
site of measurable disease > 2.5cm, a treatment-free interval of > 3 weeks (for 
cytotoxic chemotherapy, hormonal therapy, or cytostatic agents), nb 4 weeks applied 
for radiotherapy to the imaging site, a life expectancy of > 3 months, haemoglobin of > 
10g/dL, granulocyte count of > 1.5 x 10®/L, platelet count of > 100 x 10®/L, adequate 
creatinine clearance (calculated > 50ml/min), adequate hepatic function (bilirubin < 1.5 
ULN, serum transaminases < 2.5ULN),ECOG performance status 0 - 2 inclusive, able 
to give fully informed consent and comply with the protocol. In addition those patients 
in Group B had to have breast tumours which had c-erbB2 receptor positivity grade 3+ 
by immunohistochemistry, or positive by a fluorescent in situ hybidisation test (FISH). 
Subject exclusion criteria were as follows: pregnant or lactating patients, 
sexually active patients who were not employing adequate contraception (pregnancy 
tests were performed in all women of childbearing potential, this population were also 
strongly advised to avoid pregnancy in this study), patients with uncontrolled medical 
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conditions, patients unable to lie flat, and patients with evidence or previous diagnosis 
of cerebral metastases. 
The initial recruitment to the study was poor, so for that reason an application 
for an amendment was made to the ethics committee and subsequently granted to 
include: patients with primary breast cancer (not just locally advanced or metastatic) in 
group A, measurable lesions greater or equal to 2cm in diameter, and to perform the 
post-treatment scan in Arm B at the earlier timepoint of 2-5 days post-trastuzumab, 
rather than the original timepoint of 1 month. The reason for this final amendment was 
that trastuzumab is often combined with cytotoxic agents in patients with metastatic 
breast cancer, and this would provide the opportunity for those patients who were 
suitable to enter the study and have cytotoxic chemotherapy as soon as possible after 
the post-trastuzumab scan. 
3.4.2. Radiotracer synthesis and scanning 
[11C]Choline was synthesized via the reaction of [11C]methyliodide with 2-
dimethylaminoethanol (DMAE) and isolated and purified by solid-phase extraction 
(SPE) method(Zheng et al. 1996).The target radioactivity was 370MBq for each scan 
which is equivalent to 1.036 mSv(Kobori et al. 1999). A short transmission scan lasting 
2 minutes for subject positioning, and a second longer transmission scan for 
attenuation correction were performed prior to radiotracer injection. All patients were 
scanned on a CTI/Siemens HR+ ECAT962 tomograph as described in chapter 2. 
[11C]Choline was administered via bolus intravenous injection over 10-30 
seconds followed by a 6ml normal saline flush. Patients were scanned for 
approximately 65 minutes in 2D; the data were reconstructed by filtered back 
projection and binned into time frames as shown below in table 3.1. 
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Table 3.1 Reconstruction of [11C]choline time frames (version 1) 
No. Duration Type Accumulated 
Frames Time (min:sec) 
1 30s Background 1 00:30 
9 30s Frames 10 5:00 
5 60s Frames 15 10:00 
5 120s Frames 20 20:00 
5 180s Frames 25 35:00 
6 300s Frames 31 65:00 
The scans were initially reconstructed into the following time frames as shown 
above, however after our previous experience with [18F]FLT it was thought that faster 
frames at the start of dynamic imaging would be optimal for discerning radiotracer 
delivery, the new protocol was devised and is shown below in table 3.2. This resulted 
in a 10s extra duration in scanning time post-radiotracer injection. The second 
reconstruction format was employed 9 months after the study was initiated, and only 
the first 3 patients in the study were scanned using the protocol in Table 3.1. 
Table 3.2 Reconstruction of [11C]choline time frames (version 2) 
No. Duration Type Accumulated 
Frames Time (min:sec) 
1 30s Background 1 00:30 
5 10s Frames 6 1:30 
2 20s Frames 8 2:10 
2 30s Frames 10 3:10 
5 60s Frames 15 8:10 
3 120s Frames 18 14:10 
2 180s Frames 20 20:10 
3 300s Frames 23 35:10 
3 600s Frames 26 65:10 
3.4.3 Blood sampling and [11C]Choline metabolite analysis 
Continuous arterial blood sampling was performed at a rate of 300ml/hr for the 
first 10 minutes via a 22G arterial cannula inserted in the radial artery (as described in 
chapter 2). Discrete samples were taken for cross-calibration of radioactivity and 
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metabolite analysis as shown below in table 3.3. Therefore the total volume of blood 
taken per scan was 150ml. Patients had haemoglobin levels checked routinely after 
the study to ensure that there was no anaemia. 
Table 3.3 Blood sampling protocol for [11C]Choline-PET study 
Syringe Isotope Scan 
No. 
Volume Time 
BL [11C] Dyl 5ml Baseline 
1 [11 CI Dy l 10ml 2:30 Metabolites 
2 n i c i Dyl 10ml 3:30 Metabolites 
3 [11 CI Dy l 10ml 5:00 Metabolites 
4 [11 CI Dyl 10ml 7:30 Metabolites 
5 [11C1 Dyl 10ml 10:00 Metabolites 
6 [11C1 Dy l 10ml 15:00 Metabolites 
7 [11 CI Dyl 5ml 20:00 
8 [11 CI Dy l 10ml 30:00 Metabolites 
9 [11 CI Dyl 10ml 45:00 Metabolites 
10 [11 CI Dy l 5ml 50:00 
11 [11C] Dyl 10ml 60:00 Metabolites 
To measure the contribution of [11C]-radiolabelled metabolites the radioactivity in an 
aliquot of blood and plasma (1ml) was measured using a sodium iodide well counter. 
The remainder of blood (7ml) was centrifuged at14,000 rpm to obtain plasma. The 
radioactivity profile in plasma was determined with a reverse-phase HPLC linked to 
radioactivity and absorbance detectors and connected to a PC based integrator. The 
plasma samples were deproteinised by solvent extraction, concentrated by rotary 
evaporation, re-suspended in mobile phase and an aliquot (1ml) analysed using a 
reverse-phase HPLC. The column (Luna, 250 x 4.6mm; lOum diameter; Phenomenex) 
was washed with the mobile phase: a mixture of sodium di-hydrogen phosphate 
(0.25M) and methanol (80:20, v/v) at a flow rate of 3 ml per min. The eluate was 
monitored for radioactivity. Both detectors were linked to a PC based integrator which 
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recorded the radioactivity profile and enabled the correction for [11C]-radioactivity 
decay and background and integration of radioactive components. The amount of 
[11C]choline and other radioactive components at each sample time was calculated as 
a percentage of each radioactive component in each analyte. The blood radioactivity 
and metabolite analysis was supervised by Ms S Osman of Hammersmith Imanet Ltd 
®. 
3.4.4. Image and Data Analysis 
The images from time frames 12-20 were added together to form an 
'add image' using Analyze® software, on which tumour and normal regions were 
identified. The perimeter of each suitable lesion was drawn manually and used to form 
an object map. Lesion identification was also attempted using earlier time frames, 
however this was unsatisfactory due to a poor signal to noise ratio so the strategy was 
abandoned. The object map was then applied to the complete dynamic image as 
described in previous chapters, and combined with a timing file to form time activity 
curves. The TACs were decay corrected for Carbon-11, weight, and body surface area 
(see chapter 1 for analysis techniques). Modelling and semiquantitative analysis was 
used to generate SUV at 60 minutes, AUG at 60 minutes. Modified Patlak Ki, Parent 
Plasma Ki, IRF60, and FRT (ratio of the IRF at 60 mins to that at 1 minute). 
3.4.5 Immunohistochemistry 
Patients who had suitable, recently taken biopsies were approached for 
consent for use of tissue. All immunohistochemistry was performed by Dr Jie Jiang, 
Histopathology Department, Charing Cross Hospital, London - apart from Ki-67 
immunostaining (which was done by Dr David Peston from the same Department 
(using the same method as described in chapter 2)). 
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4 pm thick sections were cut from formalin-fixed, paraffin-embedded archival 
tissue blocks and mounted on 3-aminopropyltriethoxysilane (APES; Sigma) treated 
slides and dried overnight at 37 °C. The sections were placed in a 60 °C oven for 1 h 
prior to being dewaxed in xylene and rehydrated through graded alcohols. Endogenous 
peroxidase was blocked by immersing in 2% hydrogen peroxide in methanol for 10 
min. Antigen retrieval was carried out by pressure cooking, using 10 mM citrate buffer 
pH 6.0 and immunohistochemistry (IHC) was performed as previously described (Taylor 
et al. 1998) and according to the manufacturers' instructions using mouse monoclonal 
antibodies for oestrogen receptor P-S118 (cat. no. 2511; New England Biolabs, Herts, 
UK), total MARK (cat no 4696 New England Biolabs, Herts, UK) phosphorylated 
MARK (pMAPK, cat. no. 4376; New England Biolabs), progesterone receptor ( cat. no. 
MU328-UC; Biogenex, USA), phosphorylated c-erbB2 (cat no 2249, New England 
Biolabs), mouse AKT-1 (cat. no 2967, New England Biolabs), and rabbit antibodies for 
pAKT (cat no 3787, New England Biolabs) and c-erbB2 (cat. no. A0485; Dako). The 
rest of staining procedure followed the streptavidin-biotin-peroxidase complex of the 
ABC protocol, which was described previously (Zidan et al. 1997). One previous 
positive sample was used as a positive control. 
ER (phosphorylated serine 118) and pMARK levels were scored by a trained 
histopathologist, using the modified McCarty's H-scoring system, which was based on 
the percentage of positive cells and the intensity of staining to provide a total score 
varying from 0 to 300. The staining was designated as negative (H-score <50), weakly 
positive (+; H-score of 51-100), moderately positive (++; 101-200) or strongly positive 
(+++, 201-300)(McCarty et al. 1984). The staining pattern of TMARK, R-AKT and 
AKT1 are cytoplasmic and nuclear, therefore they were scored as + if there was only 
cytoplasmic staining, and as ++ if both of nuclear and cytoplasmic staining were 
present. The areas showing the representative Ki-67 expression in each section were 
chosen, and the minimum of 1,000 tumor cells were counted manually under light 
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microscopic fields (x 400) using a computer-assisted image-analyzing system (VIVl-30; 
Olympus, Tokyo, Japan) 
c-erbB2 and phospho-c-erbB2 were scored using the universal method recommended 
in the Dako HercepTest^" evaluation system and shown in table 3.4 below. 
Table 3.4: Grading of c-erbB2 staining intensity in tissue 
Negative: No immunostaining of the cytoplasmic membrane 
identified; or faint or blush staining involving a portion 
of the circumference of the cytoplasmic membrane in 
less than 10% of the neoplastic cell population. 
Low positive (+): 
Medium positive (++): 
Weak but definitive staining of the membrane over 
100% of the cytoplasmic circumference in 11- 30% of 
the neoplastic cell population 
Strong positive staining of the membrane over 100% 
of the cytoplasmic circumference in 31-50% of the 
neoplastic cell population 
High positive (+++): Strong positive staining of the membrane over 100% 
of the cytoplasmic circumference in 51-100% of the 
neoplastic cell population 
3.4.6 Statistical analysis 
The difference between tumour and normal tissue uptake was evaluated on a 
lesion by lesion basis using the Wilcoxon matched pairs test. 
Repeatability was analysed using the same tests as outlined in secion 2.3 
using GraphPad prism version 4.0 and Microsoft Excel. Pearson's correlation 
coefficient was used to determine if there was a significant correlation between the 
immunohistochemistry tests and the [11C]choline-PET parameters. The Mann-Whitney 
test was used to determine if there was any significant difference between the PET 
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parameter values for those scored +1 or +2 by immunohistochemistry; except for 
phosphoHer-2, where the Kruskal-Wallis one way analysis of variance was used as 
there were three different immunohistochemical groups (0, +2, and +3). 
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3.5 Results 
3.5.1. Patient Characteristics 
22 patients aged between 39 and 71 yrs entered the study in total, of whom 21 
had at least one [11C]choline scan; the other patient could not be scanned due to 
radiochemistry production failures on two occasions. The scans were well tolerated. 
The mean radioactivity administered per scan was 347.43 ± 6.29 MBq. The patient 
characteristics for the two studies are summarised in Tables 3.5-3.6 below, 
respectively. 
Table 3.5 [11C]Choline Repeatability Study Patients 
Pt Tumour Type AJCC 
Clinical 
stage* 
Histologica 
Grade 
Oestrogen 
receptor 
staining 
No. of 
scans 
1 Lobular II II E r++ 2 
2 Inflammatory IV III Negative 2 
3 Ductal II III Negative 2 
4 Ductal II III Negative 2 
5 Ductal IV II Er + 1 
6 Ductal IV II Er ++ 2 
7 Mucinous II II Er +++ 1 
8 Ductal III II Er +++ 2 
9 Ductal IV II Er ++ 2 
10 Ductal IV 111 Negative 2 
11 Ductal Lll III Negative 2 
12 Ductal LI II Er +++ 2 
13 Ductal LI III Negative 2 
14 Ductal LI ill Er + 2 
(*AJCC clinical staging of breast cancer- see Appendix 2). 
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Table 3.6 [11C]Choline Response to Treatment Study Patients 
Pt Tumour Type AJCC 
Clinical 
stage* 
Histologica 
Grade 
Oestrogen 
receptor 
staining 
No. of 
scans 
15 Ductal LI III Negative 1 
16 Ductal III III Negative 1 
17 Ductal Lll II Negative 2 
18 Ductal Lll III Negative 2 
19 Ductal III III Er +++ 2 
20 Ductal IV III Negative 2 
21 Ductal IV III E r++ 2 
3.5.2 [11C]Choline Analysis in Arterial Plasma 
The [11C]-radioactivity profile in plasma showed [11C]choline and one 
other radioactive component more polar than [11C]Choline. It is highly likely that the 
metabolite in this case was [11C]betaine, although conclusive experiments were not 
done in this study to prove this, evidence that this is the main metabolite of choline in 
humans has been published elsewhere (Barak et al. 1983; Roivainen et al. 2000). The 
metabolism analysis of arterial plasma samples in 19 patients showed that 
[11C]Choline decreased rapidly post-injection such that at 60 mins the mean 
radioactivity in arterial plasma due to choline was 15.15 ± 2.16% (range 7.98 -
41.99%).The polar radioactive components were observed to increase with time. A 
typical profile of [11C]choline concentration in arterial plasma is shown below in Figure 
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3.1, followed by HPLC chromatograms illustrating the metabolism of choline are 
shown in Figure 3.2. 
Figure 3.1: Plasma concentration of m c i c h o l i n e and metabolite post-iniection 
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Figure 3.1 above shows the metabolite profile of [11 C]choline post-injection. 
[11 C]-derived radioactivity due to [llCJcholine is seen to decrease over time, with a 
corresponding increase in concentration of an [11 C]radiolabelled metabolite (most 
likely to be [llCJbetaine. At 60mins post-injection the mean radioactivity due to 
[11C]choline w/as 15.1%. 
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Figure 3.2. HPLC Chromatoqrams of Arterial Plasma Post-lniection with 
rUCIChol ine 
Figure 3.2 above shows the relative contributions of [11C]choline and major 
metabolite, [11C]betaine to the [11C]radioactivity in arterial plasma during the 60min 
scanning period. The HPLC chromatograms displayed above were kindly provided by 
Ms S Osman of Hammersmith Imanet®. 
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3.5.3. Comparison of tumour and normal tissue uptal<e of [11C]Choline 
All 21 patients were included in this part of the analysis which sought to 
evaluate the differences in pharmacokinetic parameters describing [11C]choline 
uptake and retention between breast tumours/metastases and normal tissues on a 
lesion by lesion basis (total no. of tumour lesions = 25). Tracer uptake was visible in 
all tumour lesions; no new lesions were identified by [11C]choline-PET which had not 
been previously identified by other radiological methods. The results for the various 
parameters in breast tumour/metastases and corresponding normal tissues are shown 
in Table 3.7 (patients in the repeatability study are in italics, and those in the response 
study are shown in normal font); and depicted graphically in Figure 3.3. Arterial 
sampling failed in patient 20; therefore only semiquantitative analysis (SUV and AUG) 
was performed in this particular patient. 
There was a significant difference between tumour and normal breast for 
SUV, AUG, IRF60, modified and parent plasma Patlak Ki (Wilcoxon p<0.0001), but not 
FRT (p=0.204). Tumour uptake was lowest in a skin metastasis from a ductal tumour 
(Ki = 4.08 X 10^ ml plasma..ml tissue"\ s'\ SUV x 10 ® 2.86 m^.ml'^), and highest in a 
lung metastasis (Ki=18.21 x 10^ ml plasma..ml t issue'\ s"\ ,SUVx 10 ® 12.89 m^.ml'^). 
Index to Table 3.7 (below), where SUV=SUV x 1(X^ m^/ml, AUC=AUC at 60min 
m^. sec/ml, Ki= modified Patlak Ki x 10-4 (ml plasma/ml tissue/s), Ki parent = Patlak Ki 
from parent plasma x 10-4 (ml plasma/ml tissue/s), FRT= ratio of the IRF at SOmin to 
Imin, IRF60= IRFxIOr^/s). 
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Table 3.7 Tumour and normal tissue uptake of [11C]Choline 
Patient Region SUV AUG Ki Ki Parent FRT60 IRF60 
1 breast tumour 4.598 0.210 5.658 8.216 0.496 10.370 
Nbreast 1.068 0.056 3.694 4.600 0.358 2.182 
2 breast tumour 4.620 0.184 5.063 6.486 0.388 6.581 
Nbreast 2.493 0.067 2.474 1.620 0.322 1.803 
3 breast tumour 2.806 0.107 4.077 5.285 0.602 7.159 
Lung 2.020 0.052 4.018 4.291 0.724 3.761 
4 breast tumour 6.771 0.262 7.843 9.148 0.455 9.936 
Nbreast 1.470 0.074 1.671 1.889 0.366 2.079 
5 breast tumour 5.537 0.209 5.694 6.106 0.540 6.690 
Nbreast 4.601 0.155 4.094 4.244 0.265 3.545 
6 lung met. 9.798 0.387 12.947 14.042 0.591 12.530 
Lung 1.834 0.084 2.758 3.396 0.266 1.385 
7 breast tumour 6.359 0.173 8.928 9.555 0.825 8.829 
Nbreast 1.476 0.036 1.873 1.957 0.827 1.892 
8 breast tumour 7.492 0.330 11.098 9.705 0.323 9.057 
Nbreast 1.303 0.063 2.075 2.506 0.369 2.041 
9 axillary node 1 12.890 0.504 18.212 17.389 0.474 20.260 
cervical node 2 11.026 0.434 16.122 18.554 0.492 16.630 
cen/ical node 3 10.910 0.440 16.025 16.565 0.529 17.570 
Lung 2.290 0.100 3.637 4.674 0.382 3.345 
10 lung met 8.587 0.332 12.778 14.309 0.540 14.220 
Lung 1.733 0.071 2.129 2.780 0.377 2.698 
11 breast tumour 7.362 0.199 10.967 12.402 0.523 11.390 
Nbreast 1.127 0.036 1.828 2.180 0.350 1.890 
12 breast tumour 9.931 0.266 13.456 14.896 0.595 14.740 
axillary node 4.151 0.173 6.214 7.403 0.271 5.879 
Nbreast 1.437 0.052 0.441 1.853 0.412 1.911 
13 breast tumour 7.067 0.305 15.972 18.462 0.488 14.900 
Nbreast 2.215 0.089 3.939 4.316 0.540 4.513 
14 axillary node 7.874 0.183 11.547 12.812 0.600 13.260 
Muscle 1.651 0.051 3.816 3.799 0.728 3.806 
15 breast tumour 7.782 0.316 8.886 12.056 0.467 12.460 
Nbreast 2.260 0.087 3.199 3.550 0.511 3.376 
16 axillary node 9.818 0.403 12.666 13.906 0.511 13.350 
Lung 2.868 0.091 2.867 3.081 0.576 3.188 
17 cervical node 7.328 0.307 7.882 10.871 0.347 10.150 
axillary node 6.182 0.234 4.115 7.039 0.326 7.511 
Muscle 2.340 0.103 2.901 3.723 0.487 3.133 
18 breast tumour 5.728 0.243 5.409 6.087 0.323 6.351 
Nbreast 0.831 0.045 1.015 1.154 0.196 0.903 
19 breast tumour 8.1067 0.3196 17.97 20.797 0.447 19.73 
Nbreast 0.816 0.0357 2.717 2.9062 0.3288 1.917 
20 Lung met 1 7.589 0.345 n/a n/a n/a n/a 
Lung met 2 6.451 0.311 n/a n/a n/a n/a 
Lung 2.319 0.121 n/a n/a n/a n/a 
21 lymph node 10.430 0.395 15.074 16.847 0.634 16.150 
Lung 3.567 0.152 5.262 6.530 0.490 5.455 
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Figure 3.3 Comparison of tumour and normal tissue m c i c h o l i n e uptake 
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Figure 3.3 above shows the difference between tumour and normal tissue 
pharmacokinetic parameters describing [11C]choline uptake, where A) is SUV at 
60min, B) is AUC at 60min, C) is Ki obtained by modified Patiak analysis, D) is Ki 
obtained by classical (i.e. parent plasma) Patiak analysis, and E) is the IRF at 60min. 
The Wilcoxon p was <0.0001 for all of the above parameters, but not significant for 
FRT. 
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Overall, tissue uptake of choline was of the order lung < normal breast < tumour < 
spleen < liver. Typical examples of TAG curves (corrected for activity and body surface 
area) in tissues from patient 4 and patient 9 are shown in Figure 3.4. 
Figure 3.4. Time Activity Curves for rUCIcholine in different tissues 
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Figure 3.4 - top panel shows the activity (corrected for decay and BSA) 
measured in diiferent tissue regions in patient 4 who had a primary breast tumour, and 
bottom panel shows the uptake in a lung metastasis and metastatic cervical node in 
patient 9. 
There was a good fit of the Patlak and spectral models to the raw tumour data 
(Figure 3.5). Tumour Patlak Ki calculated using parent plasma as an input function was 
17.9% higher than Ki calculated using modified Patlak analysis (see chapter 1 -
mathematical modelling section for an explanation of the Patlak-Rutland plot). 
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Whilst the TAG curves suggest that uptake of [11C]choline reaches steady 
state early in the scan (see asymptotic nature of TAG curves in Figure 3.4 after 5 
mine), the linear phase of the Patlak plots in Figure 3.5 below suggest that a net 
irreversible retention component of the tracer is present. The increasing slope towards 
the end of the Patlak plot is likely to be due to rapid elimination of [11G]choline from 
the blood. Dynamic imaging for a longer duration would help clarify whether indeed 
irreversible retention is indeed saturable, in which case a plateau in the Patlak plot 
would be expected. 
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Figure 3.5 Patlak and Spectral models of choline uptake 
a) Comparison of Modified Patlak fits in tumour and nonval breast tissue from 
patient 4 
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3.5.4 Repeatability of [11C]Choline PET 
Thirteen patients were entered into this section of the study, of which 10 had 
repeatability scans. Of the remaining three patients, one patient did not return for a 
repeatability scan due to back pain, and there was a radiochemical production failure 
for the other 2 patients. Repeatability was assessed on a lesion-by-lesion basis for a 
total of 12 lesions. The mean (± SD) gap between repeatability scans was 3.75 ± 1.75 
days, during which none of the patients received any treatment. Most (70%) of the 
patients had relapsed disease; the remainder were newly diagnosed. 
[11C]Choline uptake was found to be reproducible for all the parameters under 
investigation the exception of FRT60 and the IRF value @ 1 minute. The Pearson 
correlation coefficient (r) for Ki (modified Patlak) was 0.89, p<0.0001, for parent 
plasma Patlak: r=0.85, p=0.0003, and SUV r=0.945, p<0.0001 - see results in full in 
table 3.8, below. The results are also depicted graphically in Figure 3.6, below. 
Table 3.8 Repeatability of semi-quantitative and modelled parameters in tumour 
lesions 
Parameter GOV 
Pearson 
Correlation 
coefficient r" 
Wilcoxon 
p value 
SD of mean 
relative 
difference (%) 
F-test 
SUV 60 8.439 0.945 0.892 0.542 12.37 0.695 
AUC60 9.396 0.928 0.861 0.685 14.78 0.570 
Ki 14.664 0.894 0.798 0.787 21.21 0.787 
Parpat Ki 14.430 0.845 0.714 0.946 26.06 0.849 
FRT60 14.426 0.587 0.345 0.946 21.00 0.894 
IRF60 13.380 0.894 0.799 0.542 19.52 0.964 
IRF1 15.078 0.477 0.200 1.000 21.45 0.937 
From table 3.8 above, it is evident that semiquantitative measures (SUV and 
AUG) appeared to be more robust than modelled data which are heavily dependent 
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upon the arterial plasma input function for their calculation. The spontaneous 
fluctuation range - i.e. mean variability value calculated by: 
(value for scan 2 - value for scan 1) x 2 
(value for scan 1 + value for scan 2) 
is shown in below in Table 3.9. 
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Table 3.9: Spontaneous fluctuation range for each [11C]Choline pharmacokinetic 
parameter 
Parameter IVIean variability ± 95% Confidence Interval 
SUV 60 -0.01129± 2.038 X 10"^ 
AUC60 -1.16X 10"^± 8.92 m^s.ml"' 
Ki -3.80 X 10^± 4.22 X 10"''ml plasma, ml'^ tissue. s"\ 
Parpat Ki -1.46x10"^ ±4 .98 x l O ^ ml plasma, ml tissue. s"\ 
FRT60 0.030 ±0.412 
IRF60 -0.025 ±4.380 x lO^ s"' 
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Figure 3.6 Repeatability of choline PET parameters in tumour lesions 
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Figure 3.6 above shows the repeatability for 13 lesions identified in 10 patients 
for A) SUV, B) Modified Patlak Ki, C) IRF60, and D) FRT60:1, see table 3.8 for 
statistical analysis results. 
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3.5.5 Correlation of [11C]Choline-PET parameters with immunohistochemistry of 
breast tumour lesions 
This was examined in 10 patients from both the repeatability and the response 
to trastuzumab studies. Six of the patients were newly diagnosed with breast cancer. 
With the exception of one biopsy which was taken 8 months prior to the scan all other 
biopsies were performed within 4 weeks of the baseline scan. The results of the 
immunohistochemistry are shown in Table 3.10, and Figure 3.7 (kindly provided by Dr 
Jiao). 
Table 3.10. Immunohistochemistry analysis of tumour samples 
Patient New (N) or 
Relapse (R) 
Biopsy 
Site 
ER Her2 P-
Her2 
P-
MAPK 
T-
MAPK 
P-
AKT 
AKT1 
1 N Breast + + + + - + + + + + ++ + + 
2 N Breast + + + + + + - + + + + + + 
3 R Breast - - - + + + + + + 
4 N Breast - + + + + + + + + + ++ + + 
5 N Breast - + + + + + + + + + + + + + + 
6 R Axilla + + + + + + + + + + + ++ + + 
7 R Breast + + + + + + + + + + + + 
8 N Node - + + + - + + + + ++ + + 
9 N Breast - + + + - + + + + + + 
10 N Breast + + + - - + + + + + + + 
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Figure 3.7 Immunohistochemistry of tumour biopsies. 
a) CerbB2 -grade III b) Phospho-CerbB2: negative 
c) CerbB2 -grade III 
e) PMAPK-grade 
g) PMAPK-grade +++ McCartys 
d) Phospho-CerbB2 grade III 
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i t 
f) TMAPK-showing 
cytoplasmic staining only 
h) TMAPK-showing nuclear 
and cytoplasmic staining 
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The results of the Pearson's correlation analysis are shown below in Table 3.11. No 
significant correlations were found for any of the parameters with the 
immunohistochemistry. 
Table 3.11 Pearson's Correlation between pharmacokinetic parameters and 
tumour 
immunohistochemistry 
SUV60 Modified 
Patlal( Ki 
FRT60:1 IRF@60min 
PhosphoMAPK 0.3526 -0.1708 0.2209 -0.3184 
Total MAPK 0.2276 0.06205 -0.2400 0.01702 
PhosphoAkt 0.1366 -0.2699 0.2043 -0.3082 
Total Akt -0.1213 0.3169 -0.4119 0.3911 
PhosphoHer2 0.2491 0.07406 0.3725 0.02239 
Ki-67 LI 0.2342 0.3771 -0.04731 0.04863 
As a secondary measure, Spearman's correlation coefficient was also 
employed; however the results were also non-significant for all of the parameters. The 
results of the Mann Whitney test and Kruskal-Wallis test (used for phosphoher2) are 
shown below in table 3.12. 
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Table 3.12 Assessment of differences in IVIcCarty score by [11C]Choline-PET 
parameters 
SUV60 Modified 
Patlak Ki 
FRT60:1 IRF@60min 
PhospholVIAPK 0.76 0.61 0.35 0.48 
Total MAPK 0.71 0.89 0.71 0.89 
PhosphoAkt 0.91 0.35 0.49 0.61 
Total Akt 1.00 0.52 0.38 0.27 
PhosphoHer2 0.23 0.85 0.33 0.81 
(values represent p values obtained from the Mann-Whitney test for 
PhosphoMAPK, total MAPK, PhosphoAkt, and Total Akt; the Kruskal-Wallis test was 
used to calculate p values to separate the three categories of PhosphoHer2 staining). 
The table above suggests that [11C]choline-PET was unable to distinguish 
between different McCarty's scores of the various immunostains used in the study; 
however it is worth noting the fact that the McCarty's score is not fully quantitative and 
encompasses a range of possible values of stain intensity. The difference between a 
high +2 score and a low +3 score may in fact be minimal, which is not translated into 
the statistical analysis comparing the two groups' correlation with [11C]choline-PET 
parameters. To date, quantitation of breast cancer MAPK activity has only been 
reported in vitro(Nurcombe et al. 2000). 
The final study in this chapter investigates the effect of a known MAPK 
inhibitor, trastuzumab, on [11C]choline uptake and retention. 
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3.5.6 Measurement of response to trastuzumab with [11C]Choline 
Eight pat ients en tered this study, of wh ich two could not be scanned post-
t ras tuzumab due to rad iochemica l product ion fai lure in one and a change in t rea tment 
(addi t ion of cytotoxic chemotherapy) in the other. Of the remain ing six pat ients, eight 
lesions were imaged using [11C]cho l ine-PET. 
Full pharmacok ine t ic parameter analys is was possib le in all but one of the six 
pat ients w h o refused to have arter ial sampl ing . Scans were per fo rmed between 2 days 
and 4 w e e k s of the mos t recent t ras tuzumab inject ion. Only one pat ient had a 
comp le te response clinically, this occur red in a cl inically pa lpable axi l lary node wh ich 
b e c a m e impalpable. T h e changes in pharmacok ine t ic parameters pos t - t ras tuzumab 
compa red to basel ine are shown below. 
Due to the concerns about the val idity of FRT as a sui table parameter for this 
s tudy (namely poor repeatabi l i ty da ta seen in the prev ious study, and the inabil i ty to 
d is t inguish be tween tumour and non- tumour t issue) 1RF60 w a s emp loyed as the 
spect ra l analys is parameter to measure response. T h e percentage decrease and 
increase in parameters and cor respond ing cl inical response is shown be low in Tab le 
3.13. 
233 
Table 3.13 C o m p a r i s o n of C h a n g e s in Pharmacok inet ic Parameters and Clinical 
R e s p o n s e 
Patient^ Lesion SUV AUC Ki IRF60 Clinical 
response* 
14 Axil la -47 .58 -45 .70 -47 .57 -42 .50 CR 
17 Cerv ica l -26 .72 -52 .96 5.71 -11 .66 PR 
Node 
17 Axi l la -62 .15 -126 .77 -29 .50 -58 .29 PR 
18 Breast -17 .30 -14 .08 12.01 -6 .47 PD 
19 Breast 13.88 11.59 0.09 2 23 S D 
20 Lung m e t l -47 .75 -29 .48 n/a n/a PD 
20 Lung met 2 -39 .90 -65 .20 n/a n/a PD 
21 Lymph node 18.23 15.09 48 .64 43.41 PD 
{where: ^patients as described previously in Table 3.7. *Clinical response: CR = 
complete response, PR = partial response, SD = stable disease, and PD = progressive 
disease as defined in the RECIST criteria.) 
Typica l changes in PET images in a pat ient wi th a partial cl inical response 
(#17), and one wi th progress ive d isease (#21) are shown be low in F igure 3.8. All the 
lesions wh ich had a cl inical response (comple te or partial) had a dec rease in SUV, 
AUG, and 1RF60. However lesions wh ich p rogressed were also assoc ia ted wi th a 
dec rease in one pat ient (#20) and an increase in another (#21). T h e smal l number of 
lesions in this s tudy prohibi ts any def ini t ive stat ist ical analys is to assess if 
[11C]cho l ine -PET parameters change post - t ras tuzumab is di f ferent be tween 
responders and non-responders . 
T h e repeatabi l i ty data w a s used to de te rmine if the changes for individual 
lesions pos t - t rans tuzumab were stat ist ical ly signif icant. The B land-A l tman plots for 
these results are shown in F igure 3.9. Many of the changes in the kinetic parameters 
were non-s igni f icant post - t ras tuzumab. In summary : for S U V there were 5 lesions 
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which showed a s igni f icant decrease; in compar ison the cl inical responses in these 
les ions were ; 1 CR, 2 PRs, and 2 PD; for A U G there were 3 s igni f icant decreases in 2 
les ions wi th PR and one wi th a PD. Most of the changes for the mode l led parameters 
we re nonsigni f icant except for one lesion wh ich had a signi f icant increase; this w a s 
assoc ia ted wi th a cl inical PD. 
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Figure 3.8 ri1C1Choline-PET Images of response and non-response to 
trastuzumab 
a) Patient 17 Cervical node b) clinical response 
Base me 
tumour 
Day 3 Post-trastuzumab 
c) Apical pleural node in patient 21 d) No significant change 
Day 4 Post-trastuzumab Baseline 
tumour tumour 
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Figure 3.9 Significance Plots for ri1C1Choline-PET Pharmacokinetic Response 
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Figure 3.9 above shows the differences in parameters pre and post trastuzumab 
treatment, values inferior to the lower dotted line represent a significant increase, those 
above the upper dotted line represent a significant decrease, and those within in the 
dotted lines represent no significant change where A) is AUC at 60 mins (in 
m^.sec/ml), B) is SUV x1Cr^ m^/ml, C) is IRF value at 60 mins/s, and D) is modified 
Patlak Ki ml plasma/ ml tissue/s). Ki and IRF was not possible in one patient with two 
lesions as this patient refused arterial blood sampling. 
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3.6 Discussion 
This s tudy sough t to eva lua te the potent ia l of [11C]chol ine as a potent ial PET 
radiotracer in breast cancer . No prior reports of the cl inical utility of [11C]cho l ine-PET 
in breast cancer have been publ ished previously. Th is s tudy has prov ided a detai led 
analys is of the d i f ferences in pharmacok ine t ics of uptake in [11C]cho l ine in tumour 
compa red to normal t issue, measured the metabo l i sm of [11C]chol ine, assessed the 
repeatabi l i ty for each parameter , assessed corre lat ions wi th ex-v ivo 
immunoh is tochemis t ry analyses; and f inal ly examined the ef fects of the c -e rbB2 
inhibitor, t ras tuzumab. C o m p a r e d to the focus of the prev ious chapter , (namely 
[18F]FLT wh ich is a p roposed marker of TK1 activity and hence DNA prol i ferat ion), 
[11C]cho l ine is a p roposed marker of phosphocho l ine wh ich has a more d iverse range 
of biological funct ions wi th in the cell wh ich we re descr ibed in Chapter 1. 
Dynamic imaging wi th arterial b lood sampl ing was per fo rmed to complete ly 
assess the pharmacok inet ics of [11C]cho l ine in t umour and non- tumour t issue. The 
arter ial sampl ing w a s necessary as it has been found previously i) that the T A C curve 
for [11C]cho l ine in venous p lasma var ies great ly f rom that in arterial p lasma in 
humans , and ii) the input funct ion der ived f rom arter ial b lood does not adequate ly 
represent the t rue input funct ion into t issue due to per ipheral metabo l i sm of chol ine 
(Roiva inen et al. 2000) . T h e f inding of higher [11C]chol ine in t umour t issue compared 
to normal , sugges ts that the mal ignant phenotype is assoc ia ted wi th simi lar al tered 
m e m b r a n e chol ine phosphol ip id metabo l i sm in h u m a n breast cancer to that seen in 
vi tro s tud ies (Aboagye et al. 1999). T h e uptake of [11C]chol ine was found to be 
s igni f icant ly h igher in human breast cancer compared to cor responding normal t issue 
for all of the parameters except FRT60. Possib le exp lanat ions for this inc lude the 
d e p e n d e n c e of FRT60 on the IRF va lue @ 1 minute, which is subject to var iat ions in 
the t iming of f r ame acquisi t ion, del ivery and extract ion f rom p lasma of the radiotracer 
f rom plasma. W e had sought to improve the f rame acquisi t ion, and shorter f rames 
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(10s) we re per fo rmed for the major i ty of pat ients, but this has had little impact on the 
results. A s an a l ternat ive the IRF va lue at 60 minutes was used, which, at th is late 
t imepoint , represents a sur rogate for radiotracer retent ion and hence [11C]chol ine 
phosphory la t ion. It w a s not surpr is ing there fore that the repeatabi l i ty of FRT60 was 
d isappoint ing. A s descr ibed above, the dependence on the IRF va lue at 1 minute 
s e e m s to be the major contr ibut ing factor, and this w a s conf i rmed by the even poorer 
repeatabi l i ty da ta for this parameter . Shor ter t ime f r ames were used at the start of 
dynamic imag ing to try and prevent th is being due to f rame acquisi t ion; therefore the 
me thod to correct this p rob lem remains unclear. T h e other contr ibut ing fac tors could 
be var ia t ion in b lood f low be tween scans wh ich wou ld af fect del ivery of [11C]chol ine. 
T h e fact that FRT60 w a s not reproduc ib le sugges ts that this parameter should not be 
used in fu ture compar isons . 
T h e repeatabi l i ty for the other parameters , SUV, AUG, Ki, and IRF60 w a s much 
super ior inferr ing that they should be used for quant i ta t ion of [11C]chol ine uptake and 
retent ion. W h e t h e r the mode l led pharmacok ine t ic parameters (Ki, IRF60) are 
advan tageous to semiquant i ta t ive techn iques for [11C]chol ine remains to be val idated; 
both can be used to di f ferent iate t umour f rom normal t issue wi th a Wi l coxon p of 
<0 .0001 but in a radiot racer wh ich exhibi ts rapid metabo l ism such as this, it wou ld 
s e e m preferable to use a method that is rel ies upon metabol i te-cor rected data. 
T o de te rmine if [11C]cho l ine-PET w a s a marker of MARK activity, 
immunoh is tochemica l indices were corre lated wi th the pharmacok inet ic parameters . 
Th is sect ion of the s tudy w a s ambi t ious, however unfor tunate ly it w a s h indered by the 
low number of t umour b iopsies and the t ime taken between the biopsy and the PET 
scan. No signi f icant corre lat ions were found for any of the PET parameters with the 
immunoh is tochemica l stains. Overal l , one third of pat ients in the study had metastat ic 
d isease, ef fect ively precluding a b iopsy as the lesions were in inaccessib le areas, of 
the remainder many pat ients were not rebiopsied due to progress ion th rough initial 
t reatment . T h e opt imal t ime interval be tween a biopsy and [11C]cho l ine-PET is 
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unknown as M A P K activity may change over t ime, and if the biopsy is done too c lose 
to the t ime of the PET scan changes due to the biopsy procedure itself could occur 
wi th in the ROI. Increased [11C]cho l ine uptake has been reported in an imal mode ls of 
musc le in f lammat ion w h e r e it w a s unab le to be di f ferent iated f rom a C6 rat tumour 
g l ioma model ; suggest ing even wo rse tumour select ivi ty than [18F ]FDG(van W a a r d e et 
al. 2006) . Indeed, [11C]cho l ine-PET has been proposed as a useful marker of in f lamed 
synov ium in pat ients wi th arthri t is (Roiva inen et al. 2003) . Increased uptake of 
radio label led cho l ine is a marker of CK activity in breast cancer ce l ls (Al -Saeedi et al. 
2007) , and th is can be d o w n regula ted by E R K inhibi t ion(Liu et al. 2002) ; however 
fur ther s tudy of the dynamic re lat ionship be tween CK and p h o s p h o M A P K in vivo is 
required. 
T h e f inal s tudy sought to de te rmine changes post- t reatment wi th t ras tuzumab. 
Whi ls t changes in [11C]cho l ine-PET were v iewed post - t reatment in responders , the 
repeatabi l i ty data showed that the vast major i ty of these we re non-signi f icant, as 
dec reases also occur red in a pat ient wi th PD. Perhaps detect ion of non- response by 
the quant i ta t ive parameters , modi f ied Pat lak Ki and IRF60, war ran ts fur ther 
invest igat ion as both of these parameters we re able to detect a s igni f icant increase in 
a pat ient wi th PD. Clear ly more pat ients are needed to ascerta in whe ther [11C]chol ine 
is a useful marker of M A P K inhibit ion. 
In summary , [11C]cho l ine is useful for di f ferent iat ing breast tumour f rom normal 
t issue, and is reproduc ib le for the major i ty of pharmacok inet ic parameters , but requires 
careful cons iderat ion of factors such as in f lammat ion for select ion of ROls, correct ion 
for metabol i tes in arterial p lasma, and needs a larger samp le size to conclus ive ly 
de te rmine its fu ture role as an in v ivo b iomarker for act ivat ion and t rea tment - induced 
inhibit ion of MAPK. 
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CHAPTER 4: Study of [18F]-AH111585-PET Pharmacokinetics, 
Efficacy, and Sensitivity in Patients with IVIetastatic Breast 
Cancer. 
4.1 Hypothesis 
[ 18F ] -AH111585 -PET can detect h u m a n metastat ic breast cancer lesions in 
vivo. 
4.2 Aims 
i) To quant i fy the uptake and retent ion of [18F ] -AH111585 in 
breast t umour les ions using S U V and mathemat ica l model l ing 
techn iques 
ii) T o compare the uptake in t umour lesions wi th that of the 
cor respond ing normal t issue 
iii) To compare the PET data wi th images obta ined using 
compu ted tomography (CT) 
iv) T o determine if using the heart as an ROI wou ld provide the 
s a m e results as an arterial input funct ion obta ined f rom radial 
artery sampl ing dur ing the scan. 
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4.3 Introduction 
A s ang iogenes is is essent ia l for the deve lopment of metas tases and susta ined 
tumour growth , a radiotracer wh ich has been des igned to bind to ang iogenes is -
assoc ia ted integr ins up regulated in t umours should have increased s ignal in tumour 
lesions compa red to normal t issue. A s Gaspar in i et al have shown an associat ion 
be tween express ion of the a v p s integr in and re lapse- f ree survival in both node-posi t ive 
and node-negat ive breast cancer , metastat ic breast cancer was chosen as a mode l 
sys tem in th is study. A successfu l novel radiotracer for use in onco logy should have 
appl icat ions for detect ing c o m m o n tumour types such as breast cancer. 
A s th is w a s a f i rs t - in-man study, a heal thy vo lunteer study w a s per fo rmed prior 
to the pat ient s tudy to assess the safety, biodistr ibut ion, and rad iodos imetry of [18F]-
A H 1 1 1 5 8 5 . 
4.4 Methods 
T h e st ructure of the [18F ] -AH111585 radiotracer used in the study has been 
descr ibed by Indrevol l et a l ( lndrevol l et al. 2006) , and is shown in Figure 4.1 below. 
[18F ] -AH111585 w a s synthes ised by Hammersm i th Imanet Ltd ® on an au tomated 
modu le ( T R A C E R l a b FXF-N; G E Heal thcare) by coupl ing of an aminoxyfunct iona l ized 
precursor of [18F ] -AH111585 wi th 4 - [18F} - f luorobneza ldehyde at pH 3.5 to fo rm the 
ox ime [18F] -AH111585; a ful l descr ip t ion of the rad iosynthes is has been publ ished 
e lsewhere by Glaser et al (Glaser et al. 2 0 0 8 ) . 
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Figure 4.1. Structure of AH111585 as described by Indervoll et al. 
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Pr ior to pa t ien t s tud ies , a se r ies of 3 in v i t ro compe t i t i on b ind ing a s s a y s w i th 
[ 125 l ]Ech i sa t i n (a d is in tegr in de r i ved f r o m s n a k e v e n o m w h i c h b inds to R G D 
d e p e n d e n t in tegr ins) on m e m b r a n e f rac t ions E A / H y 9 2 6 (a hybr id of h u m a n umbi l i ca l 
ve in endo the l i a l ce l ls a n d A 5 4 9 h u m a n lung c a n c e r ep i the l ia l cel ls) w a s p e r f o r m e d by 
G E Hea l t ca re Ltd ® . T h e resu l ts s h o w e d tha t t he af f in i ty of th is pep t ide for t he av(33/ 
a v p s in tegr ins w a s 8 .2 (± 2.4) n M ( Indrevo l l et al. 2006 ) . 
4.4.1 Ethical Approval 
T h e H a m m e r s m i t h Hosp i ta ls N H S T rus t R e s e a r c h Eth ics C o m m i t t e e (London , 
UK) g r a n t e d e th ica l app rova l fo r t he s tudy . T h e admin is t ra t i on of t he rad ioact iv i ty w a s 
a p p r o v e d by t he Admin i s t r a t i on of Rad ioac t i ve S u b s t a n c e Adv i so ry C o m m i t t e e Un i ted 
K i n g d o m . T h e Med ica l Hea l th Regu la t i ons Au tho r i t y s a n c t i o n e d t he use of [18F] -
A H 1 1 1 5 8 5 . 
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4.4.2 Procedure for radioactivity counting in blood and urine 
Discrete b lood samp les (5ml) we re taken at 5, 10, 15, 30, 60, 90 and 150 min 
post- in ject ion of [18F] -AH111585. T h e radioact iv i ty in an al iquot b lood and p lasma 
(1ml) w a s measu red using a sod ium iodide wel l counter . T h e remainder of b lood (7ml) 
w a s cent r i fuged at 14,000 rpm to obtain p lasma. T h e radioactivi ty profi le in p lasma 
w a s de te rm ined using an on- l ine sys tem wi th a sol id phase samp le enr ichment co lumn 
l inked to a reverse-phase H P L C radioact iv i ty and absorbance detectors connec ted to a 
PC based integrator. T h e p lasma samp les we re de-pro te in ised by sol id phase samp le 
enr i chment co lumn w a s h e d wi th 0.01 M d i - a m m o n i u m hydrogen phosphate (13.5ml) 
and fur ther ana lysed using a reverse-phase HPLC. T h e co lumn (Gemini , 250 x 1 0 m m 
id) w a s w a s h e d wi th the mobi le phase: a mix ture of po tass ium d i -hydrogen phosphate , 
pH4.0 ( l O m M ) and methano l (45:55, v/v) at a f low rate of 3 ml per min. 
T h e e luate w a s moni tored for radioactivi ty. Both detectors were l inked to a PC 
based integrator wh ich recorded the radioact iv i ty profi le and enab led the correct ion for 
[18F]-radioact iv i ty decay and background and integrat ion of radioact ive componen ts . 
T h e amoun t of [18F ] -AH111585 and other radioact ive componen ts at each samp le 
t ime w a s ca lcu la ted as a percentage of each radioact ive componen t in each analyte. 
T h e radioact iv i ty in 1 ml a l iquots of b lood and p lasma were coun ted on a sod ium 
iodide wel l counter and used to ca lcu late the p lasma/b lood ratio. 
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4.4.3 Biodistribution and Radiation Dosimetry in Healthy Volunteers 
The biodistr ibution and radiation dosimetry was determined by pl iysicists f rom GE 
Heal thcare®. Briefly, absolute values of [18F]activity in 10 organs were determined directly 
f rom quali tat ive analysis of the PET images together with the in vitro measurements of 
[18F]activity in whole blood, plasma, and urine fol lowing MIRD schema of a 70kg 
hermaphrodi te using Organ Level Internal Dose Assessment (OLINDA®) sof tware(Stabin 
et al. 2005) . 
4.4.4 Breast Cancer Patient study 
The study of patients with advanced breast cancer started enrolment after the 
study of the 8 healthy volunteers had been completed. The patients for the study were 
recruited f rom the oncology clinics in Char ing Cross Hospital (part of Hammersmi th 
Hospitals NHS Trust) under the supervis ion of Professor Coombes. All patients were given 
a study information leaflet and had at least 24 hours prior to deciding about participating in 
the study. 
Patients eligible for the study were aged > 25 years with a diagnosis of metastat ic 
breast cancer - histological conf irmation of the primary tumour was required in all patients. 
The other inclusion criteria were as fol lows: post-menopausal /surgical ly sterile/ or had a 
negative pregnancy test (i.e. urinary human chorionic gonadotrophin, HCG, test) on the 
day of scanning, and be able to consent /comply with the study protocol. One metastasis 
had to measure at least 1 cm in diameter, and not have been irradiated previously - new 
lesion in a previously irradiated field were al lowed. The patient had to have clinically 
satisfactory haematological and biochemical serum test results and Eastern Co-operat ive 
Oncology Group Performance Status of 0-2 (see Appendix 1) (Oken et al. 1982). 
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The exclusion criteria were: lactation, previous inclusion in the study, receipt of 
another investigational medicinal product within 30 days prior to the study, administrat ion 
of chemotherapy within 3 weeks of the study, and occupat ional monitor ing of ionising 
radiat ion exposure. All pat ients had a CT scan and other relevant imaging (e.g. a bone 
scan) of the metastat ic site of interest within 4 weeks of the [18F] -AH111585-PET scan. 
The CT scans were reported by an independent consultant radiologist. Study recruitment 
was diff icult for patients as there was no incentive to participate, and because most 
patients with advanced metastat ic breast cancer were receiving chemotherapy. 
4.4.5 Scan procedure- Patients 
Prior to scanning a size 24G cannula was inserted into the radial artery under 2% 
l ignocaine local anaesthet ic. A size 22G cannula was inserted into an antecubit tal vein in 
the contralateral a rm to al low radiotracer administrat ion. 
All pat ients were imaged on the same Siemens/CTI ECT962/HR+ tomograph in 
Hammersmi th Imanet® that had a 15.5 c m axial field of view (transaxial, 58cm). The field 
of v iew was centred on the tumour lesion of interest. A short t ransmission scan lasting 2 
minutes was per formed using rotating [68Ge] sources to check the posit ion of the field of 
view. This was fol lowed by a longer t ransmission scan lasting 20 minutes which was used 
for attenuat ion correction. 
Fol lowing release of the radiolabelled isotope by the quality control department in 
Hammersmi th Imanet, the dose vial was inspected in the PET scanning room to conf irm 
the contents, pH, presence of impurit ies, and activity of the injectate. [18F]-AH111585 was 
injected as an intravenous bolus over 30 seconds in a vo lume of between 6-1 Omls 
fol lowed by a 6ml normal saline flush. The amount of radioactivity in arterial blood was 
measured for 10 min using a cont inuous on-l ine radioactivity detector. Discrete samples 
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were taken for i) cross cal ibration of t l ie blood radioactivity detect ion system with the PET 
camera ii) assay of the partit ion of the label between red cells and plasma, iii) assay of the 
parent compound and labelled metabol i tes in p lasma, and iv) assay of the free fract ion of 
the [18F]-AH111585 in plasma. The t iming of the discrete samples is shown in table 4.1 
below. 
Table 4.1 Discrete Blood Sampling Protocol for the Patient Study 
Baseline* 4ml Baseline haematocrit 
1 10ml 2:30 1 2 metabolites 
2 10ml 5:00 3 4 metabolites 
3 10ml 10:00 5 6 metabolites 
4 4ml 15:00 7 8 
5 10ml 30:00 9 10 metabolites 
6 4ml 45:00 11 12 
7 10ml 60:00 13 14 metabolites 
8 10ml 1:30:00 15 16 metabolites 
9 10ml 2:30:00 17 18 metabolites 
The HPLC eluates were col lected, the total vo lume was recorded and the 
radioactivity al iquots ( 2 x 5 ml) were counted. Data were all decay corrected to start of 
injection. Peak areas for [18F]-AH111585 were analyzed and expressed as a ratio of total 
radioactivity in the original p lasma samples. A model -based algori thm was used to correct 
for loss of parent [18F]-AH111585 on the solid support. For this, metabol i te data were 
f i t ted to a straight line to derive a slope and intercept. These parameters were then used to 
scale the data such that the Y-intercept was 1. The analysis was done in MatLab version 6. 
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4.4.6 PET Imaging of Patients 
Images were acquired in 3D over 61.5 minutes and reconstructed using both 
iterative and f i l tered back projection, according to tine fol lowing t ime frames. 
Table 4.2 Frame acquisition for the Patient Study 
No. Durat ion 
(s) 
Type Accumulated 
Frames T ime (min: sec) 
1 30 Background 1 00:30 
6 10 Frames 7 01:30 
4 15 Frames 11 02:30 
4 30 Frames 15 04:30 
6 120 Frames 21 16:30 
5 180 Frames 26 31:30 
3 600 Frames 29 61:30 
Physical examinat ion, and monitor ing of the patients' heart rate, blood pressure, 
temperature, oxygen saturation, injection site, ECG, and other safety analyses were 
performed prior to, during, and after the study as shown in table 4.3. Patients were well 
hydrated during and after the scan to promote adequate renal excret ion of the isotope. 
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Table 4.3. Study Schedule of Events for Subjects with Late Stage Breast Cancer 
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Informed Consent 
Study Entry Criteria 
Demographic Information 
Medical History 
Prior/Concomitant Medication 
Physical Examination • • • 
Injection Site Monitoring • • • • • 
Pregnancy Test 
(Pre-Menopausal Females) 
ECG ' • • • • • • • • • 
Pulse Oximetry • # # # • • • • • 
Vital Signs . . • • • • • • • 
Blood Samples (Serum 
Biochemistry, Haematology)^ 
• • • • 
Blood Sample for Coagulation" • • • 
Urinalysis " • • • 
Pre-treatment Events 
Transmission Scan 
AH111585 ('°F) Injection . 
Post-treatment Events 
(Adverse Events)"* 
Dynamic imaging 
Blood and Plasma for Activity 
Counting 
• • • • • • • 
Urine for Activity Counting" 
^ Continuous ECG performed from - 5 min to +15 min. Lead II was used for continuous 
monitoring. 
^ At baseline, before vital signs and pulse oximetry were measured, the subjects were resting for 
at least 5 minutes. 
3 Blood samples of subjects with late stage breast cancer were taken from arterial blood. 
'* Time points indicated were preferred t ime points, urine was collected as voided. 
Shaded areas depict where continuous monitoring was performed 
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4.4.7 Patient Characteristics 
7 female patients with metastat ic breast cancer aged between 37 and 68 
years (mean=51.9) were enrol led in t f ie study. T i ie initial plan i iad been to study 8 
patients in total, however it was decided to conclude the trial after 7 patients had been 
enrol led as no addit ional benefit was perceived f rom studying 1 more patient, and the 
study object ives had been completed. 
Patient characterist ics are shown in table 4.3. All patients except 1 (who had 
received endocr ine t reatment only) had received chemotherapy previously for breast 
cancer. On reviewing the histology of the original breast tumours, all except 1 were 
oest rogen receptor (ER) positive, and all were c-erbB2 negative. 
Table 4.4 Patient Characteristics 
Patient 
no 
T ime f rom 
original 
d iagnosis 
(years) 
Primary 
tumour 
removed 
No. of 
previous 
chemo® 
regimes 
Previous 
endocr ine 
t reatment 
Histology * 
1 7 Y 5 Y Grade 2 IDC, 
ER 210/300, PR 60/300, 
c-erbB2 - v e . 
2 1 N 0 Y Grade 2 IDC, 
ER 300/300,PR 120/300, 
c-erbB2 - v e . 
3 2 Y 2 Y Grade 2 IDC, 
ER 300/300 PR 300/300 
c-erbB2 -ve 
4 8 Y 1 Y Grade 2 IDC, 
ER 300/300,PR 210/300, 
c-erbB2 -ve 
5 2 Y 4 N Grade 3 IDC, 
ER - v e , PR - v e , 
c-erbB2 -ve 
6 9 Y 2 Y Grade 2 IDC, 
ER 210/300, PR -ve, 
c-erbB2-ve 
7 8 Y 1 Y Grade 2 IDC, 
ER 220/300, PR 60/300, 
c-erbB2-ve 
(where $= chemotherapeut ic, * IDC = invasive ductal carcinoma). 
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4.4.8 Activity injected for the Patient Study 
The max imum permitted dose to be administered for the patient study was 370l\/IBq 
(compared to 165MBq for healthy volunteers). Af ter discussion with the physics team in 
Hammersmi th Imanet®, it was decided that the target activity for the upper limit should be 
lowered for pat ients to 200MBq if the heart was in the field of view. This was to prevent 
count saturat ion of the scanner as the acquisit ion was in 3D. The activity administered to 
the individual patients are shown below in Table 4.10. 
Table 4.5 Activity of [18F]-AH111585 Administered to Patients with Advanced Breast 
Cancer 
Patient Dose of [18F]-
AH111585 Injected 
(MBq) 
Specific 
Activity(MBq/^mol) 
Radiochemical 
purity 
1 198.85 101141 100% 
2 214.12 134208 100% 
3 244.32 128534 95% 
4 277.85 150936 100% 
5 202.70 129697 100% 
6 210.12 135117 100% 
7 292.02 170585 100% 
4.4.9 Region of Interest Analysis 
Regions of interest were manual ly drawn on entire tumour lesions and 
corresponding normal t issues using the computed tomography scans for gu idance where 
appropriate, on the iterative images, to create object maps. In tumour regions where there 
was obvious central necrosis then the periphery was sampled as a r ing-shaped region, 
and the central core was sampled as a sphere. Sampl ing of the cardiac contents was 
performed as a separate study and is descr ibed at the end of this chapter. The maps were 
then applied to the complete dynamic fi l tered back projection PET data set to obtain t ime 
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activity curves for each region using the Ana lyze® image analysis sof tware (Biomedical 
Imaging Resource, Mayo Foundat ion Rochester, MN, USA). 
The utility of the cardiac ROI as an arterial input funct ion was assessed in three 
patients where the heart was in the field of v iew (patient 2 - breast lesion, patient 5 lung 
metastases, and patient 6 pleural and lymph node metastases) a combined image of 
f rames 3 to 6 was formed. A region of interest (assumed to be the left ventricle) was 
placed on 4 consecut ive slices, to fo rm an object map. This was then appl ied to the 
dynamic data set to obtain a radioactivity versus t ime curve. 
To avoid arterial blood sampl ing in future studies, the total blood input funct ion 
obta ined f rom radial artery sampl ing with that of the heart was compared. The total blood 
input funct ion was used as the data obtained f rom the PET scan reflected activity in whole 
blood, as opposed to p lasma alone. The tumour regions which were identif ied and used 
for analysis and corresponding CT slice numbers are shown below in Table 4.6. 
Table 4.6. Regions of Interest for the Patient Study 
Patient Region name on PET 
scan 
PET Slice no. Total no. of 
slices object 
drawn in 
Corresponding 
CT slice no. 
1 Muscle 31-34 4 2/29 
1 Vessel 31-34 4 2/29 
1 Tumour (SCF node) 4 2/29 
2 Normal liver 3-7 5 2/25 
2 Normal spleen 3-7 5 2/25 
2 Heart 26-30 5 2/18 
2 Normal breast 31-41 11 n/a 
2 Normal bone (vertebra) 16-19 4 See bone scan 
2 Breast tumour 11 n/a 
2 Bone metastasis 34-37 4 See bone scan 
3 Normal liver (liver) 50-53 4 3/10 
3 Normal spleen (spleen) 50-53 4 3/10 
3 Right kidney cortex 19-22 4 :%18tO'V19 
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Table 4.6. Regions of Interest for the Patient Study (contd) 
Patient Region name on PET PET Slice no. Total no. of Corresponding 
scan slices object CT slice no. 
drawn in 
3 Liver metastasis 36-40 5 3/Y4 
Right anterior (Rant) 
3 Liver metastasis 55-58 4 3/11 
Right middle (Rmid) 
3 Liver metastasis 46-49 4 3/fO 
Left middle (Imid) 
3 Liver metastasis 45-57 13 3/f 0 fo 3/f 2 
Right lateral (RIat) 
3 Liver metastasis 50-56 7 3/V0-3/M 
Right superior post 
(Rsuppost) 
3 Liver metastasis 54-59 6 3/7-3/9 
Left superior (Isup) 
4 Normal liver (liver) 23-27 5 5/10 
4 Normal spleen (spleen) 23-27 5 5/10 
4 Liver metastasis 23-27 5 5/70 
5 Normal lung 37-39 3 2/11 
5 Lung metastasis 20-24 5 2/76 
1(tumour1) 
5 Lung metastasis 2 37-39 3 2/7 Y 
(tumour2) 
5 Lung metastasis 3 37-39 3 2/77 
(tumourS) 
5 Lung metastasis 4 18-21 4 2/27 
(tumour4) 
6 Normal lung 38-42 5 3/10 
6 Right ant tumour (Rant) 25-32 8 3/77-3/75 
6 Inferior anterior tumour 12-19 8 3/78-3/79 
6 Mediastinal lymph 10-14 5 3/76-3/78 
node 
Periphery = 
plymphnode 
Central necrotic 
region= centre lymph 
node 
7 Liver 36-38 3 3/5 
7 Liver met 36-38 3 3/5 
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4.5 Results 
4.5.1 Healthy volunteer radiation dosimetry and biodistribution 
5 males and 3 females aged between 53 and 63 years (mean=59.9) were enrolled. 
The mean administered dose of radioactivity was 163.7±6.2 MBq. The study was wel l 
tolerated. There were no ser ious adverse events. 
The [18F]-radioactivi ty profile in p lasma showed [18F]-AH111585 and other more 
polar radioactive components than [18F]-AH111585. [18F]-AH111585 decreased slowly 
f rom 95% at 5 min to 4 7 % of the radioactivity at 150 min. The polar radioactive 
components were observed to increase with t ime. 
Images of the biodistribution study in a healthy volunteer are shown in Figure 4,2. 
There was no signif icant di f ference between male and female subjects for biodistr ibution of 
[18F]-AH111585. 57±15% of administered [18F] activity was excreted, 37±14% via the 
urinary pathway, and 20±5% via the gastrointest inal tract. The highest mean initial activity 
was seen in the liver (15±1%), wal ls of the upper and lower intestines (11 ±7%), kidneys 
(9±2%), lungs (7+1%), and contents of the cardiac chambers (5±1%). 
The organs with highest normal ised cumulat ive activit ies were (in order f rom 
highest to lowest); urinary bladder contents and bladder wall > liver > walls of the small 
and large intestines > contents of the smal l intestines > the kidneys. The mean effective 
dose was calculated as 26±4 | jSv/MBq (Miller and McParland, unpubl ished data). 
There was an unexpected f inding in the first healthy volunteer, an area of 
increased uptake within the left f ronto-temporal region of the brain. This area had been 
included in the scan due to the patient's short stature. There was no history to suggest an 
intracranial lesion; neurological and physical examinat ion had been normal. An urgent MRl 
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scan was requested which revealed a 4 c m contrast-enhancing lesion in l<eeping wi th the 
[18F]-AH111585 PET scan, suggest ive of a mening ioma (see Figure 4.3). The volunteer 
was referred for a neurosurgical opinion, and the lesion was completely resected. 
Histology conf i rmed that the lesion was a meningioma, and the patient has now made a 
full recovery wi thout any residual neurological deficit. 
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Figure 4.2. ri8F1-AH111585 PET Images overtime in a Healthy Volunteer 
t=5 min t=52 min t=106 min t=172 min 
Coronal PET images of a healthy volunteer above, where t= time post injection of [18F]-
AH111585, showing high initial uptake in the liver, kidneys, heart, and intestines, followed 
by progressive increases in activity in the gall bladder, urinary bladder contents and 
bladder wall. An abnormal focus of high uptake is seen in the left temporal region. 
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Figure 4.3. Corresponding transverse M8F1-AH111585-PET and MRI images of a 
healthy volunteer. 
Transverse [18FJ-AH111585-PET image (left) and contrast-enhanced MRI Image (right) of 
the healthy volunteer shown previously in Figure 4.2, clearly reveal a mass lesion in the 
left temporal region, this was an unexpected incidental finding which was confirmed as a 
meningioma after surgical resection. This is likely to have been non-specific due to blood-
brain barrier breakdown. Note also the high uptake centrally due to the vascular nature of 
the choroid plexus. 
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4.5.1 Advanced Breast Cancer Study Patients and Regions of Interest 
The study was wel l to lerated in all patients. No serious adverse event occurred. All 
of the enrol led patients were able to complete the study. 232.5± 37.6MBq (range= 198.8 to 
292.3) of [18F]-AH111585 was injected. 18 out of 19 possible lesions were imaged with 
both [18F] -AH111585-PET and CT. The remaining lesion was a clinically enlarged 
supraclavicular lymph node which had indefinite uptake on the PET scan and was not 
identif ied using CT (patient no.1). Due to concern about the validity of this region on the 
PET image, SUV analysis was performed only, and the lesion was not included in the 
overall summary statistics. Except for this lesion, there was good correlation between the 
CT and PET images, all lesions that were visible on CT (within the same field of view as 
the PET scanner) were visible on the PET scans and vice-versa (see Figure 4.4). 
There was also good correlat ion between a [99m]Technet ium-label led bone scan 
and the [18F] -AH111585-PET scan of patient 2 who had bone metastases. In addit ion to 
detect ing metastat ic bone lesions, tumour uptake was visible in the primary grade II ductal 
carc inoma which had not been removed in the same patient (see Figure 4.5), [18F]-
AH111585 clearly identif ied metastat ic breast lesions in regions where the normal t issue 
background activity was low (lung, breast) as areas of increased activity; however 
metastases in areas with high background activity such as the liver were seen as regions 
of hypointensity. The areas of hypointensity in the liver on the [18F] -AH111585-PET scan 
did correspond with the CT images of the same region (see example in Figure 4.4) in all 
pat ients imaged with liver metastases. 
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There was signif icant heterogeneity in uptake within single lesions, particularly 
those wi th necrot ic centres, where the peripheral r ing-enhancement is in keeping with 
act ive angiogenesis - see Figure 4.4. In patient no.6 there was obvious decreased uptake 
in the centre of a posterior pleural metastasis (see Figure 4.4a) which was not obviously 
identif iable as necrosis on the corresponding CT scan. There was also signif icant variation 
in uptake between dif ferent tumour lesions within the same patient, and between patients 
(see Table 4.7). 
The t ime for [18F]-AH111585 to reach peak activity was dependent on the site of 
the metastat ic lesion. Shorter t imes (less than 10 minutes) were seen in regions which are 
wel l perfused such as the lungs (Figure 4.7) and liver (Figure 4.9) and longer t imes 
(approximately 30 minutes) were seen in a pr imary breast tumour and bone metastasis. 
No patients in the study had central nervous sys tem metastases, however the fact that 
there was uptake in a mening ioma in a healthy volunteer suggests that [18F]-AH111585 
also has potential for imaging this site. 
The Patlak and spectral analysis results indicate that there is a degree of 
irreversible binding of [18F]-AH111585 within lesions, dissociat ion of the radiolabel led 
l igand within the region was not seen within the t ime durat ion of the study (61.5mins). The 
slow metabol ism of the agent compares favorably to that seen with other [18F]label led 
PET probes (Kenny et al. 2005). Of the 15 patients and healthy volunteers, only one had 
developed an ant ibody to [18FJ-AH111585. Further evaluat ion of this immunological 
response is currently being performed. 
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Figure 4.4 Transverse ri8F1-AH111585 PET Images and CT Images in Patients 
4.4a) Patient no.6: Increased peripheral enhancement in necrotic metastases 
Necrotic lymph node 
Posterior necrotic 
mass 
4.4b) Heterogeneity of [18F]-AH111585 uptake within a pleural metastasis 
R i ^ pleural metastasis 
4.4c) Liver metastases seen as regions of hypointensity 
Liver metastases Liver metastases 
spleen 
spleen 
260 
Figure 4.5. M 8F1-AH111585 PET in a Primary Breast Tumour with Bone Metastases 
Breast tumour 
fif 
Sagittal and transverse views of a left breast tumour (grade 2 
intraductal carcinonr)a) In patient 2. 
Bone metastasis ; .•* 
V .• -
Sagittal section off 18FJAH-111585 
PET image and corresponding 
Technetium l^^MTc] bone scan 
showing thoracic bone metastases 
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4.5.2 Metabolism of [18F]-AH111585 
The compound was slowly metabolised. At 60 mins post intravenous injection the 
percentage of measured radioactivity in arterial plasma due to [18F]-AH111585 (± SEM) 
was 74.48± 3.18%, with the remainder due to metabolites. 
Figure 4.6 Summary of ri8F1-AH111585 metabolism data for patients 
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Proportion of unmetabolised [18FJ-AH111585 to total [18F]-radioactivity in plasma 
as a function of time, measured as described in the methods section; bars are ± SEM, n = 
7 patients. 
An example of the HPLC analysis of the metabolites and parent compound for 
patient in the study analysis are shown in Figure 4.7, the number of polar metabolites and 
contribution to overall radioactivity was seen to increase overtime. The exact nature of the 
metabolites was not characterised in this study, but could in future be analysed using 
techniques such as mass spectrometry. 
262 
Figure 4.7 HPLC Analysis of ri8F1-AH111585 and Metabolites in Arterial Plasma. 
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Radiochromatograms of[18F]-AH111585-derived radioactivity in arterial plasma, assessed 
at 2.5min (A) and at 60min (B) after injection of the radioligand. 
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The slow metabolism of this compound is a favorable factor, as it suggests that static 
studies could be commenced at 30-60 minutes post injection of the radiotracer and is 
beneficial for mathematical modelling as sophisticated correction algorithms are unlikely to 
be necessary. 
4.5.3 Mathematical analysis results 
The results of the semiquantitative analyses and quantitative (i.e. modelled) 
analyses are shown in Tables 4.7, 4.8, and 4.9. Tumour regions are highlighted in bold, 
necrotic regions in grey, and normal tissue regions are white. 
The data presented are analyses of radioligand uptake in 19 tumour regions from 
18 CT-detectable lesions and 1 supraclavicular fossa lymph node. In the first patient only 
SUV and area under the curve calculations were performed because of concern about the 
validity of ROl definition as the lesion was detected on physical examination but not by 
CT. Graphical comparison of uptake corrected for decay, dose, and body surface area, in 
selected tumour and corresponding normal tissue regions are shown in Figures 4.8-4.10. 
Rapid delivery and washout of [18F]-AH111585-derived activity was evident in 
normal lung tissue (see Figure 4.8B). In contrast, tumour activity increased continually 
over the imaging period, reaching a plateau at about 40-60 min. Large variations in [18F]-
AH111585 were seen among individuals, among different tumour types, and even 
between tumours of the same cancer type. For example, inpatient 5 (with four lung 
metastases) the SUV ranged between 5.31 and 106.57 x 10"^ (m^/ml). In general, lung 
metastases showed the highest SUV; the primary tumour and liver metastases showed 
lower uptake than the lung metastases. 
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Table 4.7 Results of SUV and AUG Analysis in Tumour and Non-Tumour Tissue 
Patient Region SUV AUG 
1 tumour 3.737 0.122 
muscle 2.372 0.078 
2 tumour 5.313 0.129 
n breast 1.503 0.044 
3 Rant 8.980 0.262 
Lmid 9.911 0.295 
Lsup 8.008 0.212 
Rmid 8.853 0.241 
RIat 3.680 0.110 
Rsuppost 8.868 0.246 
Liver 11.417 0.044 
4 tumour 7.468 0.276 
Liver 10.039 0.425 
5 Tumourl 96.251 2.768 
Tumour2 6.870 0.290 
Tumours 5.309 0.147 
Tumour4 106.57 3.406 
Lung 2.464 0.100 
6 ranttum 18.189 0.472 
rposttum 16.796 0.454 
centrelnode 3.897 0.100 
infantmet 17.882 0.477 
outerpost 14.105 0.373 
plymphnode 14.034 0.386 
postcentre 7.803 0.207 
lung 2.750 0.104 
7 livermet 9.371 0.346 
liver 9.841 0.348 
(where SUV = SUV corrected for body surface area measured at 60 minutes post-injection 
X 1(T^ m2.mr\ and AUC= area under the curve at 60 minutes in m^.sec.mf^). 
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Table 4.8 Results of Patlak Analysis In Tumour and Non-Tumour Tissue 
Patient 
1 
Region 
tumour 
Ki 
n/a 
Ki (parent) 
n/a 
muscle n/a n/a 
2 tumour 3.817 4.430 
n breast 1.601 1.658 
3 Rant 9.399 9.876 
Lmid 11.760 10.048 
Lsup 9.367 9.640 
Rmid 10.156 10.480 
RIat 3.748 3.950 
Rsuppost 9.656 10.048 
Liver 9.812 10.794 
4 tumour 3.747 4.370 
Liver 4.730 5.818 
5 Tumourl 68.761 72.682 
Tumour2 2.350 3.038 
Tumours 3.960 4.155 
Tumour4 72.547 78.084 
Lung 1.036 1.263 
6 ranttum 27.490 28.687 
rposttum 21.820 23.824 
centrelnode 1.688 3.305 
infantmet 24.585 26.472 
outerpost 17.396 19.183 
plymphnode 22.145 21.066 
postcentre 11.760 12.339 
lung 2.403 2.967 
7 livermet 7.424 9.971 
liver 6.875 9.442 
(where Ki= Irreversbile retention obtained using Modified Patlak analysis (x 7(J® ml plasma, 
ml tissue s Ki (parent) = Irreversbile retention obtained using parent plasma input 
function analysis i.e. Classical Patlak (x 70 ® ml plasma, ml tissue s'\) 
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Table 4.9 Results of Spectral Analysis in Tumour and Non-Tumour Tissue 
Patient Region IRF 1min IRF 56.5 FRT VD K1 MRT 
1 tumour n/a n/a n/a n/a n/a n/a 
muscle n/a n/a n/a n/a n/a n/a 
2 tumour 11.75 5.413 0.461 0.534 6.354 840.415 
n breast 5.56 1.470 0.264 0.183 1.325 1381.132 
3 Rant 62.97 7.207 0.114 1.653 16.434 1005.842 
Lmid 59.10 8.180 0.138 0.842 29.358 286.804 
Lsup 26.61 6.980 0.262 0.688 5.655 1216.622 
Rmid 28.65 9.046 0.316 2.206 23.200 950.862 
RIat 41.270 3.191 0.077 0.365 10.085 361.924 
Rsuppost 56.450 7.735 0.137 0.802 13.691 585.786 
Liver 123.400 5.777 0.047 0.853 93.173 91.550 
4 tumour 72.380 3.424 0.047 0.478 27.962 170.946 
Liver 86.700 0.829 0.010 0.357 18.373 194.307 
5 Tumourl 353.000 60.250 0.171 15.018 313.732 47.869 
Tumour2 54.270 2.218 0.041 0.290 12.801 226.545 
Tumours .200 3.290 0.155 0.344 4.816 714.286 
Tumour4 313.200 58.290 0.186 13.859 62.227 2227.168 
Lung 19.660 1.050 0.053 0.139 4.168 333.493 
6 ranttum 101.000 25.120 0.249 5.668 23.467 2415.307 
rposttum 93.580 21.430 0.229 4.632 22.788 2032.649 
centrelnode 9.621 4.800 0.499 0.469 0.974 4815.195 
infantmet 99.980 23.350 0.233 2.579 17.686 1458.216 
outerpost 56.880 18.310 0.322 4.116 66.872 615.504 
plymphnode 68.210 16.030 0.265 4.096 14.834 2761.224 
postcentre 74.130 10.250 0.138 1.102 10.600 1039.623 
lung 23.520 2.470 0.105 0.298 6.612 450.696 
7 livermet 14.490 5.967 0.041 0.767 44.405 172.728 
liver 14.490 5.566 0.037 0.828 42.263 195.916 
(where IRFImin = Impulse response function at 1 minute x 10~^, IRF56.5min= Impulse 
response function at 56.5 minutes x 10'^, FRT= fractional retention of the tracer = 
IRF56.5min/IRF1min). VD= Relative volume of distribution (ml plasma/ml of tissue). K1= 
Rate of delivery of [18FJ-AH111585 obtained by spectral analysis x (pi plasma/ml 
tissue/sec). MRT = Mean residence time of tracer in tissue region (in sec). 
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Figure 4.8 Typical Time versus Radioactivity Curves from Tumour Regions and 
Corresponding Normal Tissue 
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Figure 4.8: A, shows the uptake of [18FJ-AH111585 in a primary breast tumour and normal 
breast tissue in patient 2; B, shows a lung metastasis and normal lung in patient no. 5. In 
both the figures above, the higher uptake in the breast tumour and a lung metastasis is 
clearly discernible from that of normal tissue. 
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Figure 4.9 Heterogeneity of uptake within a single tumour lesion 
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Figure 4.9 shows the difference in [18FJ-AI-I111585 uptal<e between the necrotic centre of 
a lymph node, and the periphery of the same lesion from patient 6. 
Figure 4.10. ri8Fl-AH111585 uptake in a liver metastasis and normal liver 
30-1 
1 
E 2 0 -
X 
> 10H 
Z3 
(0 
o 
o4^ 
o liver 
• tumour 
° o 
• o o, 
O 
I I I I I 1 
0 10 20 30 40 50 60 
Time (min) 
Figure 4.10. In contrast to the previous lesions the liver metastasis has low uptake 
compared to the normal liver (data presented from patient 2). 
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[18F]-AH111585 derived activity cleared rapidly from both blood and plasma with a 
half-life of about 10 min; the plasma-to-blood activity ratio was greater than 1 at all time 
points (see Figure 4.11). Analysis of the kinetic data indicated that the radioligand was 
irreversibly trapped in tumours within the imaging time during the scanning period (1 h). 
Figure 4.11 ri8F1-Radioactivitv in Arterial Blood and Plasma 
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Figure 4.11 above shows a typical example (from patient 6) of the [18F]-derived 
radioactivity measured in arterial blood and plasma. The terminal half-lives of blood and 
plasma were 9.30 and 10.95 min, respectively indicating rapid clearance of the radiotracer 
to tissue. 
In the Patlak plots of tumour lesions, an exponential phase followed by a 
discernible linear phase was seen, indicating irreversible trapping: the slope (Ki) was 
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higher than normal tissue (see Figure 4.12). The results were similar for both the Modified 
Patlak and Classical Patlak analyses (see Figure 4.13 and table 4.13). 
Figure 4.12 Modified Patlak analysis of a tumour lesion compared to normal tissue 
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Figure 4.12 above shows the difference in [18FJ-AI-I111585 Patiak slopes for a lung 
metastasis from patient 6, compared to normal lung tissue in the same patient. The values 
for Ki were 21.8 and 2.4 x 10'^ ml plasma/ml tissue/sec, respectively. 
Figure 4.13 Classical Patlak analysis in a tumour lesion 
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Figure 4.13 above shows a Classical Patlak analysis performed for the same tumour 
lesion as that illustrated in Figure 4.12; the value for Ki was 23.8 x 10'^ ml plasma/ml 
tissue/sec. 
Ki was higher for non-liver metastatic lesions and the primary breast tumour than 
the corresponding normal tissue. Spectral analyses also demonstrated an irreversible 
kinetic component of [18F]-AH111585 in tumour lesions; the FRT results were higher for 
all non-liver metastases and the majority of liver metastases compared to normal tissue 
(see table 4.14). K1, which reflects delivery, was slower in metastases than normal liver. 
The liver metastases were seen as areas of hypointensity compared to normal 
liver; although the kinetic parameters were similar to those in other metastatic lesions. 
Region of interest identification is more difficult in areas of hypointensity, and due to 
concern about spillover from normal liver tissue the statistical analysis were performed 
separately for liver and non-liver tissue. Similarly, there were potential errors for 
quantifying uptake in necrotic regions which are surrounded by a high-uptake tumour rim; 
hence the necrotic regions were not included in the statistical analyses of tumours. 
4.5.4 Summary of Statistical Analysis 
Significant differences existed between tumour and normal tissue uptake of the 
radioligand for SUV, FRT, MRT (non-liver lesions: SUV, p=0.002, FRT, p =0.0039; liver 
lesions: SUV/FRT, p=0.0078 and MRT, p=0.0391). For Ki analysis the difference was 
significant for non-liver lesions only (classical and modified Patlak; Ki p =0.002). The 
necrotic centres of lymph nodes from patient 6 were not included in the statistical analysis 
because of concern about possible spillover effects. 
The results of the two-tailed paired t-test and Wilcoxon matched pairs test 
comparing uptake in tumour lesions versus normal tissues for all the parameters detailed 
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in the results tables (4.7 and 4.9 above) are shown below. As the normal uptake in the 
liver was high, the lesions were analysed in the following groups: 1) all tumour lesions, 2) 
non-liver tumour lesions, and 3) liver-only metastases. 
273 
Table 4.10 Difference between tumour and normal tissue uptake for all parameters 
Parameter No. of Lesion type T-test Wilcoxon 
Lesions p value p value 
SUV 19 All (inci pt 1) 0.076 0.0549 
18 Not incI pt 1 0.0777 0.049 
11 Non-liver (incI pt 1) 0.0466 0.0010 
10 Non-liver (not incI pt 1) 0.0469 0.0020 
8 Liver 0.0640 0.0078 
AUG 19 All (inci pt 1) 0.1234 0.1747 
18 Not incI pt 1 0.1262 0.1738 
11 Non-liver (incI pt 1) 0.0597 0.0010 
10 Non-liver (not incI pt 1) 0.0607 0.0020 
8 Liver 0.0011 0.0078 
Ki 18 All 0.0215 0.0088 
10 Non-liver 0.0127 0.0020 
8 Liver 0.4596 0.6406 
Ki parent 18 All 0.0266 0.0358 
10 Non-liver 0.0135 0.0020 
8 Liver 0.111 0.0234 
IRF @ 1 min 18 All 0.3675 0.4705 
10 Non-liver 0.033 0.0059 
8 Liver 0.002 0.0156 
IRF@ 56.5 18 All 0.0099 0.0008 
min 10 Non-liver 0.0095 0.0020 
8 Liver 0.0765 0.1094 
FRT 18 All <0.0001 0.0003 
10 Non-liver <0.0001 0.0039 
8 Liver 0.0189 0.0078 
VD 18 All 0.0184 0.0052 
10 Non-liver 0.0170 0.0020 
8 Liver 0.4028 0.9453 
KI 18 All 0.9068 0.9566 
10 Non-liver 0.1299 0.0020 
8 Liver 0.0048 0.0391 
MRT 18 All 0.0031 0.0068 
10 Non-liver 0.0322 0.0645 
8 Liver 0.0190 0.0391 
The Wilcoxon test shows that the [18F]-AH111585 uptake parameters SUV, 
AUG, IRF@1min, FRT, Ki obtained by parent Patlak analysis, and K1 were able to 
differentiate between tumour and normal tissue in both liver and non-liver lesions when the 
sites of metastases were grouped separately. The difference between tumour and non-
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tumour uptake was significant for non-liver lesions but not for liver metastases for the 
following parameters: Ki obtained by Modified Patlak analysis, VD, and FRT@56.5 min. 
The converse was true for MRT where there was a significant difference between liver 
lesions and normal lesions, i.e. increased MRT in lesions compared to normal liver, but 
there was a lack of significance for non-liver lesions. 
4.5.5 Comparison of the heart and radial artery sampling 
This was assessed in three patients (nos. 2, 5, and 6). As the ROI obtained from 
the heart represents total blood (i.e. there was no separation for plasma), the input 
function generated was compared to the total blood curve obtained by radial artery 
sampling performed during the scan. The results are depicted below in Figure 4.14, and 
suggest that there was good correlation between the two types of datasets; however 
definitive statistical analysis of the correlation was not performed due to the small sample 
size (n=3). 
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Figure 4.14 Comparison of Heart ROI and Total Blood Input Function 
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Figure 4.14 above, shows the [1 SFJ-derived activity measurements in radial artery blood 
(labelled Blood) compared to the surrogate cardiac ROI (labelled heart) from patients 2 
(Figure A), 5 (Figure B), and 6 (Figure C). 
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4.6 DISCUSSION 
This study has for the first time shown that the RGD-containing integrin receptor 
binding iigand, [18F]-AH111585, demonstrates irreversible uptake in metastatic breast 
cancer; is stable in vivo, and rapidly cleared from blood. The power to separate potential 
areas of tumour angiogenesis from necrotic areas could aid treatment e.g. for planning 
radiotherapy, and selection of targeted agents. The ability of [18F]-AH111585 to non-
invasively quantify avps and avp5 associated neovascularisation may become both a 
prognostic and predictive factor for treatment response in cancer patients. 
The ideal qualities for a radiotracer which targets angiogenesis-associated 
integrins include: suitability for imaging common cancers (e.g. breast, lung, colorectal), 
high tumour-background ratio, fast-blood clearance to minimise non-target radioactivity. 
The time taken for the radiotracer to reach its target should be rapid, dissociation should 
be slow, so that maximal accumulation in the tumour is achieved(Liu 2006). This tracer 
fulfils most of the above criteria. There was a significant difference for both semi-
quantitative and modelled parameters between tumour uptake and normal tissue uptake in 
non-liver lesions. 
[18F]-AH111585 was found to be safe and well tolerated, with no adverse events In 
the 7 patients studied. All lesions identified by CT were visualised by the radiotracer (within 
the corresponding field of view). The one exception was in a clinically palpable 
supraclavicular lymph node which was not conclusively seen on the CT scan; the high 
density of vessels in this region and anatomic location are likely to have been contributing 
factors. The high in vivo stability of the radioligand together with its retention in tissue may 
have been reflected in the fact that most tumours (excluding liver lesions) demonstrated 
hyperintense uptake. Although there is potential for partial volume effects with lung 
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lesions, all of the tumours analyzed in this study were greater than 1cm, which obviates 
significant partial volume effects. 
[18FJ-AH111585 was found to be homogeneously distributed in the tumours or 
appeared within the tumour rim; this finding is consistent with the general principles 
regarding the distribution of angiogenesis within the outer zones of breast tumours, where 
viable regions exist (Fox et al. 1995; Fox et al. 1995; Koukourakis et al. 2000). The high 
liver background activity may have been due to the densely vascularised nature of the 
sinusoidal vessels, rapid blood flow which was identified in the preliminary biodistribution 
study where very high initial activities were seen in the liver, and the metabolism of [18F]-
AH111585 by the liver. The exact nature of the metabolites is yet to be elucidated, as is 
the binding capability of the metabolites of [18] AH111585 to with av(33/ av[35 integrins. 
K1, which reflects delivery, was slower in metastases than normal liver. MRT was 
higher in metastases than normal liver in the majority of lesions (6 out of 8). The fact that 
the liver has a dual blood supply from the hepatic artery and the portal vein, could mean 
that the systemic arterial input function overestimated the true tissue input function, 
therefore affecting the pharmacokinetic parameters. Prominent accumulation of RGD 
peptide ligand in the liver has also previously been reported in humans(Chen et al. 2004). 
Statistical noise in spectral analysis can also affect both K1 and MRT. The spleen also 
showed high uptake, this is thought to be due to blood pooling. 
However, it has also been shown previously that liver metastases from breast 
cancer do not exhibit marked angiogenesis and instead rely on co-opting existing blood 
vessels (Stessels et al. 2004). Stessels et al, found that the median level of carbonic 
anhydrase 9, CA9, (a well known marker of hypoxia) was 0 in the 45 metastases which 
were examined; this was in contrast to colorectal liver metastases where the level of CA9 
was much higher and suggests that liver metastases from breast carcinoma lack hypoxia-
driven activation of their pro-angiogenic switch. However it should be remembered that 
279 
CA9 is not itself a direct biomarker of angiogenesis per se, rather, it is seen as a iiypoxia 
marker. The values for the pharmacokinetics for [18F]-AH111585 uptake in this study in 
liver metastases are comparable to those in non-liver lesions (see tables 4.12-4.14). The 
high background signal in the liver presents challenges for use of this agent in patients 
with liver metastases and requires further study. 
This study summarises the radioligand kinetics of an RGD peptide in humans. The 
rise in SUV over time in tumours compared with the rapid clearance in blood and normal 
lung tissue is consistent with selective high-affinity receptor binding and adequate 
pharmacokinetic properties. Both primary and metastatic lesions showed radioligand 
uptake which was higher than that of the corresponding normal tiisues (p=0.002) with the 
exception of liver metastases, which were still detectable but with reversed contrast. 
Nonetheless, the absolute values (SUV values corrected for body weight between 2 and 
39 g/ml; or Ki between 2 and 69 x 10'® ml plasma/ml tissue/s) were high enough for clinical 
use. 
The variable uptake between tumour lesions in the same patient may be due to 
differences in angiogenesis in the tumour microenvironment; this finding warrants further 
investigation. The kinetic modelling allowed quantitative assessment of the radioligand-
receptor interactions. The linear phase of the Patlak plots implied a net-irreversible binding 
of the radioligand to tumours within the imaging time. The values for Ki from modified 
Patlak analysis were lower than those obtained by classical Patlak; which suggests that 
some of the [18F]-AH111585 metabolites may exhibit receptor-binding properties. 
Compartmental analysis of the data would help discern the magnitude of reversible or 
irreversible binding components with the tissues. 
Secondary to the net-irreversible trapping of the radioligand in tumours during the 
imaging period, the residence time of [18F]-AH111585 was higher in tumours than 
adjacent normal tissues; suggesting that a later imaging time (e.g. 60 min post-injection) 
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would be suitable for clinical studies of breast cancer. In contrast, a study by Beer et al in 
patients with squamous carcinoma of the head and neck found that uptake of the 
[18F]galacto-RGD peaked at 10-15min, then plateaued or had a slight decrease over 60 
min; and was associated with reversible kinetics(Beer et al. 2007). 
The biodistribution of [18F]galacto-RGD is similar to [18F]-AH111585(Beer et al. 
2006). As there is high background in the liver and the spleen with both of these 
radiotracers, imaging of angiogenesis in these regions will be challenging. Only one breast 
carcinoma was included in the Beer study. If the SUV values for that tracer (corrected for 
body weight) are compared to [18F]-AH111585 in the patient primary breast cancer 
lesions - the values are quite similar - 3.1 in the Beer study compared to 2.1 in this 
study(Beer et al. 2006). This current study did not perform correlations with tumour levels 
of the target integrins as the metastases were deep-seated, therefore biopsies would have 
involved an invasive procedure for patients with advanced breast cancer. 
Whilst the possibility of [18F]-AH111585-PET detecting both tumour cells and 
tumour neovasculature cannot be completely excluded in this study, in the epithelial breast 
cancer cell line, MCF-7, the level of expression of the av(33 integrin was as low as 
0.88%(Beauvais et al. 2004). It is important to remember that avp3/5 expression on tumor 
cells and endothelial cells are both considered as therapeutic targets. 
The results using the heart as an ROI to derive an arterial input function did 
underestimate the initial peak radioactivity as measured by the on-line arterial blood 
sampling. This may be explained by lack of a fully reliable definition of the left ventricle, so 
that some right ventricular blood may also have been sampled with venous mixing leading 
to an overall decreased activity per unit volume, or a partial volume effect, or the use of 
averaged counts over a time frame for the heart data rather than complete dynamic set as 
was used for the whole blood. Normally the arterial input function obtained by arterial 
sampling is subject to delay and dispersion effects between the arrival of the arterial blood 
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in the tissue of interest and tlie corresponding point of assay (Cunningham at al. 1994). A 
correction factor could be calculated from a larger dataset to detect a trend, which would 
be suitable for larger clinical studies that use image-based derived input functions. 
[18F]-AH111585 has shown promising activity in this study, and may be useful for 
monitoring the response to antiangiogenic agents, including anti-VEGF, anti-VEGFR, and 
anti-av33 receptor agents. 
Future studies of this agent should i) correlate uptake of [18F]-AH111585 with 
tumour expression of av(33 measured by immunohistochemistry, ii) assess the utility to 
detect angiogenic growth in other particular tumour types, iv) assess the effect of novel 
anti-angiogenic agents, and iv) predict tumour response within an individual patient to a 
particular therapy. 
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In conclusion, [18F]-AH111585 is safe, well tolerated, can detect primary and 
metastatic tumour lesions, and is only minimally metabolised in vivo. These findings 
should promote [18F]-AH111585 as a novel PET radiotracer, and warrant further 
evaluation as a predictive factor and an agent in monitoring treatment response. 
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Chapter 5: CONCLUSION 
This thesis has evaluated the potential of three novel PET radiotracers in breast 
cancer. Each of the radiotracers is proposed as biomarkers for diverse biological 
processes within the cell which contribute to the hallmarks of cancer; namely proliferation, 
activation of growth factor pathways, and development of an autologous blood supply. The 
main focus of the studies has been to provide an in-depth pharmacokinetic analysis of the 
radiotracers in tumour tissue using dynamic PET imaging and mathematical modelling 
techniques. Whilst the number of patients involved in the studies means that they are pilot 
in nature, some definitive conclusions have been reached. 
For [18F]Fluorothymidine one can state that i) this is a marker of proliferation in 
breast cancer; ii) that quantitative parameters are superior to semi-quantitative in terms of 
correlation with Ki-67 LI,(Kenny et al. 2005) iii) that tumour uptake of [18F]FLT is 
reproducible, iv) that early decreases in [18F]FLT can discriminate between responders 
and non-responders to treatment with FEC chemotherapy (Kenny 2007), and v) that 
cardiac blood pool sampling is a promising non-invasive alternative to radial arterial 
sampling, but may need shorter early time frames to determine peak activity. 
[11C]Choline was the focus of the second chapter. From these studies the results 
show that i) [11C]choline-PET can distinguish between breast tumour lesions and normal 
tissue; ii) uptake of [11C]choline is repeatable in breast tumours; iii) early changes in 
[11C]choline uptake can be observed post-treatment with the c-erbB2 inhibitor, 
trastuzumab. The results of the analysis to correlate [11C]choline uptake with 
phosphoMAPK may have been affected by the timing of the tumour biopsies. In relation to 
response to treatment with trastuzumab the results suggest that significant clinical 
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responses are associated with a decrease in [11C]choline retention; further larger studies 
are clearly required. 
Finally, the potential of [18F]-AH111585 was evaluated in a first in man phase 1/2 
study. This study showed that i) there was irreversible retention of the radiotracer in breast 
cancer; ii) that uptake was significantly higher in tumour compared to normal tissue; and iii) 
that cardiac blood pool analysis is a useful surrogate to radial artery sampling to provide 
an arterial plasma input function(Kenny 2008). 
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APPENDIX 1 
Eastern Co-operative Oncology Group Performance Status (ECOG) 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or 
chair 
5 Dead 
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APPENDIX 2: American Joint Committee on Cancer: Breast Cancer Staging 
(Singletary at al. 2002) 
Stage I 
. T1*, NO, MO 
Stage IIA 
. TO, N1,M0 
. T1*, N1,M0 
. T2, NO, MO 
Stage MB 
T2, N1, MO 
T3, NO, MO 
Stage IMA 
. TO, N2, MO 
. T1*, N2, MO 
. T2, N2, MO 
. T3, N1, MO 
. T3, N2, MO 
Stage NIB 
. T4, NO, MO 
. T4, N1,M0 
. T4, N2, MO 
Stage NIC 
. Any T, N3, MO 
Stage IV 
• Any T, Any N, M1 
* [Note; T1 includes Tlmic] 
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